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Chapter 1
HAEMOSTASIS 
Maintaining the integrity and patency of the vascular system is essential for the viability 
of humans. When vascular injury has occurred, fast formation of a thrombus at the 
site of injury is essential to seal the wound, resulting in haemostasis. Haemostasis is a 
tightly regulated process, which involves the activation of endothelial cells, platelets, 
procoagulants and the inhibition of fibrinolytic factors. Haemostasis can be separated 
in two phases called primary and secondary haemostasis, which occur simultaneously.1 
In primary haemostasis, a platelets plug is rapidly formed at the site of injury, whereas 
in secondary haemostasis, blood coagulation is initiated, either with negatively charged 
surfaces (intrinsic pathway) or with tissue factor (extrinsic pathway). The cascade leads to 
the generation of thrombin and the formation of a fibrin network.2 The thrombus provides 
an effective restriction for bleeding. Hence, an imbalance of normal haemostasis caused 
by pathologic disorders may lead to thrombosis or hemorrhage, which may account for 
morbidity and mortality.
FIBRINOGEN
Fibrinogen is a central protein in the hemostatic system. At the final stage of the blood 
coagulation system, thrombin converts the soluble fibrinogen into fibrin monomers, 
which then polymerize to an insoluble fibrin clot. Furthermore, fibrinogen induces platelet 
adhesion and aggregation via the αIIbβ3 integrin, thus promoting blood coagulation.
In addition to their primary function in blood clotting, fibrinogen and fibrin also 
play a role in various physiological reactions including fibrinolysis, cellular and matrix 
interactions, wound healing and neoplasia.  Moreover, fibrin(ogen) is also involved in 
platelet aggregation, regulation of Factor (F) XIII activity and inflammatory reactions.3-4 
Fibrinogen is a plasma glycoprotein that is mainly synthesized by hepatocytes in the 
liver.5 In plasma, the circulating concentration of fibrinogen is maintained between 2 and 
4 mg/mL (6 -12 μM), and its half-life is about 3-4 days.6  Fibrinogen is an acute phase 
protein, its levels are up-regulated 2 to10-fold through the action of interleukin 6 (IL-6) 
and glucocorticoids during the acute-phase response to inflammation, infection and tissue 
injury.7-10 In addition, plasma fibrinogen levels are associated with many demographic and 
environmental factors in healthy individuals. The fibrinogen levels are associated with 
age, body mass, gender, race, season, smoking, physical exercise, diet and use of several 
drugs.11
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Structure of fibrinogen 
Fibrinogen molecules are elongated 45 nm structures that consisting of one central E region 
interconnected by α-helical coiled-coil segments to 2 peripheral D regions. The fibrinogen 
molecule comprises two sets of identical disulfide-bridged halves, each consisting of 
three polypeptide chains termed Aa, Bβ and γ.12 These six polypeptide chains assemble to 
construct a hexamer (AαBβγ)2, joined together with 29 disulfide bonds.
13 
The fibrinogen molecule contains at least 12 domains, which are grouped into three 
major regions named E region, D region and aC region. In the central E region, the amino-
termini of the 6 polypeptide chains are connected by five symmetrical disulfide bridges, the 
nonsymmetrical disulfide bridges formed in this region is called the disulfide ring.13-15 The 
two distal D regions store the carboxy-terminals of the Bb and g chain and part of the Aa 
chain. Both D and E regions contains binding sites for fibrin assembly, cross-linking and 
platelet interactions.16 The two aC regions, comprising the flexible carboxy-terminal two 
thirds of the Aα chain (residues 221–610 in human fibrinogen),17-19 are involved in fibrin 
assembly,20 activation of factor XIII,21 modulation of fibrinolysis22-23 and cell adhesion.24-25
The common human fibrinogen molecule contains 2964 amino acids and has a 
molecular weight of approximately 340 kilo Dalton (kDa). The Aa, Bb and g polypeptide 
chains consist of 610, 461 and 411 amino acids with molecular weights of 68 kDa, 55 kDa 
and 49 kDa respectively.26-28
The 3 polypeptide chains Aα, Bβ and γ are encoded separately by the fibrinogen alpha 
(FGA), fibrinogen beta (FGB) and fibrinogen gamma (FGG) genes, which are clustered 
in a region of approximately 50 kilobases (kb) and located on chromosome 4q23-32. The 
8.4 kb-FGG gene contains 10 exons and is oriented in tandem with the 5.4 kb-FGA gene, 
which contains 6 exons. The FGG gene is located 10 kb upstream of the FGA gene. Both 
genes are transcribed in the direction opposite the 8.2 kb-FGB gene, which is located 13 
kb downstream of the FGA gene and contains 8 exons.29 Assembly of the 6 separate chains 
takes place sequentially in the endoplasmic reticulum within 5 minutes of synthesis.30-31
Fibrinogen heterogeneity 
Fibrinogen has a high degree of heterogeneity which fulfills its multiple functions 
in healthy individuals. It has been speculated that fibrinogen can occur in more than 
one million different forms as there are enormous possible combinations of genetic 
polymorphic site, alternative processing of fibrinogen messenger ribonucleic acids 
(mRNAs), posttranslational modifications and proteolytic degradation.32 Moreover, 
abnormal modifications are associated with diseases but more investigations are needed 
to clarify they are the real causes or whether they are the consequences of the diseases. 
1
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Chapter 1
Inherited variations in the fibrinogen genes
Numerous polymorphisms have been identified in the three fibrinogen genes. The majority 
of them are located in the non-coding regions, except for the Arg448Lys polymorphism 
in the Bβ gene and the Thr312Ala polymorphism in the Aα gene. An association between 
the Bβ Arg448Lys polymorphism and variations of clot structure has been suggested,33 but 
contradictory results were reported.34 The Aα Thr312Ala polymorphism is associated with 
thromboembolic disease.35-36 The most extensively studied polymorphisms are located in 
the FGB gene, since in vitro studies suggested that the synthesis of the Bβ chain is the rate 
limiting step of the mature fibrinogen production and therefore the FGB gene is considered 
to be involved in determining the fibrinogen plasma levels.37-38 A consistent association 
between FGB promoter genotypes and elevated plasma levels of fibrinogen plasma 
concentrations confirmed this hypothesis.39-41 On the other hand, the variations of FGA 
and FGG genes are reported to play a role in regulating fibrin clot structure.33 Therefore 
we focused on the variation in the FGG and FGA genes in this thesis. More recently, the 
relation between haplotype-tagging polymorphisms in the total fibrinogen gene cluster 
and fibrinogen plasma levels or the risk of cardiovascular diseases was investigated.42-45 
Noninherited variations 
Posttranslational modifications
In addition to the genetic variations in the fibrinogen genes, many variants in fibrinogen are 
noninherited. They are the result of alternative splicing, posttranslational modifications and 
proteolytic degradation. Fibrinogen molecules are modified posttranslationally in different 
degrees as a result of phosphorylation, glycation, glycosylation, oxidization, sialylation 
and deamidation. These modifications may affect the characteristics of fibrinogen, and 
affect proteolysis and polymerization.32,46 
Proteolytic degradation
At the carboxyl-terminal of the Aα chains, partial proteolytic degradation can occur, which 
is the main cause of heterogeneity of the fibrinogen molecule (Figure 1). Fibrinogen is 
mainly synthesized in the high molecular weight (HMW) fibrinogen with two intact 
carboxyl ends of the Aα chain (molecular weight [MW] 340 kDa, 70% of total fibrinogen). 
Partial degradation of one Aα chain results in the low molecular weight (LMW) form 
(MW 305 kDa, 26% of total fibrinogen) and partial degradation of both Aα chains leads to 
LMW′ fibrinogen (MW 270 kDa, 4% of total fibrinogen).47-48 The ratio of molecular weight 
variants varies according to the physiological condition, for example, the percentage of 
HMW fibrinogen increases during an acute phase reaction.49-50
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The three molecular weight forms are a mixture of molecules with numerous 
degradation sites in the carboxyl terminus of the Aα chain. The main termination residues 
of the degraded Aα chains were Asn-269, Gly-297 and Pro-309.51 However, no enzyme 
(included plasmin, gelatinase, trypsin, matrix metalloproteases, and elastase) has been 
identified that explains the proteolytic cleavage of HMW to LMW and LMW′ fibrinogen.51 
Previous studies showed that the rate of fibrin polymerization, clot stability, fibrin 
degradation and angiogenesis were influenced in the LMW and LMW′ fibrinogen when 
compare to HMW fibrinogen.32,46,52
Alternative mRNA processing variants
The extended AaE variant (aE, Fib420)
There are two alternative processing variants from the fibrinogen genes (Figure 1). One of 
them is the result of alternative transcription of the FGA gene and includes exon six, which 
contains additional 236 amino acids. This form results in the generation of a minor form 
with an extended AaE chain (aE). The carboxy(C)-terminus of both Aa chains has been 
extended and its molecular weight is 420 kDa, hence it also termed fibrinogen-420.53-54 
Only 1 to 2% of the total fibrinogen molecules is aE.
55  The aE levels are three times 
higher in newborns than in adults.56 The C-terminus of aE was reported to have chaperone-
like activity,57 supporting integrin-mediated cell adhesion,58 mediate leukocyte adhesion 
and migration via the binding with leukocyte integrins αMβ2 and αXβ2.
59 However, the 
physiological role of aE C has not yet been fully elucidated.
The fibrinogen gamma variants (g′) 
Another natural alternative processing variant is the fibrinogen g′ variant, which comprises 
8% to 15% of the total circulating fibrinogen (Figure 1, reviewed in 60). Fibrinogen g′ is a result 
of alternative messenger RNA processing and polyadenylation at the C-terminal of gA. The 
last 4 amino acids encoded by exon 10 (gA 408-411 AGDV) are replaced by the 20 unique 
anionic amino acids encoded by intron 9 (g′ 408-427 VRPEHPAETEYDSLYPEDDL), 
leads to the formation of g′.61 The extended g′ chain is thus larger than gA chain (MW 
51.5 kDa and 49.4 kDa, respectively). In the systemic circulation, g′ is mostly present as 
a heterodimer together with the common γA chain (γA/g′), while less than 1% is present 
in the homodimeric g′/g′ form.62  Approximately 3% to 34% of the g′ occur as a shortened 
version, termed g423P, which probably arises by post-secretary in vivo processing of g427L 
fibrinogen chains. The g423P has impaired thrombin binding potential since the 424–427 
sequence (EDDL), which is required for thrombin binding, is not included.
1
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The extension of g′ fibrinogen contains a high affinity binding site for thrombin, which 
results in antithrombin I activity.7 In addition, g′ fibrinogen contains an extra binding site 
for the factor XIII (FXIII) B subunit8, 9 and lost its platelet integrin aIIbb3 binding site, 
which results in reduced platelet-fibrin(ogen) interactions.10 Several studies reported 
functional and structural differences between fibrinogen gA and fibrinogen g′ fibrin 
matrices, such as slower fibrinopeptide B release,63-64 slower fibrin polymerization for g′ 
fibrinogen,63,65 thinner fibers and more branch points with scanning electron microscopy 
on fibrin g′ fibrin matrices.63-64 The elevated g′ levels and g′/total fibrinogen ratio have been 
reported in cardiovascular diseases,66-68 whereas decreased g′ levels and g′/total fibrinogen 
ratio have been associated with venous disease.69 Furthermore, the FGG haplotypes are 
associated with thrombotic risk.43,70-71 These associations indicate the g′ may play a role in 
cardiovascular events.
Aα
Ββ
γ
Aα
Ββ
γ
Aα
Ββ
γ
Aα
Ββ
γ
Aα
Ββ
γ
Figure 1. Schematic representation of major fibrinogen variants in plasma
Bars indicate relative lengths of fibrinogen Aa, Bb and g chains, while the white bars represent elongated 
sequences of aE and g′ fibrinogen variants. Adapted from de Maat et al., 2005.46
FIBRIN POLYMERIZATION
Fibrin formation is initiated by thrombin cleavage of a highly specific site Arg16 at the 
amino(N)-terminus of the Aα chains, resulting in release of fibrinopeptides A (FpA). 
Cleavage of FpA results in the exposure of a new polymerization site termed ‘A’.72 The 
complementary binding sites are called ‘a’, which are the adjacent molecules located 
between g337 and g379 in the D region, and are always exposed.73-75 Fibrin monomers 
polymerize via these specific non-covalent A:a interactions and form half-staggered 
Fibrinogen 
variants
Molecular 
weight 
(kDa)
Occurance 
(%)
HMW-FBG 340 70
LMW-FBG 305 26
LMW′-FBG 270 4
aE-FBG 420 1-2
g′-FBG 340 8-15
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oligomers that lengthen into double-stranded protofibrils (Figure 2). These intermolecular 
interactions have been described as knob-hole interactions.76 During the lateral aggregation, 
branch points are created and which is essential to yield a complex three-dimensional 
fibrin network.77-78
Subsequently, thrombin cleavage after Arg14 at the N-terminal of the Bb chains 
releases fibrinopeptides B (FpB) and exposes an independent N-terminal ‘B’ polymerization 
site. The ‘B’ polymerization site interacts with an exposed, complementary ‘b’ binding site 
in the Bb chain of the D region of another molecule (Figure 2). This cleavage has been 
hypothesized to promote the lateral aggregation of existing fibrin protofibrils, resulting in 
an increase in the fiber thickness.72 However, several snake venom enzymes (FpA release 
only) are possible to initiate fibrin formation, and also lateral aggregation can occur 
without FpB cleavage.79-82
The fibrin network is stabilized by plasma transglutaminase factor (F) XIII, which 
is activated by thrombin to form FXIIIa, and cross-links the fibrin clot covalently via 
glutamine–lysine bridging between two g chains.83-84 This intermolecular bridging also 
occurs more slowly between two a chains,85-86 and even occurs between one g and one 
a chain.87 These cross-links further strengthen the fibrin clot and protect the clot against 
mechanical, chemical, and proteolytic degradation.88
a b ab
FpB
FpA FpA
FpB
β-module β-moduleγ-module γ-module
fibrinogen
D-region E-region D-Region
coiled coil coiled coil
a b ab
B
A A
B
β-module β-moduleγ-module γ-module
fibrinogen monomer
D-region E-region D-Region
coiled coil coiled coil
two A and two B ‘Knobs’
a b ab
B
A A
Baba b aba b
B
A A
B
D-region E-region D-Region
D-region E-region D-Region D-region E-region D-Region
(a)
(b)
(c)
Figure 2. Schematic representation of fibrin monomer and their assembly into protofibrils 
(a) Fibrin monomer. (b) Cleavage of FpA and FpB, results in the exposure of a new polymerization site 
termed ‘A’ and ‘B’. (c) Fibrin monomers interact with adjacent molecules, assembly into protofibrils and 
promote the lateral aggregation. Adapted from Janmey et al., 2009.89 
1
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FIBRINOLYSIS 
Fibrinolysis is a highly regulated system, which plays an important role in the dissolution 
of blood clots and in the maintenance of a patent vascular system. A dynamic balance 
between fibrin formation and fibrinolysis is essential, since excess activation of fibrinolytic 
system may lead to bleeding disorders whilst the opposite may lead to thrombosis.90 In the 
fibrinolytic system (Figure 3), fibrin is degraded into soluble fibrin degradation products 
by the active serine protease plasmin, which is converted from its zymogen plasminogen 
by two types of plasminogen activators (PA).91  In the circulatory system, the activation of 
plasminogen is enhanced by tissue-type plasminogen activator (t-PA) in the existence of 
fibrin or at the quiescent endothelial cell surface,92 whereas urokinase-type plasminogen 
activator (u-PA) binds to a specific u-PA receptor (u-PAR) at the migrating capillary 
endothelial cells surface, inflammatory cells surface or endothelial microparticles,93 
thereby facilitates extracellular proteolysis during tissue remodeling and repair, regulates 
cell migration, adhesion and proliferation.94
The fibrinolytic system is controlled by several specific inhibitors, such as a2-
antiplasmin (α2-AP), plasminogen activator inhibitor 1 (PAI-1) and thrombin-activatable 
fibrinolysis inhibitor (TAFI). Most of them are belonged to the serine protease inhibitors 
(SERPINS) superfamily. The α2-AP inhibits plasmin rapidly by the formation of an 
irreversible complex via its free active site and free lysine binding sites.95 Moreover, PAI-
1 is the major physiological inhibitors of PA activity in the circulation, which inhibits the 
protease activity by formation of a reversible complex. Apart from PAI-1, the PA activity 
can be inhibited by plasminogen activator inhibitor-2, α2-macroglobulin, α2-AP, α1-
antitrypsin, C1-inhibitor and plasminogen activator inhibitor-3.96  TAFI is activated by 
thrombin and makes a connection between coagulation and fibrinolysis. Activated TAFIa 
degrades the C-terminal lysine and arginine residues from fibrin and provide a protection 
against plasmin.96 In summary, fibrin plays an active role in fibrinolysis. It acts as substrate 
and co-activator for plasmin, and participates in its inhibition.
MODULATORS OF THE FIBRIN STRUCTURE 
The fibrin clot structure can be described by the fiber thickness, length, porosity, permeability, 
degree of branching, and extent of cross-linking.97 These variables determine properties 
of clot, such as stiffness and rate of fibrinolysis. Multiple factors regulate the fibrin clot 
formation, properties and function, including pH, ionic strength, calcium concentration, 
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fibrinogen concentration and thrombin concentration.98-101 For example, an increased 
fibrinogen concentration and a decreased thrombin concentration lead to thicker fiber and 
more branch points, resulting in stiffer clots. Moreover, procoagulant activity affects the 
fibrin clot structure and stability, such as FXIIIa-induced fibrin cross-linking, interactions 
with platelet and vascular cells, which support the formation of dense fibrin networks that 
resist fibrinolysis.102-103 In addition, fibrinogen polymorphisms (e.g. Bβ Arg448Lys33 and 
Aα Thr312Ala polymorphisms104), fibrinogen variants (e.g. HMW-fibrinogen52, LMW-
fibrinogen52 and g′ fibrinogen) and pathophysiological condition (e.g. patients with type II 
diabetes mellitus,105 premature coronary artery disease106 or myocardial infarction107) also 
influence polymerization processes and may give an altered fibrin structure.
Taken together, the total effect of genetic and environmental influences determines the 
structure and function of the fibrin clot. The stability and characteristics of fibrin network 
play important roles in haemostasis and thrombosis. Alternations in fibrin structure could be 
a causative factor in the various hemorrhagic and thrombotic disorders, and understanding 
of the mechanism may lead to the development of therapeutic interventions to manage 
cardiovascular diseases. 
t-PA u-PA
PAI-1
Plasminogen
Fibrinogen
Plasmin
Fibrin
Thrombin
FDP
a  -AP2
TAFI
Figure 3. Fibrin degradation by the fibinolytic system
1
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FIBRINOGEN AND WOUND HEALING 
Wound healing is a dynamic, interactive and complex process, which consists of three 
sequential but overlapping phases: (1) inflammation (2) proliferation and (3) remodeling.108 
The wound healing process involves a series of cellular and biochemical events, such as 
cell adhesion, migration, proliferation, neovascularization, extracellular matrix (ECM) 
deposition and degradation. These events comprise the intricate interactions between 
many different cell types, extracellular matrix, soluble mediators (for instance growth 
factors and cytokines) and proteinases.109-110
Fibrinogen is a central protein in the coagulation cascade and it also plays a pivotal 
role in wound repair. After endothelial injury, a platelets plug is rapidly formed, followed 
by the formation of a fibrin network. The activated platelets are included in the fibrin 
network through the binding of fibrin to platelet integrin, the aIIbb3 receptors. The resulting 
insoluble fibrin clot is the first protection against local hemorrhage in wounds. In addition 
to its function in haemostasis, the fibrin network provides an important provisional, 
biodegradable ECM that stabilizes the wound and facilitates cell invasion during wound 
healing process.
One of the important processes of wound healing is angiogenesis, which is the 
formation of new capillaries from pre-existing vessels in the ECM of the wounded tissue 
by migration and mitogenic stimulation of endothelial cells (EC).110 This process consists 
of several steps, which including the stimulation of ECs by growth factors, degradation 
of the extracellular matrix by proteolytic enzymes, invasion of matrix by the migration 
and proliferation of EC, and finally the formation of capillary tube.111 It is also highly 
depends on fibrin structure and the interactions between fibrin and proteins. The rate of 
fibrinolysis and angiogenesis are affected by the structure of fibrin matrix, for instance a 
faster fibrinolysis rate was observed in coarse matrix.112 Furthermore, many haemostasis 
proteins (such as t-PA, plasminogen and FXIII) bind to fibrinogen and fibrin, which affect 
the fibrinolysis rate and hence influence the angiogenesis process.113-114 The fibrin matrix is 
also physically associated with other matrix proteins, such as fibronectin and vitronectin, 
which provide a bridge between smooth muscle cells and fibrin.16 
Besides being the temporary scaffold to support the wounded tissue, fibrin matrices 
actively recruit cells to modulate cell-cell and cell-matrix interactions. Previous studies 
have shown that many cell types have affinity to fibrin matrices, such as EC,115 smooth 
muscle cells,116 fibroblasts117 and leukocytes.118 These cells interact with fibrin matrices 
directly through cell surface integrin receptors (e.g. avb3, avb5, a5b1, aMb2, aIIbb3) and 
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non-integrin receptors, such as Vascular Endothelial(VE)-Cadherin, intercellular adhesion 
molecule (I-CAM), P-selectin and platelet glycoprotein Ib-α (GP1ba).16,119  In addition, 
fibrin matrices serve as a reservoir for cytokines and growth factors during tissue repairing, 
in particular the high affinity binding with angiogenic growth factors vascular endothelial 
growth factor (VEGF) and fibroblast growth factor-2 (FGF-2).120-121 
In summary, fibrin is an essential matrix to prevent local hemorrhage, to interact with 
proteins, proteases, protease inhibitors, growth factors and cells, to induce and modulate 
cell responses, and to facilitate the wound healing process. Since fibrin matrices are a 
great potential for wound repair and tissue regeneration, they have been utilized as fibrin 
sealants for multiple tissue engineering applications, including peripheral nerves repair, 
bone regeneration, skin grafting after burn, and induction of angiogenesis.122-126 
AIM AND OUTLINE OF THE THESIS 
The aim of this thesis is to investigate the role of fibrinogen variants and fibrinogen 
elastase degradation products in cardiovascular diseases (CVD), and to understand the 
contributions of fibrinogen g′ variants in wound healing. 
In Chapters 2-4, we investigate the relationship between common genetic variations 
of fibrinogen and CVD. In Chapters 5-9, one of the natural fibrinogen variants, the 
fibrinogen g′ variant, is extensively studied. Finally, the relationship between fibrinogen 
elastase degradation products and stroke is evaluated in Chapter 10.
As previous described, an elevated plasma fibrinogen level is a well-known 
independent risk predictor for CVD. Genetic variations in the fibrinogen genes influence 
the plasma fibrinogen concentrations and the clot structure, thereby potentially contributing 
to the cardiovascular events. In Chapter 2, we investigate the association between plasma 
fibrinogen levels and the presence of cerebral small vessel disease (SVD) based on 
magnetic resonance imaging (MRI) of the brain. In addition, the relationship between 
common variations in FGG, FGA and FGB genes and SVD is examined. We perform the 
study as part of the Rotterdam Scan Study, a population based imaging study in individuals 
aged between 60 and 90 years.
Since vascular disease is associated with dementia and Alzheimer’s disease, we 
hypothesized an association between altered fibrin clot structure and dementia. In Chapter 
3, we investigate whether common variations in the FGG and FGA genes, which are 
involved in regulating clot structure, are associated with an increased risk of dementia and 
Alzheimer’s disease. The study is performed in the Rotterdam Study, a population-based 
1
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prospective cohort study among persons of 55 years and over. In Chapter 4, we further 
investigate the involvement of genetic variations in the FGG and FGA genes in stroke in 
the Rotterdam Study.
Previous studies have reported associations between the plasma levels of fibrinogen 
g′ variant, the fibrinogen g′/total fibrinogen ratio and deep venous thrombosis, myocardial 
infarction and coronary artery disease. These results indicate that FGG gene variations, 
which are a main determinant of the plasma fibrinogen g′ levels, may contribute to 
the pathology of thrombotic disease and influence the risk of CVD. In Chapter 5, we 
conduct a case-control study, the COntrolled study of genetically determined COagulation 
disorders in patients with transient ischemic attack or ischemic Storke (COCOS study), 
including 124 stroke patients and 125 population controls, to determine the role of 
fibrinogen g′ levels and common FGG gene variations in ischemic stroke. In Chapter 
6, we hypothesize that acute phase reaction alters the mRNA processing of fibrinogen g′, 
thereby increasing the g′/total fibrinogen ratio. In addition, an increased g′ ratio during the 
acute phase of cardiovascular disease may modulate the secondary thrombotic risk. We 
test these hypotheses in patients with ischemic stroke (IS), pulmonary embolism (PE) and 
unstable angina pectoris (UAP).
Subsequently, we compare the differences in fibrinogen g′ levels and g′/total fibrinogen 
ratio between patients with ischemic stroke and control persons in Chapter 7. Furthermore, 
we study whether there is an association between these levels and short-term outcome in 
ischemic stroke. On the other hand, the role of fibrinogen g′ in intracerebral hemorrhage 
(ICH) has not yet been elucidated, we therefore aim to determine the association between 
g′ levels and the g′/total fibrinogen ratio in patients with ICH compared with healthy 
controls in Chapter 8.
We suggest that the functional differences between gA and g′ fibrin are associated 
not only with CVD, but also in combination with the altered matrix structure, influence 
angiogenesis and wound healing. In Chapter 9, we investigate the effects of the gA and γ′ 
fibrinogen variants on the in vitro endothelial cell characteristics and in vivo wound healing.
Previously, an association has been found between levels of leucocyte elastase and the 
risk of cardiovascular events and ischemic stroke.  In Chapter 10, the effect of fibrinogen 
elastase degradation products (FgEDP) levels in patients with ischemic stroke is evaluated 
using a newly developed assay, which enables the assessment of elastase proteolytic 
activity by measuring FgEDP levels. 
Finally, the results of our studies are discussed in Chapter 11. We attempt to increase 
the understanding and insight for the future prospects of fibrinogen variants in CVD and 
wound healing.
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ABSTRACT
Fibrinogen levels and fibrinogen clot structure have been implicated in the pathogenesis 
of vascular disease. We examined fibrinogen levels and variation in fibrinogen genes 
(fibrinogen g (FGG), a (FGA) and b (FGB)), which have been associated with fibrin clot 
structure and fibrinogen levels, in relation to cerebral small vessel disease (SVD). 
This study was performed as part of the Rotterdam Scan Study, a population based 
study in 1,077 elderly patients undergoing cerebral MRI. Plasma fibrinogen levels and 
haplotypes were determined. We examined the association between fibrinogen levels and 
haplotype with silent brain infarcts and white matter lesions using logistic regression 
models. We constructed seven haplotypes (frequency>0.01) that describe the total 
common variation in the FGG and FGA genes. Haplotype 2 (GATAGTG) was associated 
with the presence of silent brain infarcts compared with the most frequent haplotype 
(GGTGGTA) (OR 1.41, 95% CI 1.03 to 1.94). Haplotype 3 (GGCGATA) was associated 
with periventricular white matter lesions in the highest tertile of the distribution (OR 1.40, 
95% CI 1.01 to 1.92). No association was found between plasma fibrinogen levels and 
SVD.
Our study provides evidence for an association of common variation in the FGG and 
FGA genes with cerebral SVD. It is possible that the structure of the fibrin clot rather than 
plasma fibrinogen levels plays a role in the pathogenesis of cerebral SVD.
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INTRODUCTION
Silent brain infarcts and cerebral white matter lesions are commonly detected on brain 
imaging in the elderly. Both result from small vessel disease (SVD) and have been 
associated with an increased risk of stroke and dementia.1 The pathogenesis of SVD is 
incompletely understood. Established risk factors are age and hypertension, although 
inflammatory, haemostatic and endothelial factors have also been implicated in the 
development of SVD.2-3
Fibrinogen has both inflammatory and haemostatic properties, and higher plasma 
levels have been associated with an increased risk of coronary artery disease, ischaemic 
stroke and dementia.4-5 Also, there is increasing evidence that altered structure of the 
fibrin clot may be involved in the pathogenesis of atherosclerosis and thrombotic disease.6 
Genetic and environmental influences contribute to the variation in plasma fibrinogen 
concentration and fibrin clot structure. Fibrinogen is primarily synthesised by hepatocytes 
and consists of two symmetric sets of three chains (Aa, Bb and g), encoded by three 
separate genes, fibrinogen a (FGA), fibrinogen b (FGB) and fibrinogen g (FGG), clustered 
on chromosome 4. The FGB gene is thought to be involved in determining fibrinogen 
plasma levels while the FGA and FGG genes are believed to play a role in regulating fibrin 
clot structure.7
We hypothesised a role for both fibrinogen plasma levels and clot structure in 
the pathogenesis of SVD. Therefore, we investigated the association between levels 
of fibrinogen in plasma and the presence of SVD, including silent brain infarcts and 
periventricular and subcortical white matter lesions, on MRI of the brain. In addition, 
we investigated the association between common variations in FGG, FGA and FGB 
genes, which are associated with fibrin clot structure and fibrinogen levels, and SVD. We 
performed the study as part of the Rotterdam Scan Study, a population based imaging 
study among those aged between 60 and 90 years.
METHODS
Study population
The Rotterdam Scan Study was designed to study causes and consequences of brain 
changes in the elderly.8 In 1995–1996, participants aged 60–90 years were randomly 
selected in strata of age (5 years) and sex from two large ongoing population based studies, 
the Zoetermeer Study and the Rotterdam Study.9 A total of 1077 non-demented elderly 
2
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subjects participated in the study (overall response 63%). The medical ethics committee 
of Erasmus Medical Centre approved the study and all participants gave informed consent.
Measurement of fibrinogen levels
Plasma concentrations of fibrinogen were determined in citrated plasma that was stored 
at –80°C. Prior to measurement, plasma samples were thawed at 37°C for 10 min. 
The method used was based on the Von Clauss10 clotting rate assay (Fibrinogen-C kit; 
Instrumentation Laboratory, Breda, The Netherlands) and performed on an Automated 
Coagulation Laboratory (ACL 300; Instrumentation Laboratory).
Measurement covariates
We obtained information on the following variables by interview and physical examination 
in 1995–1996: systolic blood pressure, diastolic blood pressure, body mass index, smoking 
and carotid intima thickness as a measure of carotid atherosclerosis.11-12
Single nucleotide polymorphisms selection and genotyping
The Seattle Single Nucleotide Polymorphisms (SNPs) programme for Genomic 
Applications has identified various SNPs in the FGG and FGA genes and the common 
haplotypes can be identified by haplotype tagging SNPs. By genotyping seven haplotype 
tagging SNPs, we were able to infer haplotypes and describe the common variation across 
the FGG and FGA genes. The length (total number of SNPs known to date) of the FGG 
and FGA genes are 8.6 kb (64 SNPs) and 7.6 kb (44 SNPs), respectively. We genotyped 
in the FGG and FGA genes the FGG 5836 G>A (rs2066860, intron 7), FGG 7874 G>A 
(rs2066861, intron 8), FGG 9340 T>C (rs1049636, intron 9), FGA 2224 G>A (rs2070011, 
exon 1), FGA 3655 G>A (rs2070014, intron 2), FGA 3807 T>C (rs2070016, intron 2) and 
the FGA 6534 A>G (rs6050, exon 5) polymorphisms that tag haplotypes covering the total 
common variation in the FGG and FGA genes. In addition, we genotyped the functional 
–148 C>T polymorphism (rs1800787) in the FGB gene that has been shown to directly 
affect FGB promoter activity.13 The FGB gene has a length of 8.1 kb and to date 75 SNPs 
have been identified. All polymorphisms have been described at http://www.ncbi.nlm.nih.
gov/SNP.
DNA was isolated using standard procedures and genotyping was performed using 
baseline samples stored at –80°C. Genotypes were determined in 2 ng genomic DNA 
with the Taqman allelic discrimination assay (Applied Biosystems, Foster City, California, 
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USA). Primer and probe sequences were designed using the SNP assay by design service 
of Applied Biosystems. Reactions were performed with the Taqman Prism 7900HT 384 
wells format in 2 μLof reaction volume.
Haplotype alleles present in the population were inferred by means of the haplo.em 
function of the program Haplo Stats (http://cran.r-project.org/web/packages/haplo.stats/
index.html), which computes maximum likelihood estimates of haplotype probabilities.14-15 
Information on all SNPs was available for 899 persons.
Outcome measures on MRI
All participants underwent MRI of the brain in 1995–1996. Axial T1 weighted, T2 weighted 
and proton density scans on 1.5T MRI scanners (for participants from Zoetermeer: MR 
Gyroscan, Philips, Best, the Netherlands and for participants from Rotterdam: MR 
VISION, Siemens, Erlangen, Germany) were made. Slice thickness was 5 or 6 mm, with 
an interslice gap of 20%.
Infarcts were defined as focal hyperintensities on T2 weighted images, 3 mm 
in size or larger. Proton density scans were used to distinguish infarcts from dilated 
perivascular spaces. Lesions in the white matter also had to have corresponding prominent 
hypointensities on T1 weighted images in order to distinguish them from cerebral 
white matter lesions. A history of stroke and transient ischaemic attack was obtained by 
self-report, and by checking medical records in all 1,077 participants. An experienced 
neurologist (PJK) subsequently reviewed the medical history and scans and categorized 
the infarcts as silent or symptomatic. Silent brain infarcts were defined as evidence of 
one or more infarcts on MRI, without a history of a (corresponding) stroke or transient 
ischaemic attack. Participants with both symptomatic and silent infarcts were categorised 
in the symptomatic infarct group.
White matter lesions were considered present if visible as hyperintense on proton 
density and T2 weighted images, without prominent hypointensity on T1 weighted scans. 
Two raters independently scored periventricular and subcortical located white matter 
lesions. Both intra-reader and inter-reader studies (n=100) showed good to excellent 
agreement (k=0.79–0.90, r=0.88–0.95). A detailed description of the scoring method has 
been reported previously.16 Briefly, severity of periventricular white matter lesions was 
rated semiquantitatively at three regions (grade 0–9). A total volume of subcortical white 
matter lesions was based on the approximate number and size of the lesions in the frontal, 
parietal, occipital and temporal lobes (volume range 0–29.5 ml).
2
Elim_Ch_thesis2.indd   33 5/21/12   11:00 AM
34
Chapter 2
Data analysis
Because of the skewed distribution of fibrinogen levels, we used log transformed fibrinogen 
in the analyses. We examined the association of levels of fibrinogen with the presence of 
silent brain infarcts and periventricular and subcortical white matter lesions (third tertile 
versus the lower tertile of the distribution) by means of logistic regression models, adjusted 
for age and sex. Only for the analyses on silent brain infarcts did we exclude persons 
with symptomatic brain infarcts. We examined the associations per standard deviation 
(SD) increase in log transformed fibrinogen and in quartiles using the lowest quartile 
as the reference category. In addition, we adjusted for cardiovascular factors, including 
systolic and diastolic blood pressure, body mass index, current smoking and carotid intima 
thickness.
Hardy–Weinberg equilibrium of fibrinogen polymorphisms was tested using c2 tests. 
We examined the association of the –148 C>T FGB promoter polymorphism with the 
presence of silent brain infarcts and periventricular and subcortical white matter lesions 
(third tertile versus the lower tertile of the distribution) by means of logistic regression 
models, using the CC genotype as the reference category. To test the associations of 
haplotypes of the FGG and FGA genes with levels of fibrinogen, silent brain infarcts 
and white matter lesions, we used the program Haplo Stats (http://cran.r-project.org/web/
packages/haplo.stats/index.html).14-15, 17 The probability for each haplotype pair in each 
individual was assigned and then an individual’s phenotype was directly modelled as a 
function of each inferred haplotype pair, weighed by their estimated probability, to account 
for haplotype ambiguity. The association between fibrinogen haplotypes and fibrinogen 
levels, silent brain infarction and white matter lesions was examined by means of the 
haplo.glm function of Haplo Stats.14 This approach is based on generalised linear model, 
and computes the regression of a trait on haplotypes and other covariates. In these analyses 
the most frequent haplotype was used as the reference category. It is important to note 
that in this type of analysis, haplotypes rather than subjects are used as the exposure. We 
adjusted for age and sex, and additionally for cardiovascular factors. As plasma fibrinogen 
levels are an important determinant of clot structure we repeated the analyses adjusting for 
plasma fibrinogen. An interaction between fibrinogen levels and clot structure on disease 
risk has been suggested. Therefore, we repeated the analyses stratifying on high levels 
(above the median) and low levels (below the median) of fibrinogen.
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RESULTS
We identified 213 persons (mean age 75.5 (SD 7.0) years, 58.0% female) with silent brain 
infarcts on brain MRI, most of which had lacunar infarcts (n=198), 358 persons (mean 
age 76.2 (SD 7.3), 54.0% female) with subcortical white matter lesions and 327 (mean 
age 76.7 (SD 7.1) years, 56.0% female) with periventricular white matter lesions. The 
baseline characteristics of the total study population are shown in Table 1. Table 2 shows 
the constructed haplotypes and their frequencies in our population.
Table 1. Baseline characteristics of the study population (n=1,077)
Characteristic  
Mean age (y) 72.2
Sex (female) (%) 52
Body mass index (kg/m2) 26.7 (3.6)
Systolic blood pressure (mm Hg) 147.3 (21.6)
Diastolic blood pressure (mm Hg) 78.7 (11.7)
Intima media thickness (mm) 0.9 (0.2)
Current smokers (%) 17
Diabetes mellitus (%) 7
Fibrinogen (g/L)* 3.7 (3.2–4.4)
-148 C>T FGB (n (%))
   CC genotype 662 (65.4)
   CT genotype 303 (29.9)
   TT genotype 47 (4.6)
Values are mean (SD), unless otherwise stated.
*Because of skewed distribution, median (interquartile range) is given.
Levels of log transformed fibrinogen were not associated with silent brain infarcts or 
white matter lesions on MRI (Table 3). This did not change after additional adjustment for 
cardiovascular factors or when only lacunar infarcts (n=198) were analysed. All individual 
polymorphisms were in Hardy–Weinberg equilibrium.
No significant association was found between the –148 C>T FGB polymorphism and 
SVD. Compared with the CC genotype (reference), the age and sex adjusted odds ratio (OR) 
(95% confidence interval (CI)) for the presence of silent brain infarcts for the CT genotype 
was 1.36 (0.96 to 1.92) and 1.30 (0.61 to 2.78) for the TT genotype (p for trend 0.10). 
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Table 2. Construction of haplotypes and their frequencies 
FGG gene FGA gene
Haplotype 5836G>Ars2066860 
7874G>A
rs2066861 
9340T>C
rs1049636 
2224G>A
rs2070011 
3655G>A
rs2070014 
3807T>C
rs2070016 
6534A>G
rs6050 Frequency
1 G G T G G T A 0.26
2 G A T A G T G 0.25
3 G G C G A T A 0.18
4 G G T G G C A 0.13
5 G G C A G T A 0.11
6 A G T G G T A 0.03
7 G G T A G T G 0.01
FGA, fibrinogen a gene; FGG, fibrinogen g gene.
Table 3. 
Association of fibrinogen with silent brain infarcts, periventricular and subcortical white matter lesions. 
Silent brain infarcts
OR (95% CI)
Periventricular white 
matter lesions
OR (95% CI)
Subcortical white 
matter lesions
OR (95% CI)
Log transformed 
fibrinogen per SD
1.03 (0.88-1.22) 0.98 (0.84-1.14) 0.94 (0.81-1.09)
1st quartile 1.00 (ref) 1.00 (ref) 1.00 (ref)
2nd quartile 1.47 (0.90-2.33) 0.85 (0.55-1.33) 1.13 (0.74-1.71)
3rd quartile 1.43 (0.89-2.31) 1.00 (0.65-1.54) 1.03 (0.68-1.57)
4th quartile 1.07 (0.65-1.74) 0.88 (0.57-1.37) 0.83 (0.54-1.27)
OR and 95% CI adjusted for age and sex.
 
Table 4. Association of haplotypes of the FGG and FGA gene with silent brain infarcts, periventricular and 
subcortical white matter lesions. 
Haplotype
Silent brain infarcts
OR (95% CI) 
Periventricular 
white matter lesions
OR (95% CI) 
Subcortical white 
matter lesions
OR (95% CI)
1 1.00 (ref) 1.00 (ref) 1.00 (ref)
2 1.41 (1.03-1.94) 1.29 (0.96-1.72) 0.90 (0.67-1.19)
3 1.33 (0.93-1.89) 1.40 (1.01-1.92) 0.87 (0.64-1.20)
4 1.39 (0.94-2.05) 1.25 (0.87-1.79) 0.95 (0.74-1.42)
5 1.30 (0.85-2.00) 1.08 (0.73-1.60) 0.76 (0.52-1.12)
6 0.43 (0.16-1.14) 0.99 (0.49-1.99) 0.66 (0.33-1.33)
7 1.03 (0.28-3.76) 2.08 (0.75-5.77) 0.98 (0.35-2.77)
OR and 95% CI adjusted for age and sex. 
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The age and sex adjusted OR (95% CI) for periventricular white matter lesions was 1.03 
(0.75 to 1.42) for the CT genotype and 1.26 (0.64 to 2.48) for the TT genotype (p for trend 
0.60). The age and sex adjusted OR (95% CI) for subcortical white matter lesions was 
1.12 (0.82 to 1.53) for the CT genotype and 0.74 (0.36 to 1.50) for the TT genotype (p for 
trend 0.99). These estimates did not change after additional adjustments for cardiovascular 
factors. The –148 C>T FGB polymorphism was not associated with fibrinogen levels in 
our population. The age and sex adjusted mean of log transformed fibrinogen (95% CI) 
was 1.33 (1.31 to 1.35) for the CC genotype, 1.34 (1.31 to 1.37) for the CT genotype and 
1.37 (1.30 to 1.44) for the TT genotype.
Haplotype reconstruction of the FGG and FGA genes resulted in 26 haplotypes, but 
only seven haplotypes had a frequency of >0.01 in our population. We disregarded 19 
rare haplotypes with a frequency <1%, adding up to a total frequency of 3.8%. Haplotype 
alleles were coded as haplotype numbers 1 to 7 in order of decreasing frequency in the 
population (coding from 5836 G>A, 7874 G>A, 9340 T>C, 2224 G>A, 3655 G>A, 3807 
T>C, 6534 A>G, haplotype 1=G-G-T-G-G-T-A, haplotype 2=G-A-T-A-G-T-G, haplotype 
3=G-G-C-G-A-T-A, haplotype 4=G-G-T-G-G-C-A, haplotype 5=G-G-C-A-G-T-A, 
haplotype 6=A-G-T-G-G-T-A and haplotype 7=G-G-T-A-G-T-G). Haplotype analyses 
were based on 899 participants for whom information on all SNPs was available.
Compared with haplotype 1, haplotype 2 was associated with a higher prevalence 
of silent brain infarcts and haplotype 3 was associated with more periventricular white 
matter lesions in the highest tertile of the distribution (Table 4). Additional adjustment 
for cardiovascular factors did not markedly change the associations. If anything, they got 
stronger (OR (95% CI) for silent brain infarcts (haplotype 2) 1.48 (1.08 to 2.03) and for 
periventricular white matter lesions (haplotype 3) 1.42 (1.02 to 1.96)). Analysing lacunar 
infarcts only (n=198) gave similar results.
No association was found between haplotypes and plasma levels of fibrinogen, and 
adjustment for plasma fibrinogen did not change the estimates. Stratifying on high and low 
plasma fibrinogen also did not change the associations.
2
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DISCUSSION
In this study, common variation in the FGG and FGA genes was associated with the 
presence of silent brain infarcts and periventricular white matter lesions on brain MRI. 
No associations were found between levels of fibrinogen or the –148 C>T FGB promoter 
polymorphism and silent brain infarcts or white matter lesions. Haplotypes of the FGG, 
FGA and FGB genes were not associated with fibrinogen levels.
Although an association between plasma fibrinogen levels and SVD has been 
suggested,18 we were not able to confirm this finding. In addition, no association was 
found between the –148 C>T FGB promoter polymorphism and SVD. This is in contrast 
with a previous study by Martiskainen et al. that reported an association between the –455 
G>A FGB promoter polymorphism, which is in perfect linkage disequilibrium (r2=1) with 
the –148 C>T polymorphism, and lacunar infarction.19 However, no fibrinogen levels were 
available in this study. Also, the study by Martiskainen et al. included only stroke patients 
while the Rotterdam Scan Study is population based, which may account for differences 
in results. Several other studies focused on the possible association between the –148 C>T 
polymorphism and ischaemic stroke, and their results were inconclusive.20–22 It should 
be noted that in our population the –148 C>T FGB polymorphism was not significantly 
associated with fibrinogen levels. In an elderly population such as ours, the effects of the 
–148 C>T polymorphism on fibrinogen levels may be attenuated. Recently, such a decrease 
in raising effect on fibrinogen levels was shown for the –455 G>A polymorphism.23
The lack of an association between FGG and FGA haplotypes and plasma levels of 
fibrinogen is in line with previous findings.24-25
To date, no study has examined common genetic variation in FGG and FGA in 
relation to cerebrovascular disease. However, common variation in these genes has been 
associated with other manifestations of vascular disease, independent of fibrinogen levels. 
Recently, Uitte de Willige et al. studied haplotypes that describe the common variation in 
the FGG, FGA and FGB genes in relation to the risk of deep venous thrombosis.25 The 
haplotype of FGG (FGG-H2), tagged by 7874 G>A (rs2066861) and comparable with 
haplotype 2 in our study, was associated with an increased risk of deep venous thrombosis. 
A study by Mannila et al. reported an association between haplotypes containing FGG 
SNP 9340 T>C (rs1049636; in their study named 1299+79 T>C), that tags haplotype 3 
in our study, and FGA SNP 2224 (rs2070011; in their study named –58 G>A), that tags 
haplotype 2 in our study, and the risk of myocardial infarction.24 Several studies have 
examined individual polymorphisms in the FGG and FGA genes and vascular disease risk. 
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The 6534 A>G (rs6050; also referred to as Thr312Ala) polymorphism in the FGA gene 
has been associated with venous thromboembolism, pulmonary embolism and post-stroke 
mortality among patients with atrial fibrillation.26-27
Although not associated with fibrinogen levels, there is evidence that variation in the 
FGA and FGG genes has functional implications. Uitte de Willige et al. reported that the 
FGG-H2 was associated with reduced levels of fibrinogen g′ (and a reduced g′/g ratio), 
a product of alternative splicing of the FGG gene. It is not clear how this reduced ratio 
influences fibrin formation and degradation. Several studies have provided evidence for 
a role of plasma fibrinogen g′ in disease risk.28-29 Recently, Mannila et al. showed that the 
FGA 2224G>A SNP constitutes an independent determinant of fibrin clot porosity and is 
involved in epistatic interactions on plasma fibrinogen concentration.30
Also, evidence for a functional role of the FGA 6534 A>G SNP exists. This SNP 
occurs in a region important for FXIII dependent cross linking processes and may affect 
fibrin clot structure or stiffness. It is not clear how this increase in clot stiffness leads 
to a tendency to embolise. Perhaps stiffer clots are more brittle, leading to an increased 
tendency to fragmentize under conditions of blood flow.7,31 Interestingly, the FGA SNP 
2224 G>A in the study by Mannila et al. and the FGG-H2 haplotype in the study by Uitte 
de Willige et al. are in strong linkage disequilibrium with the 6534 A>G polymorphism.
In our study, common variation in the FGG and FGA genes was associated with 
silent brain infarcts and periventricular white matter lesions, but not with subcortical 
white matter lesions. It has previously been suggested that different pathophysiological 
mechanisms may underlie periventricular and subcortical white matter lesions.32-33 For 
example, atrial fibrillation has been found to be predominantly related to periventricular 
white matter lesions.34 A possible explanation for this may be that periventricular white 
matter is an arterial border zone and therefore more vulnerable while the subcortical white 
matter is better vascularised.35
In conclusion, in this population based imaging study, we found that common variation 
in the FGG and FGA genes of fibrinogen was associated with SVD on brain MRI. As this 
is the first report, our study needs to be replicated. Also, more functional studies need to 
be performed to elucidate the mechanism through which these genes influence the risk of 
vascular disease. Our findings suggest that mechanisms related to fibrin clot structure are 
involved in the pathogenesis of SVD rather than plasma concentration of fibrinogen.
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ABSTRACT
Both inflammatory and hemostatic factors have been implicated in the pathogenesis 
of dementia. Previously we reported an association between higher plasma levels of 
fibrinogen and an increased risk of dementia. Whether fibrin clot structure plays a role in 
development of dementia is not known. We examined the association between variation 
in fibrinogen genes involved in fibrin clot structure (fibrinogen γ (FGG) and α (FGA)) and 
dementia. 
The study was performed within the Rotterdam Study, a prospective population-based 
study among 7,983 persons of 55 years and over, ongoing since 1990. Seven tagging 
single nucleotide polymorphisms (SNPs) in the FGG and FGA genes were determined 
in blood samples drawn at the baseline examination (1990-1993). Until January 1st 2005, 
743 dementia patients were identified. We examined the association between constructed 
haplotypes and dementia by means of logistic regression models.  
Seven haplotypes (frequency >0.01) that describe the total common variation in FGG 
and FGA genes were constructed. Compared with the most frequent haplotype 1 (G-G-
T-G-G-T-A) no association was found between haplotypes and dementia or Alzheimer’s 
disease. 
Our findings suggest that common variation in the FGG and FGA genes is not an 
important risk factor for dementia.  
Elim_Ch_thesis2.indd   44 5/21/12   11:00 AM
45
Haplotypes in the fibrinogen gene and dementia
INTRODUCTION  
Both inflammatory and hemostatic factors have been implicated in the pathogenesis 
of dementia.1, 2 We recently reported an association between higher plasma levels of 
fibrinogen, which has inflammatory and hemostatic properties, and an increased risk of 
dementia, both Alzheimer’s disease and vascular dementia.3 
Fibrinogen is primarily synthesized by hepatocytes and consists of two symmetric sets 
of 3 chains (Aα, Bβ and γ), encoded by 3 separate genes, fibrinogen α (FGA), fibrinogen 
β (FGB) and fibrinogen γ (FGG) clustered on chromosome 4. The FGB gene is thought 
to be involved in determining fibrinogen plasma levels whereas FGG and FGA genes are 
believed to play a role in regulating fibrin clot structure.4 
There is evidence that altered structure of the fibrin clot may be involved in the 
pathogenesis of vascular disease.5 In a previous study performed in the Rotterdam Scan 
Study we found an association of haplotypes of the FGG and FGA gene with cerebral 
small vessel disease as assessed with brain imaging. Since vascular disease, including 
cerebral small vessel disease, is associated with dementia and Alzheimer’s disease we 
hypothesized an association between altered fibrin clot structure and dementia.
In this study, we set out to investigate whether common variation in the FGG and 
FGA genes that are involved in regulating clot structure is associated with an increased 
risk of dementia and Alzheimer’s disease. The study was performed in the Rotterdam 
Study, a population-based prospective cohort study among persons of 55 years and over. 
METHODS
The Rotterdam Study is a population-based prospective cohort study among 7,983 persons 
of 55 years and over six baseline examinations (1990-1993) and follow-up examinations 
(1993-1994, 1997-1999 and 2002-2004) included physical examinations, screening and 
clinical work-up for dementia. The Medical Ethics Committee of the Erasmus Medical 
Center approved the study and written informed consent was obtained from all participants. 
Through linkage with records of general practitioners, the total cohort was continuously 
monitored for morbidity and mortality. This resulted in a virtually complete follow-up 
until January 1, 2005. 
The Seattle SNPs program for Genomic Applications has identified various SNPs in 
the FGG and FGA genes and the common haplotypes can be identified by haplotype tagging 
SNPs. By genotyping seven haplotype tagging SNPs we were able to infer haplotypes 
3
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and describe the common variation across the FGG and FGA genes. In the FGG and 
FGA gene the FGG 5836 G>A (rs2066860), FGG 7874 G>A (rs2066861), FGG 9340 
T>C (rs1049636), FGA 2224 G>A (rs2070011), FGA 3655 G>A (rs2070014), FGA 3807 
T>C (rs2070016) and the FGA 6534 A>G (rs6050) polymorphisms that tag haplotypes 
describing the total common variation in the FGG and FGA gene were genotyped. These 
polymorphisms have also been described at http://www.ncbi.nlm.nih.gov/SNP. 
DNA was isolated using standard procedures and genotyping was performed using 
baseline samples stored at -80º Celcius. Genotypes were determined in 2 ng genomic DNA 
with the Taqman allelic discrimination assay (Applied Biosystems, Foster City, California, 
USA). Primer and probe sequences were optimized by using the SNP-assay-by design 
service of Applied Biosystems. Reactions were performed with the Taqman Prism 7900HT 
384 wells format in the 384-wells plate (Greiner Bio-One) in 2 μL of reaction volume.
Haplotype alleles present in the population were inferred by means of the haplo.em 
function of the program Haplo Stats (http://cran.r-project.org/src/contrib/Descriptions/
haplo.stats.html), which computes maximum likelihood estimates of haplotype 
probabilities.7, 8 Information on all SNPs was available in 5,538 persons.
The diagnosis of dementia and subtypes of dementia was made following a three-step 
protocol as described previously.9 We used internationally accepted criteria for dementia 
(DSM-IIIR),10 Alzheimer’s disease (NINCDS-ADRDA),11 and vascular dementia 
(NINDS-AIREN).12 
Data analysis
Hardy-Weinberg equilibrium of fibrinogen polymorphisms was tested by means of 
Chi square tests. To test the associations of fibrinogen haplotypes with dementia and 
Alzheimer’s disease we used the program Haplo Stats (http://cran.r-project.org/src/
contrib/Descriptions/haplo.stats.html).7, 8, 13 The probability for each haplotype pair in each 
individual was assigned and then an individual’s phenotype was directly modeled as a 
function of each inferred haplotype pair, weighed by their estimated probability, to account 
for haplotype ambiguity. The association between fibrinogen haplotypes and dementia 
was examined by means of the haplo.glm function of Haplo Stats. This approach is based 
on generalized linear model, and computes the regression of a trait on haplotypes and 
other covariates. In these analyses the most frequent haplotype was used as the reference 
category. We adjusted for age and sex in the analyses. Because of low numbers, we were 
not able to assess the associations with vascular dementia.
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RESULTS
In the study population at risk of dementia with complete data on haplotypes, we identified 
563 patients with dementia, including 440 patients with Alzheimer’s disease and 63 with 
vascular dementia. The baseline characteristics of the study population are shown in 
Table 1. All individual polymorphisms were in Hardy-Weinberg equilibrium. Haplotype 
reconstruction resulted in 24 haplotypes, but only seven had a frequency of >0.01 in our 
population. Haplotype alleles were coded as haplotype numbers 1 through 7 in order of 
decreasing frequency in the population (coding from 5836 G>A, 7874 G>A, 9340 T>C, 
2224 G>A, 3655 G>A, 3807 T>C, 6534 A>G, haplotype 1=G-G-T-G-G-T-A, haplotype 
2=G-A-T-A-G-T-G, haplotype 3=G-G-C-G-A-T-A, haplotype 4=G-G-T-G-G-C-A, 
haplotype 5=G-G-C-A-G-T-A, haplotype 6=A-G-T-G-G-T-A and haplotype 7=G-G-T-A-
G-T-G). Table 2 shows the constructed haplotypes and their frequencies in our population.
We did not find associations of haplotypes with dementia or Alzheimer’s disease 
(Table 3). 
Table 1. Baseline characteristics of the study population (n=5,538)
Age, years 69.0 (8.7)
Sex, female, % 58.9
Current smokers, % 23.0
Presence of an APOE ε4 allele, % 24.8
Body mass index, kg/m2 26.4 (4.0)
Systolic blood pressure, mmHg 139.4 (22.1)
Diastolic blood pressure, mmHg 73.9 (11.4)
Total cholesterol, mM 6.6 (1.2)
High density lipid (HDL) cholesterol, mM 1.3 (0.4)
Diabetes mellitus, % 10.0
Intima media thickness (IMT), mm 0.79 (0.16)
Fibrinogen, g/L* 2.7 (2.3-3.2)
Values are mean (SD), unless otherwise stated. *Because of skewed distribution, median (interquartile 
range) is given. 
3
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Table 2. Construction of haplotypes and their frequencies 
FGG gene FGA gene
Haplotype
5836G>A
rs2066860
7874G>A
rs2066861
9340T>C
rs1049636
2224G>A
rs2070011
3655G>A
rs2070014
3807T>C
rs2070016
6534A>G
rs6050
Frequency
1 G G T G G T A 0.26
2 G A T A G T G 0.26
3 G G C G A T A 0.17
4 G G T G G C A 0.12
5 G G C A G T A 0.12
6 A G T G G T A 0.04
7 G G T A G T G 0.01
FGA, fibrinogen a gene; FGG, fibrinogen g gene.
Table 3. The association of haplotypes in the FGA and FGG genes with dementia and subtypes of dementia. 
Haplotype OR (95% CI) for dementia OR (95% CI) for 
Alzheimer’s disease
1 1.00 (ref) 1.00 (ref)
2 0.91 (0.75-1.08) 0.86 (0.71-1.04)
3 0.89 (0.73-1.09) 0.83 (0.67-1.03)
4 0.89 (0.72-1.11) 0.93 (0.74-1.18)
5 0.89 (0.71-1.12) 0.84 (0.65-1.07)
6 1.02 (0.72-1.45) 1.11 (0.77-1.61)
7 1.13 (0.63-2.02) 0.89 (0.79-1.01)
OR and 95% CI adjusted for age and sex.
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DISCUSSION
In this large population-based prospective study, we did not find an association between 
common variation in the FGG and FGA genes and dementia or Alzheimer’s disease. 
Though not associated with fibrinogen plasma levels, functional implications of 
variation in FGG and FGA on fibrin clot structure and stability that may explain an 
association with vascular disease have been described.14, 15 Recently, several studies 
reported an association between common variation in these genes and vascular disease, 
including myocardial infarction14 and venous thrombosis.16 In the Rotterdam Scan Study, 
we found an association of haplotypes in the FGG and FGA gene with presence of silent 
brain infarcts and periventricular white matter lesions. 
This is the first study to examine common genetic variation in FGG and FGA in 
relation to dementia. We cannot exclude that we have missed small haplotypes effects 
despite the large number of dementia cases in our sample. Also, the association with 
vascular dementia could not be studied because of low numbers.
To conclude, our findings suggest that common variation in the FGG and FGA genes 
is not an important risk factor for dementia.  
3
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ABSTRACT
Haplotypes of the fibrinogen gamma and alpha (FGG and FGA) genes are associated 
with the structure of the fibrin network and may therefore influence the risk of stroke. We 
investigated the relationship between common variation in these genes with ischemic and 
hemorrhagic stroke. 
The study was based on 6275 participants of the prospective population-based 
Rotterdam Study who at baseline (1990-1993) were aged 55 years or over, free from 
stroke, and had successful assessment of at least one FGG or FGA single nucleotide 
polymorphisms (SNP). Common haplotypes were estimated using seven tagging SNPs 
across a 30 kb region containing the FGG and FGA genes. Follow-up for incident stroke 
was complete until January 1, 2005. Associations between constructed haplotypes and risk 
of stroke were estimated with an age and sex adjusted logistic regression model. 
We observed 668 strokes, of which 393 were ischemic and 62 hemorrhagic, during a 
median follow-up time of 10.1 years. FGG+FGA haplotype 3 (H3) was associated with an 
increased risk of ischemic stroke (odds ratio (OR) 1.36, 95% confidence interval (CI) 1.09-
1.69) and the risk estimate for hemorrhagic stroke was 0.71 (95% CI 0.46-1.09) compared 
to the most frequent H1. The FGG and FGA genes were not associated with stroke or its 
subtypes when analyzed separately. 
In conclusion, risk of ischemic stroke was higher in FGG+FGA H3 than in H1. 
The results suggested that an opposite association may exist for hemorrhagic stroke. 
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INTRODUCTION
Fibrinogen is an important coagulation factor and its levels increase 2-4 times during acute 
phase reactions. The fibrinogen molecule comprises two identical disulphide-linked halves, 
each consisting of three polypeptide chains termed Aa, Bb and g,1 which are encoded by 
the fibrinogen alpha (FGA), fibrinogen beta (FGB) and fibrinogen gamma (FGG) genes, 
respectively, on chromosome 4.2 At the final stage of the coagulation cascade, thrombin 
cleaves fibrinopeptide A and B from the amino termini of the fibrinogen Aa and Bb 
chains, converting the soluble fibrinogen into fibrin monomers, which then polymerize to 
an insoluble fibrin clot. 
Many prospective studies have confirmed that high total fibrinogen levels are 
associated with an increased risk of ischemic heart disease and stroke,3-5 but it is still 
unclear whether fibrinogen is only an inflammatory marker of underlying atherosclerosis or 
whether it also directly contributes to the progression of cardiovascular disease (CVD) via 
effects on coagulation and/or atherogenesis.6 One of the mechanisms by which fibrinogen 
can influence the pathogenesis of atherosclerosis is the structure of the fibrin clot.7-8
To determine whether fibrinogen is causally involved in stroke risk can be done 
using the approach of Mendelian randomization.9 Briefly, when a variable is genetically 
determined and also associated with disease, an association between genetic variation and 
disease is expected. It has already been reported that the fibrin clot structure is partly 
determined by genetic factors.10-11 that a number of single nucleotide polymorphisms 
(SNPs) in the FGG and FGA genes are associated with fibrinogen levels, functions and 
clot structure.7,12-15 which are variables that have been associated with CVD.16-18 Therefore, 
studies on genetic variation provide an opportunity to further investigate the involvement 
of fibrinogen in stroke. Since variations in both the FGG and the FGA gene are reported to 
be associated with fibrin clot structure, we focused this research project on the variation in 
the FGG and FGA genes. The aim of our study was to investigate the association between 
common genetic variations in the fibrinogen FGG and FGA genes and risk of stroke in the 
Rotterdam Study, a large, prospective, population-based cohort study. 
STUDY DESIGN AND METHODS
Study population
The present study is part of the Rotterdam Study, a population-based cohort study on chronic 
and disabling diseases. The design of this study has been described in detail previously.19 
4
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All inhabitants of Ommoord, a district of the city of Rotterdam in the Netherlands, aged 
55 years and over were invited to participate. Participation rate for the study was 78% and 
a total of 7,983 subjects participated in the study. The study was approved by the Medical 
Ethics Committee of Erasmus University Rotterdam and was performed in accordance 
with the Declaration of Helsinki. Written informed consent to retrieve information from 
treating physicians was obtained from all participants. Baseline measurements were 
obtained from 1990 through 1993 and consisted of a home interview and 2 visits to the 
research center for measurements and collection of blood. 
Single nucleotide polymorphisms (SNPs) selection and genotyping
The SeattleSNPs program for Genomic Applications (http://pga.mbt.washington.edu/) 
has identified three haplotype-tagging SNPs in FGG and four SNPs in FGA, which tag 
the total common genetic variation in these genes in Caucasians. By genotyping these 
seven haplotype tagging SNPs, we were able to infer haplotypes and describe the common 
variation within the FGG and the FGA genes and also across the FGG and FGA genes. 
We performed haplotype analysis that covers both the FGG and FGA region because high 
linkage disequilibrium between the two genes complicates assigning the risk to one of the 
genes. We genotyped the FGG 4288G>A (rs2066860), FGG 6326G>A (rs2066861), FGG 
7792T>C (rs1049636), FGA -58G>A (rs2070011), FGA 1374G>A (rs2070014), FGA 
1526T>C (rs2070016) and the FGA 4253A>G (rs6050) polymorphisms that tag haplotypes 
covering the total common variation in the FGG and FGA genes. Annotation of the SNPs 
is in accordance with the nomenclature recommendations of the Human Genome Variation 
Society using GenBank Accession Number AF350254 for FGG and AF361104 for FGA as 
reference with nucleotide +1 being the A of the ATG translation initiation codon.20 These 
polymorphisms have also been described at http://www.ncbi.nlm.nih.gov/SNP. 
DNA was isolated using standard salting-out procedures and genotyping was performed 
using baseline samples stored at -80º Celsius. Genotypes were determined in 2 ng genomic 
DNA with the 5′ nuclease/Taqman allelic discrimination assay (Applied Biosystems, 
Foster City, CA, USA). Primer and probe sequences were designed using the SNP assay-
by-design service of Applied Biosystems and are available upon request. Polymerase 
chain reactions were performed with fluorescent allele-specific oligonucleotide probes on 
GeneAmp PCR System 9700 thermal cyclers with 384 wells format in 2 μL of reaction 
volume (Applied Biosystems), and fluorescence clustered endpoint reading for allelic 
discrimination was read on an ABI Prism 7900HT sequence detection system (Applied 
Biosystems). 
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Assessment of stroke
History of stroke at baseline was positive if a stroke was reported during the baseline 
interview and confirmed by medical records. After enrollment into the Rotterdam Study, 
participants were continuously monitored for strokes through automated linkage of the 
study database with files from general practitioners and the municipality. Also nursing 
home physicians’ files and files from general practitioners of participants who moved out 
of the district were scrutinized. For reported events, additional information (including 
brain imaging) was obtained from hospital records. Research physicians discussed 
information on all potential strokes with an experienced stroke neurologist to verify all 
diagnoses. A stroke was subclassified as ischemic if a computed tomography (CT) or 
magnetic resonance imaging (MRI) scan, made within 4 weeks after the stroke occurred, 
ruled out other diagnoses, or if indirect evidence (deficit limited to 1 limb or completely 
resolved within 72 hours, atrial fibrillation in absence of anticoagulants treatment) 
pointed at an ischemic nature of the stroke. A stroke was subclassified as hemorrhagic if a 
relevant hemorrhage was shown on CT or MRI scan, or if the subject lost consciousness 
permanently or died within hours after onset of focal signs. If a stroke did not match any 
of these criteria, it was called unspecified. Follow-up was complete until January 1, 2005, 
for 98.7 % of potential person years.21
Population for analysis
Of all 7,983 Rotterdam Study participants, 261 had had a stroke before baseline and 176 
refused informed consent for retrieval of stroke follow-up data. In addition, no blood 
was available for 1,217 participants and the SNP assays failed on all seven SNPs in 54 
participants, leaving 6,275 participants eligible for the present study. Blood pressure 
was measured twice in the right arm using a random-zero sphygmomanometer, with the 
participant in a sitting position. We used the average of these 2 measurements. C-reactive 
protein, total cholesterol, high-density lipoprotein (HDL) cholesterol, and uric acid 
were measured in nonfasting baseline blood with automated enzymatic procedures. We 
considered diabetes mellitus to be present if a random or postload glucose level was 11.1 
mM or higher, or if a person used antidiabetic medication. Atrial fibrillation at baseline 
was considered to be present if it was seen on electrocardiogram (ECG) during the 
center visit or if reported in medical records. The intima-media thickness was measured 
by longitudinal two-dimensional ultrasound of the carotid artery (mean of 4 locations). 
During the home interview, smoking status and medication use were assessed.
4
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Measurement of fibrinogen
Fibrinogen levels were derived from the clotting curve of the prothrombin time assay 
using Thromborel S as a reagent on an automated coagulation laboratory (ACL 300, 
Instrumentation Laboratory). 
Haplotypes construction and data analysis
We assessed the associations between individual SNPs and risk of stroke, ischemic stroke, 
and hemorrhagic stroke with Cox proportional hazards models, adjusting for age and 
sex. Hardy-Weinberg equilibrium of each fibrinogen polymorphism was tested using Chi 
square analysis. When a minor homozygotes group contains <10 subjects (e.g. FGG4288), 
we combined the minor homozygotes with the heterozygotes. Haplotype alleles present in 
the population were inferred by means of the haplo.em function of the Haplo Stats suite 
implemented in the R package (http://cran.r-project.org/src/contrib/Descriptions/haplo.
stats.html),22-24 which computes maximum likelihood estimates of haplotype probabilities, 
accounting for missing genotype data by including in the analysis the likelihood for all 
possible genotypes for the incomplete loci. Only haplotypes with frequencies at least 5% 
were used in the analyses. The haplotypes were numbered in order of decreasing frequency 
in the population.
We calculated odds ratios (OR) for stroke in fibrinogen haplotypes relative to the 
risk of stroke in the most common fibrinogen haplotype using the Haplo Stats suite. The 
probability for each haplotype pair in each individual was assigned and then an individual’s 
phenotype was directly modeled as a function of each inferred haplotype pair, weighed 
by their estimated probability, to account for haplotype ambiguity. An estimate of the 
haplotype frequencies was based on the expectation-maximization (EM) algorithm. The 
association between fibrinogen haplotypes and risk of stroke was examined by means 
of the haplo.glm function of Haplo Stats.23 This approach is based on the binary family 
of generalized linear models, and computes the regression of a trait on haplotypes and 
other covariates. In these analyses the most frequent haplotype was used as the reference 
category. We adjusted for age and sex.
RESULTS
During on average 10.1 years of follow-up, 668 strokes occurred, of which 393 were 
classified as ischemic, 62 as hemorrhagic, and in 213 patients the stroke class was not 
specified.  The median age at start of follow-up was 68 years and 59% of participants 
were female (Table 1). The total risk of stroke was highest in subjects with plasma 
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fibrinogen levels in the highest quartile (OR 1.3, 95%CI 1.0-1.8). A similar relationship 
was observed for ischemic stroke (OR 1.3, 95%CI 0.9-1.9)(Table 2). No analyses could be 
performed for hemorrhagic stroke, since fibrinogen levels were measured in only 29 cases. 
Table 1. Baseline characteristics of study population.
Number of participants 6275
Age, yrs 68 (62-75)
Female sex, % 59
Both parents Caucasian, % 98.5
Antihypertensive drug use, % 13
Systolic blood pressure, mmHg 137 (123-153)
C-reactive protein, mg/L 1.85 (0.89-3.60)
Total cholesterol, mM 6.6 (5.8-7.4)
HDL cholesterol, mM 1.3 (1.1-1.5)
Uric acid, μmol/L 310 (267-370)
Intima-media thickness, mm 0.77 (0.68-0.88)
Body mass index, kg/m² 26.0 (23.8-28.4)
Waist to hip ratio 0.90 (0.84-0.97)
Diabetes mellitus, % 15
Ever smokers, % 65
Current smokers, % 23
Atrial fibrillation, % 5
Previous myocardial infarction, % 12
Values are percentage (%) or median (25th and 75th percentile) when appropriate.
Table 2. Relationship between plasma fibrinogen levels and risk of stroke 
Fibrinogen Stroke 
(n=340)
Ischemic stroke 
(n=192)
Quartile 1 1 1
Quartile 2 1.08 (0.78-1.52) 0.79 (0.50-1.25)
Quartile 3 1.16 (0.85-1.59) 1.25 (0.85-1.84)
Quartile 4 1.34 (0.98-1.82) 1.29 (0.86-1.92)
Per SD 1.10 (0.98-1.22) 1.13 (0.98-1.31)
Analysis in 2,583 participants, with adjustment for age and sex
4
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The genotypic distributions for all 7 haplotype-tagging SNPs were in Hardy-Weinberg 
equilibrium. A total of 6.7% of subjects had 1 or 2 missing FGG or FGA SNPs and were 
included in the haplotype analysis, 1.8% of subjects was excluded because they had 3-6 
missing SNPs. Analyses of the single SNPs in the FGG and FGA showed a slightly increased 
risk for ischemic stroke in carriers of the A-allele of the FGG4288, but no association was 
seen between the other variants and risk of stroke (Supplementary Table 1). 
 
Supplementary Table 1. Association between individual SNPs in FGG and FGA and risk of stroke.  
SNP Genotype Frequency
(strokes/N)
Stroke
OR (95%CI)
Ischemic stroke
OR (95%CI)
Hemorrhagic stroke
OR (95%CI)
FGG4288 GG 594/5677 1 (ref) 1 (ref) 1 (ref)
GA&AA 55/456 1.14 (0.87-1.50) 1.41 (1.01-1.96) 1.37 (0.59-3.18)
FGG6326 GG 338/3330 1 (ref) 1 (ref) 1 (ref)
GA 266/2365 1.08 (0.92-1.27) 1.10 (0.89-1.36)
0.94 (0.57-1.56)
AA 46/405 1.14 (0.84-1.55) 0.87 (0.55-1.36)
FGG7792 TT 337/3045 1 (ref) 1 (ref) 1 (ref)
TC 268/2595 0.95 (0.81-1.11) 1.19 (0.96-1.46)
0.60 (0.69-1.01)
CC 49/506 0.88 (0.65-1.19) 1.00 (0.68-1.48)
FGA-58 GG 228/2261 1 (ref) 1 (ref) 1 (ref)
GA 327/2966 1.08 (0.91-1.28) 1.09 (0.88-1.36)
1.14 (0.68-1.94)
AA 100/909 1.12 (0.88-1.41) 1.03 (0.76-1.41)
FGA1374 GG 441/4184 1 (ref) 1 (ref) 1 (ref)
GA 187/1734 1.00 (0.84-1.19) 1.20 (0.96-1.48)
0.71 (0.39-1.26)
AA 15/184 0.84 (0.50-1.40) 0.98 (0.52-1.85)
FGA1526 TT 503/4649 1 (ref) 1 (ref) 1 (ref)
TC&CC 152/1469 0.96 (0.81-1.15) 0.95 (0.75-1.20) 1.39 (0.81-2.39)
FGA4253 ThrThr 312/3156 1 (ref) 1 (ref) 1 (ref)
ThrAla 275/2422 1.14 (0.97-1.34) 1.20 (0.97-1.48)
0.75 (0.51-1.44)
AlaAla 53/455 1.21 (0.90-1.62) 0.92 (0.60-1.41)
Presented are odds ratio and 95% confidence intervals (OR, 95%CI), adjusted for age and sex.
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Three common haplotypes were inferred in FGG. The most common FGG haplotype 
(H1), which was estimated to be present in 41% of participants, was G-G-T (Supplementary 
Table 2). Two other FGG haplotypes (H2: G-G-C and H3: G-A-T) were present in more 
than 5% of the participants.  Inferring haplotypes resulted in five haplotypes in FGA, of 
which the most common FGA haplotype (H1: G-G-T-A) was estimated to be present in 
31% of participants. Four other FGA haplotypes (H2-H5) had a prevalence of at least 5%.
The risk of stroke was similar for the various FGG haplotypes:  the OR for stroke 
for FGG-H2 and FGG-H3 were 0.97 (95% CI 0.84-1.12) and 1.10 (95% CI 0.95-1.27), 
respectively, compared with FGG-H1 (Table 3). Likewise, risk of stroke was similar for 
the FGA haplotypes. When we studied only ischemic stroke, the risks in all haplotypes 
were slightly increased when compared with FGG-H1 or FGA-H1 (Table 3). Since the 
linkage disequilibrium between the FGG SNPs and the FGA SNPs was very high (D′ of 
0.94), we also constructed extended haplotypes covering both the FGG and FGA genes. 
Haplotype reconstruction resulted in five FGG+FGA haplotypes with a frequency >5%, 
and together these five haplotypes covered 93% of the total genetic variation of this region 
(Supplementary Table 2). The total risk of stroke was similar in all FGG+FGA haplotypes. 
However, when we studied only ischemic stroke we observed for FGG+FGA-H3 an 
association with an OR of 1.36 (95% CI 1.09-1.69) compared with the reference haplotype 
FGG+FGA-H1 (Table 3). When we studied only hemorrhagic stroke, we observed an 
opposite risk estimate (OR 0.71 [95% CI 0.46-1.09]), and there was only minimal overlap 
between the 95% CI for ischemic and hemorrhagic stroke in H3. Furthermore, a slightly 
increased risk estimate for ischemic stroke was seen for FGG+FGA-H2 (OR 1.20, 95% 
CI 0.98-1.46). To account for multiple testing, permutation p-values (1000 permutations) 
were computed. The p-value for the extended FGG+FGA haplotypes was 0.07 for the 
ischemic stroke group and larger for the other analyses. The results were similar in men 
and women (results not shown). In the subgroup of subjects where fibrinogen levels were 
available (n=2,583) we also analyzed the relationship between the fibrinogen haplotypes 
and plasma fibrinogen levels and no clear relationship was observed. Only H4 showed a 
3% (p=0.05) higher plasma fibrinogen level (Table 4).
4
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Supplementary Table 2. Frequency of fibrinogen FGG and FGA haplotypes separate and combined. Only 
haplotypes with frequency > 5% were studied.
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FGG H1 G G T 40.8% FGG-H1
H2 G G C 29.4% FGG*2 FGG-H3
 H3 G A T 26.1% FGG-H2
FGA H1 G G T A 30.5% FGA*1 FGA-H1 or FGA-H5
H2 A G T G 27.1% FGA*2 FGA-H2
H3 G A T A 17.3% FGA-H7
H4 G G C A 13.0% FGA-H4
 H5 A G T A 11.8% FGA*3 FGA-H3
FGG + FGA H1 G G T G G T A 26.4% FGG-FGA*1  A1
H2 G A T A G T G 25.6% A2
H3 G G C G A T A 16.8% A3
H4 G G T G G C A 12.2% A1
 H5 G G C A G T A 11.5% FGG-FGA*4  A4
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Table 3. Association between fibrinogen haplotypes and risk of any, ischemic and hemorrhagic stroke
FGG Haplotype
Stroke
OR (95%CI)
Ischemic stroke
OR (95%CI)
Hemorrhagic stroke
OR (95%CI)
H1 (GGT) 1 (ref) 1 (ref) 1 (ref)
H2 (GGC) 0.97 (0.84-1.12) 1.17 (0.98-1.40) 0.72 (0.46-1.14)
H3 (GAT) 1.10 (0.95-1.27) 1.12 (0.92-1.35) 0.88 (0.56-1.37)
FGA Haplotype
H1 (GGTA) 1 (ref) 1 (ref) 1 (ref)
H2 (AGTG) 1.10 (0.94-1.28) 1.11 (0.92-1.35) 0.92 (0.59-1.43)
H3 (GATA) 0.99 (0.83-1.18) 1.23 (0.99-1.52) 0.66 (0.37-1.18)
H4 (GGCA) 0.99 (0.81-1.20) 1.07 (0.83-1.37) 1.12 (0.66-1.91)
H5 (AGTA) 0.94 (0.77-1.16) 1.07 (0.83-1.39) 1.00 (0.56-1.79)
FGG + FGA Haplotype
H1 (GGT-GGTA) 1 (ref) 1 (ref) 1 (ref)
H2 (GAT-AGTG) 1.12 (0.96-1.32) 1.20 (0.98-1.46) 0.98 (0.68-1.41)
H3 (GGC-GATA) 1.02 (0.85-1.22) 1.36 (1.09-1.69) 0.71 (0.46-1.09)
H4 (GGT-GGCA) 1.02 (0.83-1.25) 1.18 (0.92-1.52) 1.25 (0.81-1.91)
H5 (GGC-AGTA) 0.94 (0.76-1.16) 1.14 (0.88-1.47) 0.90 (0.60-1.33)
Analysis performed in 6,275 participants; 668 strokes, 393 ischemic and 62 hemorrhagic strokes were 
observed. Presented are odds ratio and 95% confidence intervals (OR, 95%CI), with adjustment for age, 
sex, systolic blood pressure, intima-media thickness, serum C-reactive protein level, waist-hip ratio, ever 
smoking, antihypertensive drug use, history of myocardial infarction and diabetes mellitus at baseline. 
Table 4. Fibrinogen levels for FGG+FGA haplotype carriers.
Fibrinogen level*
FGG + FGA Haplotype g/L Standard error P for difference with H1*
H1 (GGT-GGTA) 2.83 0.04
H2 (GAT-AGTG) 2.83 0.05 0.87
H3 (GGC-GATA) 2.85 0.05 0.59
H4 (GGT-GGCA) 2.91 0.05 0.05
H5 (GGC-AGTA) 2.86 0.06 0.46
* Estimated with generalized linear model.  Analyses performed in 2,583 participants.
4
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DISCUSSION 
In this population-based cohort study, we observed that the risk of ischemic stroke was 
associated with FGG+FGA-Haplotype 3 and that this relationship was opposite for 
ischemic and hemorrhagic stroke. This finding strengthens the hypothesis that fibrin 
structure may be a causal factor in the development of stroke.
Strengths of our study are the prospective inclusion of the stroke cases and the 
meticulous and nearly complete follow-up (loss of potential person-years 1.3 %). To our 
knowledge, this is the first study that assessed the association between FGG and FGA 
haplotypes and risk of stroke in the general population. Our stringent stroke monitoring 
procedures allowed us to include also stroke patients who had not been referred to a 
neurologist. In the Netherlands, the general practitioners do not refer all stroke patients 
to the neurologist, and therefore in our study population, 31% of all stroke cases had not 
been referred. As neuroimaging had not been performed in these non-referred cases, we 
could subclassify only 16% of them into ischemic or hemorrhagic. In contrast, 92% of 
strokes that had been diagnosed by a neurologist could be subclassified. In total, 32% of 
all stroke cases could not be subclassfied. The study would have had a greater power for 
the subgroup analysis when all strokes would have been subclassified. 
In this study, we focused on the FGG and FGA genes, since these genes determine the 
fibrin clot structure, which is suggested to directly affect atherosclerosis and thrombotic 
disease.7,25 Although the FGG and FGA gene encode for different peptides, we decided 
to also perform a combined haplotype analysis because both the a and g chains are part 
of one single protein, fibrinogen, and their effects on fibrin structure cannot be separated. 
In addition, variants in both genes are reported to be associated with fibrin clot structure 
and functionality has been proposed for variants in both genes.17-18,26 Because there is high 
linkage disequilibrium between the two genes, the effects cannot be assigned to one of the 
genes. In our study the strongest association with stroke risk was seen when we combined 
variants in both genes. 
The FBG promoter SNPs have been much studied previously, since increased plasma 
fibrinogen levels have been identified as a consistent risk indicator for cardiovascular 
disease and stroke3-5 and the fibrinogen b chain synthesis is rate limiting step in the 
production of mature fibrinogen in vitro.27 Indeed, several studies reported that FGB 
promoter SNPs contributed to the regulation of plasma fibrinogen concentration,28 but no 
clear and consistent association was found between these SNPs and stroke.29-31 We did not 
include the FGB gene in this study because it has not been shown to be associated with 
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fibrin structure and because it is generally considered not to be associated with thrombosis 
risk.29 In the Rotterdam study, the FGB promoter SNP rs1800787 (-148C/T) was also not 
associated with risk of stroke (unpublished data).
We did not observe associations between individual SNPs in the FGG and FGA genes 
with ischemic or hemorrhagic stroke, although participants with variant SNPs were at 
slightly higher risk of ischemic stroke than participants with wild type SNPs. In studies 
with other vascular endpoints no significant association was seen between FGG-H3 and 
myocardial infarction16,32 (Supplementary Table 2) but FGG-H3 (named FGG-H2 in that 
study) was associated with increased risk of venous thrombosis.26 Moreover, FGG-H2 
was associated with the risk of myocardial infarction in one study but not in another16,32 
and not associated with risk of deep vein thrombosis (FGG-H2 was named FGG*2 or 
FGG-H3 in these studies).26 Recently, a case-control study on ischemic stroke reported that 
haplotype H5 (named A4 in that study), was associated with an increased risk and also an 
increased risk in that study was seen for H2 (named A2).33 All studies used the haplotype 
with common alleles for all SNPs as reference group.  Also reported were associations of 
single SNPs in the FGA gene (-58G>A (rs2070011) and 4253A>G (rs6050)) or FGG gene 
(7792T>C (rs1049636)) that are associated with myocardial infarction, plasma fibrinogen 
concentration or fibrin clot characteristics,7,15-18 but these SNPs were not associated with 
stroke in our study. The differences of the observed associations between genetic variation 
in FGG and FGA with stroke, myocardial infarction and deep vein thrombosis may be 
explained by differences in etiology of these endpoints, medication and methods for 
statistical analysis.
With the extended haplotypes composed of SNPs in the fibrinogen FGG and FGA 
genes, we observed an association between FGG+FGA-H3 and ischemic stroke. In only 
one previous study, Mannila and colleagues combined SNPs in the FGG and FGA genes 
and they observed a decreased risk of myocardial infarction for a haplotype combining 
FGG 7792T>C (rs1049636) and FGA -58G>A (rs2070011).16 This haplotype would cover 
our FGG+FGA-H5, and contains the rare alleles of these two SNPs, but we did not see an 
association of this haplotype with stroke.
We were able to separate ischemic and hemorrhagic stroke in the majority of our 
stroke cases. Although the group of patients with a hemorrhagic stroke was small with 
only 62 cases, it was very interesting to observe an association between FGG+FGA-H3 
and ischemic stroke and that our data suggest that an opposite association may exist for 
hemorrhagic stroke. However, these results need to be considered with great caution and 
this observation needs to be replicated in independent populations. Interestingly, opposite 
4
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associations are what one would expect if thrombosis and bleeding were important 
mechanisms in the ischemic and hemorrhagic stroke, respectively.
 In our study, the individual SNPs were not associated with risk of ischemic stroke, 
but we observed associations with ischemic stroke when we combined the SNPs and 
constructed haplotypes. This illustrates that haplotype analysis is a more powerful analysis 
when it is uncertain if functional variants are being studied or in the presence of multiple 
susceptibility alleles, in the pattern or magnitude of their allelic associations.34
It has recently been reported that the 8486C>T SNP, tagged in haplotype 
FGG+FGA-H3, affects a cleavage stimulatory factor binding site near the gA specific 
polyadenylation site and would therefore result in a relative decrease of the formation of 
fibrinogen g′ specific mRNA, thus altering the proportion of the g′ chains.35 This would 
ultimately result in a changed fibrin clot formation since g′ fibrinogen has an antithrombin 
effects because it binds thrombin, misses the platelet binding site and can bind factor 
XIII.36 It has also been shown that this SNP is associated with elevated risk of deep 
venous thrombosis by reducing plasma fibrinogen g′ levels.26 However, we did not see an 
association between this SNP and risk of stroke in this study, and also not in another case-
control study in ischemic stroke.37
In conclusion, we found a higher risk of ischemic stroke in subjects with H3 in the 
extended FGG+FGA haplotype but not in individual SNP analysis in this population-
based cohort study and that an opposite association may exist for hemorrhagic stroke. Our 
data illustrate that haplotype analysis may reveal associations with risk of stroke that may 
be missed by single SNP analysis. 
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ABSTRACT
We determined the contribution of fibrinogen γ′ levels and FGG haplotypes to ischemic 
stroke. Associations between fibrinogen γ′ levels, fibrinogen γ′/total fibrinogen ratio, and 
FGG haplotypes with the risk of ischemic stroke were determined in 124 cases and 125 
controls. Fibrinogen γ′/total fibrinogen ratio was higher in patients than in controls during 
the acute phase of the stroke and lower in the convalescent phase 3 months after the 
stroke. FGG haplotype 3 (H3) was associated with a reduced risk of ischemic stroke (odds 
ratio 0.60; 95% CI, 0.38 to 0.94), but not with the fibrinogen γ′/total fibrinogen ratio. In 
contrast, FGG-H2 was associated with a decreased fibrinogen γ′/total fibrinogen ratio, 
but not with risk of stroke. Fibrinogen γ′/total fibrinogen ratio is associated with ischemic 
stroke, especially in the acute phase of the disease. In addition, FGG-H3 haplotype appears 
to be protective against ischemic stroke. 
Table 1.   Baseline characteristics of study participants 
Patients
(n = 124)
Controls
(n = 125)
P
Demographics
    Age, years (SD) 56 (±12) 56 (±12) NS
    Sex (female) 58 (47%) 59 (47%) NS
Index event
    Stroke: TIA  115:9 NA NA
Risk factors
    Smoking 61 (49%) 37 (30%) 0.004
    Hypertension 60 (48%) 24 (19%) <0.001
    Diabetes mellitus 18 (14%) 5 (  4%) 0.004
    Hypercholesterolemia 78 (63%) 84 (67%) 0.700
    Positive family history for cardiovascular disease 75 (61%) 56 (45%) 0.013
Data for age are presented as mean±SD. Other data are counts and (percentages). SD= Standard Deviation; 
TIA= Transient Ischemic Attack; NA= Not Applicable; NS= Not Significant 
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INTRODUCTION
Fibrinogen, a central protein in the hemostatic system, has a high degree of heterogeneity 
in healthy individuals. One variant, fibrinogen γ′, carries an extended γ chain formed by 
alternative processing of the fibrinogen γ pre-mRNA and comprises 7% to 15% of the 
fibrinogen molecules. Fibrinogen γ′ has both antithrombotic (binding sites for thrombin 
and disruption of platelet binding to fibrinogen) and prothrombotic properties (binding 
site for the factor XIII B subunit).1 Associations with deep venous thrombosis (DVT)2 
and coronary artery disease3 indicate that plasma fibrinogen γ′ levels may contribute to 
the pathology of thrombotic disease. Fibrinogen γ gene (FGG) variation is associated 
with fibrinogen γ′ levels, fibrinogen γ′/total fibrinogen ratio, risk of DVT2 and myocardial 
infarction (MI).4,.5 The aim of this study was to determine the role of fibrinogen γ′ levels 
and common FGG gene variations in ischemic stroke. 
PATIENTS AND METHODS
We performed a case-control study with 124 first-ever ischemic stroke or transient ischemic 
attack (TIA) patients, and 125 population controls, aged 18 to 75 years old. The study 
design has been described previously. 6 Baseline characteristics are given in Table 1. Blood 
was collected from an unselected subgroup of 47 patients 7 to 14 days (acute phase) and 
3 months after the stroke in tubes containing 1/10 volume of 0.129 mol/L sodium citrate. 
Fibrinogen γ′ antigen levels were measured by ELISA as described previously.2 
Pooled normal plasma calibrated against purified human γ′ fibrinogen (a gift from Dr M. 
Mosesson, Blood Center of Wisconsin, Milwaukee, WI) was used as calibrator. 
Total fibrinogen levels were measured according to von Clauss, and C-reactive 
protein (CRP) was measured using an in-house ELISA with polyclonal rabbit antihuman 
CRP antibodies (DAKO). 
Genetic Analyses
We genotyped 3 haplotype-tagging single nucleotide polymorphisms (SNPs) that tag the 
total common genetic variation in FGG in whites (http://pga.gs.washington.edu). SNP 
8486C>T (rs2066865, 10034C>T by SeattleSNPs) tagged FGG haplotype 2 (H2), SNP 
7792T>C (rs1049636, 9340T>C by SeattleSNPs) tagged FGG-H3 and SNP 4288G>A 
(rs2066860, 5836G>A by SeattleSNPs) tagged FGG-H4. FGG-H1 was assigned to subjects 
who possessed the common alleles of the 3 SNPs. Annotation of the SNPs uses AF350254 
5
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as reference sequence with nucleotide +1 being the translation initiation nucleotide. We 
genotyped the 3 SNPs using 5′ nuclease/TaqMan assays (primer sequences available on 
request). 
Statistical Analyses
Differences between groups were examined by analysis of variance (ANOVA) or by 
paired-samples t test for acute phase versus convalescent phase in patients. We adjusted 
for risk factors for vascular diseases (smoking, hypertension, diabetes mellitus, and 
hyperlipidemia). The association between haplotypes, taking the haplotype ambiguity 
into account, and risk of stroke, fibrinogen γ′ level and fibrinogen γ′/total fibrinogen ratio 
were determined using Haplo.Stats version 1.2.2 (http://cran.r-project.org/src/contrib/
Descriptions/haplo.stats.html). 
RESULTS
In the acute phase of stroke, the mean plasma fibrinogen γ′ level was higher in patients 
(0.42±0.17 g/L) than in controls (0.34±0.10 g/L; P<0.001;Table 2).The fibrinogen γ′/total 
fibrinogen ratio was calculated to adjust for the acute phase increase of fibrinogen, and this 
ratio was also significantly higher in patients (0.113±0.034) than in controls (0.100±0.029; 
P=0.002; Table 2). Adjustment for CRP and common cardiovascular risk factors did not 
influence these relationships. 
In the samples collected 3 months after the event, the mean fibrinogen γ′ level and 
fibrinogen γ′/total fibrinogen ratio (0.29±0.09 g/L and 0.088±0.02 respectively) were 
significantly lower than during the acute phase of stroke, and also significantly lower than 
in controls (Table 2).
Carriers of the FGG-H3 allele had a significantly reduced risk of ischemic stroke (OR 
0.60; 95% CI, 0.38 to 0.94). No clear association with stroke was observed for the other 
haplotypes (FGG-H1: reference; FGG-H2: OR 0.91; 95% CI, 0.58 to 1.43; FGG-H4: OR 
0.75; 95% CI, 0.30 to 1.88). 
Only FGG-H2 was associated with a significantly decreased fibrinogen γ′/total 
fibrinogen ratio in patients during the acute phase (decrease of 0.093±0.013 and 
0.085±0.020, respectively, both P<0.001), in the convalescent phase (decrease of 
0.060±0.015, P<0.001) and in controls (Figure) No association between FGG haplotypes 
and total fibrinogen levels was present. Adjustment for cardiovascular risk factors and 
CRP levels did not affect these relationships. 
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Table 2. Fibrinogen g′ levels, g′/total fibrinogen ratio and fibrinogen levels in patients and controls
Patients Controls
Acute phase Convalescent phase
N=114 N=47 N=119 P* P† P‡
Fibrinogen g′ (g/L) 0.42±0.17 0.29±0.09 0.34±0.10 <0.001 0.01 <0.001
Fibrinogen g′/total 
fibrinogen ratio
0.113±0.034 0.088±0.020 0.100±0.029 0.002 0.01 <0.001
Fibrinogen (g/L) 3.69±1.06 3.34±0.76 3.41±0.61 0.006 0.54 0.003
CRP§ (mg/L) 2.33 (0.49-8.18) 1.15 (0.62-5.17) 1.30 (0.61-3.18) 0.007 0.11 0.85
Presented are means±SD, § median and inter quartile range (IQR); P*: P-value between controls and 
patients in acute phase, P†: P-value between controls and patients in convalescent phase, P‡: P-value 
between patients in acute phase and in convalescent phase. 
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Figure. Effect of FGG haplotypes on the fibrinogen g′/ total fibrinogen ratio 
H1 in controls was used as reference group. * indicates a significant different from H1 of each group. 
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DISCUSSION
Fibrinogen γ′ levels were elevated in the acute phase of ischemic stroke and decreased 
in the convalescent phase. The increase in the acute phase is probably a result of the 
event. The decrease in the convalescent phase may more reflect the prestroke levels, which 
would suggest that the antithrombotic properties of fibrinogen γ′ are more important than 
its prothrombotic properties. This seems to be in contrast with previous studies where 
increased fibrinogen γ′ levels or fibrinogen γ′/total fibrinogen ratios were associated with 
increased risk of arterial thrombotic disease,3,7 but these latter results may have been 
influenced by the acute phase. It is a limitation of our study that it has a relatively small 
sample size, especially for the unselected group of patients that has been followed-up in 
the convalescent phase. 
Fibrinogen γ′/total fibrinogen ratio is only elevated in the acute phase of stroke and 
not in the convalescent phase suggesting that the acute phase affects alternative splicing as 
already suggested for other genes. 
We observed that carriers of FGG-H3 have a reduced risk of ischemic stroke, but this 
is not consistent with previous studies.2,4,5,8 It is unclear what the underlying mechanism 
might be because FGG-H3 gave only a slight, nonsignificant increase of fibrinogen γ′ levels 
or fibrinogen γ′/total fibrinogen ratios. As expected,2 the fibrinogen γ′/total fibrinogen ratio 
was strongly reduced in FGG-H2, both in cases (acute phase and convalescent phase) 
and in controls. This observation may be explained by the improved cleavage stimulatory 
factor binding site near the γA specific polyadenylation site in the FGG-H2 allele, which 
may inhibit the formation of fibrinogen γ′ specific mRNA.8 No relationship between 
FGG-H2 and risk of stroke was observed, which is consistent with previous studies.4,8
In conclusion, this study shows that the fibrinogen γ′/total fibrinogen ratio is increased 
in the acute phase of stroke, which may reflect an antithrombotic defense mechanism of 
the human body. Additionally, carriers of the FGG-H3 haplotype appear to be protected 
against ischemic stroke. 
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TO THE EDITOR
Recently, Nowak-Göttl et al. reported on the association between the fibrinogen g′/total 
fibrinogen ratio (g′ ratio) and thromboembolism in children.1 We and others previously 
reported on this association in adults.2-6 However, the underlying mechanism remains 
unknown. Recently, we reported that the g′ ratio is higher in the acute phase of ischemic 
stroke (IS), but not in the convalescent phase.2 This suggests that the acute phase reaction 
alters the mRNA processing of fibrinogen g, thereby increasing the g′ ratio. Furthermore, 
the anti- and prothrombotic properties of g′ fibrinogen suggest that an increased g′ ratio 
during the acute phase of cardiovascular disease may influence the secondary thrombotic 
risk.    
Fibrinogen g′ antigen levels were measured by enzyme-linked immunosorbent assay as 
described previously.4 Total fibrinogen levels were measured according to von Clauss, and 
C reactive protein (CRP) levels was measured using an in-house high-sensitivity enzyme-
linked immunosorbent assay. Statistical analysis was performed using SPSS 16.0 for 
Windows. All investigations were approved by the Medical Ethics Committee of Erasmus 
University Medical Center and were performed in accordance with the recommendations 
of the Declaration of Helsinki.
We confirmed our previous finding of an elevated g′ ratio in IS and observed 
significantly higher g′ ratios in the acute phase of IS (independent cohort of 53 patients), 
pulmonary embolism (PE, n=202)7 and refractory unstable angina pectoris (UAP, n=72)8 
compared with the g′ ratios in healthy controls (P <0.001; Table 1). These observations are 
in contrast to those of Nowak-Göttl et al., who reported a decreased g′ ratio in children with 
thromboembolism (U. Nowak-Göttl, H. Weiler, personal communication, July 2009),1 and 
also with results from adult patients with deep venous thrombosis.4 One explanation for 
the discrepancy may be the timing of blood collection. In our studies, blood was collected 
in the acute phase of the diseases. We observed a significant correlation between g′ ratios 
and CRP levels in the acute phase (Rs=0.23, P<0.001) in the patients with IS.2 Moreover, 
g′ ratios were slightly higher (0.24±0.19, n=16) in PE patients with CRP levels >100 mg/L, 
than in patients who did not have an acute phase response (CRP levels μ10 mg/L;0.20±0.06, 
n=13, P=0.54). These results together support our hypothesis that the mRNA processing of 
the fibrinogen g alters during an acute phase reaction.
The characteristics of g′ fibrinogen suggest that a high ratio during the acute phase of 
disease prevents thrombotic events in patients with UAP. In our patient group, there was 
no difference in ratios between stabilized (n=130) and refractory (n=72) patients (both 
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0.14±0.04, P=0.59). Neither were the ratios associated with clinical outcome during 18 
months of follow-up. These results suggest that elevated ratio does not predict the risk of 
acute coronary syndromes in patients with UAP.
In conclusion, the fibrinogen g′/total fibrinogen ratios are elevated in patients with 
various cardiovascular diseases (IS, PE or UAP) compared with the g′ ratios in healthy 
controls. An altered mRNA processing of fibrinogen g during the acute phase may 
contribute to this observation. However, the fibrinogen g′/total fibrinogen ratio does not 
predict short or long term outcome in patients with UAP. 
Table 1. Fibrinogen levels, fibrinogen g′ levels and fibrinogen g′/fibrinogen ratios in various cardiovascular 
diseases.
Groups n Fibrinogen, 
g/L
Fibrinogen γ′, 
g/L
Fibrinogen γ′/total 
fibrinogen ratio
P-value* P-value†
Population Controls 173 3.30 (0.59) 0.33 (0.10) 0.10 (0.03)
Patients
Ischemic stroke (IS) 53 3.87 (1.19) 0.49 (0.18) 0.13 (0.02) <0.001
Pulmonary embolism (PE)
       Non acute phase 13 2.69 (1.42) 0.53 (0.27) 0.20 (0.06) <0.001
0.54
       Acute phase 16 4.39 (2.30) 0.79 (0.33) 0.24 (0.19) <0.001
Unstable angina pectoris (UAP)
       Stabilized 130 3.36 (0.76) 0.46 (0.15) 0.14 (0.04) <0.001
0.59
       Refractory 72 3.82 (1.00) 0.53 (0.23) 0.14 (0.04) <0.001
Data presented are means (SD).
*P value of fibrinogen g′/total fibrinogen ratio between patients and healthy controls after adjustment for 
age and sex.
†P value of fibrinogen g′/total fibrinogen ratio between patient groups after adjustment for age and sex.
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ABSTRACT
Fibrinogen g′ (g′) is a natural isoform of fibrinogen, and alters the rate of formation and the 
properties of clots. It could therefore affect outcome after ischemic stroke. The prognostic 
significance of g′ fibrinogen levels is, however, still unclear. We assessed levels of g′ in 
ischemic stroke, and its association with short-term outcome. 
We included 200 ischemic stroke patients and 156 control persons. Total fibrinogen 
and g′ levels were measured; outcome at discharge was assessed by means of the modified 
Rankin Scale score (defined as unfavorable when >2). We compared levels between 
patients and controls using multiple linear regression analysis, and logistic regression 
analysis was used to assess the relationship between levels and outcome. All analyses 
were adjusted for age and sex. 
Mean g′ levels were significantly higher in patients with ischemic stroke than in 
controls (0.37 vs 0.32 g/L, p<0.001), and patients also had a higher g′/total fibrinogen 
ratio (0.102 vs 0.096, p=0.19). The g′/total fibrinogen ratio is associated with unfavorable 
outcome in patients with ischemic stroke (odds ratio per unit increase of g′/total fibrinogen 
ratio 1.27, 95%CI 1.09-1.47). 
Our study shows that patients with ischemic stroke have increased levels of fibrinogen 
g′ and suggests a trend towards an increased g′/total fibrinogen ratio in ischemic stroke. 
Increased fibrinogen g′ relative to total fibrinogen levels are associated with unfavorable 
outcome in the early phase after stroke. 
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INTRODUCTION  
Human plasma fibrinogen is an important protein in the hemostatic system, in which 
soluble fibrinogen is converted to insoluble fibrin, leading to clot formation. Fibrinogen 
is a heterogeneous protein, existing as several natural isoforms. The fibrinogen variant 
containing g′ is one such isoform, comprising 10 ± 3% of the circulating fibrinogen 
molecules.1 In the systemic circulation, g′ is mostly present as a heterodimeric protein 
with the common gA form (gA/g′), while <1% is present in the g′/g′ form.2 Fibrinogen g′ 
is a result of alternative mRNA processing, in which 20 amino acids replace the 4 amino 
acids at the C-terminal of gA.3,4 The extension of fibrinogen g′ contains additional binding 
sites for thrombin (hence the alternative name antithrombin I for g′-containing fibrinogen 
molecules)5 and for the factor XIII B-subunit,6 enhancing binding of factor XIII. The platelet 
binding site for integrin aIIBb3 is disrupted, which deducts platelet binding capacity.
7 
Recently, we and others reported that an elevated g′ level or g′/total fibrinogen ratio 
is associated with cardiovascular disease,1,8-12 especially in the acute phase of ischemic 
stroke. Results of our previous studies suggest that fibrinogen g′ levels as well as the g′/
total fibrinogen ratio alter during an acute phase reaction.1,8 This may lead to a different 
clot formation rate and to different characteristics of the fibrin network, and may therefore 
contribute to the pathology of thrombotic diseases and stroke. 
The role of fibrinogen g′ and the g′/total fibrinogen ratio in the precipitation and course 
of ischemic stroke is as yet unclear. To our knowledge, no studies have been published on 
fibrinogen g′ in relation to outcome of cardiovascular disease, ischemic stroke in particular. 
We aimed to investigate the differences in fibrinogen g′ levels and g′/total fibrinogen 
ratio, between patients with ischemic stroke and control persons. Furthermore, we studied 
whether there is an association between these levels and short-term outcome in ischemic 
stroke.
MATERIALS AND METHODS
Study population
All patients and controls participated in the Erasmus Stroke Study (ESS), which is an 
ongoing prospective registry of all patients with transient ischemic attack (TIA) or stroke 
treated at Erasmus MC University Medical Center Rotterdam since December 2005. From 
all patients, detailed clinical and radiological data, blood samples and DNA are collected. 
7
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The ESS also includes population-based control persons, mostly friends and spouses of 
patients, but no family members. All participants in the ESS provided informed consent. 
The study was approved by the Medical Ethics Committee of the Erasmus MC University 
Medical Center. 
For this case-control study we included 200 patients with ischemic stroke, and 156 
age- and sex matched stroke-free control persons. In all patients, citrated blood was 
collected and centrifuged at 4000 rpm for 15 minutes. Citrated plasma was stored at -80°C 
within 2 hours from collection. Blood was drawn 8 days (interquartile range 3-22 days) 
from the date of onset, either in the stroke unit or the outpatient clinic. 
 
Total fibrinogen and fibrinogen g′ antigen measurements
We determined total fibrinogen levels according to Von Clauss13 on a fully-automated 
blood coagulation analyzer (Sysmex CA-1500 system, Siemens Healthcare Diagnostics, 
Breda, the Netherlands). Normal Reference Plasma was used as reference plasma in 
this assay (Precision BioLogic, Dartmouth, ON, Canada), the intra-assay coefficient of 
variation was 3.5%.
Fibrinogen g′ antigen levels were measured with an enzyme-linked immunosorbent 
assay as described previously,9 with minor modifications. Briefly, plastic 96-well microtiter 
plates (Nunc maxisorp, Roskilde, Denmark) were coated with mouse anti-human g′ 
fibrinogen (2.G2.H9; Millipore, Billerica, MA, USA) and then incubated overnight at 4°C. 
Wells were blocked with bovine serum albumin for 1 hour at room temperature. Plasma 
samples were added to each well in duplicate. After 1 hour incubation at room temperature, 
horseradish peroxidase-conjugated rabbit anti-human fibrinogen (DAKO A/S, Glostrup, 
Denmark) was added to tag the immobilized patient fibrinogen g′, and incubated for 1 hour 
at room temperature. Color was developed with Tetramethylbenzidine substrate solution 
(BioMérieux, Marcy l′Etiole, France) and was terminated with H2SO4 after 15 minutes. 
The plate was read at 450 nm spectrophotometrically. Wells were washed 3 times between 
all incubation steps. Pooled normal plasma calibrated against purified human g′ fibrinogen 
was used as calibrator.1 The intra-assay variation was less than 10%. 
Definitions
Ischemic stroke was defined as focal neurological deficit of presumed vascular origin, 
lasting >24 hours or leading to death within 24 hours, with brain imaging showing no 
abnormalities or typical signs of brain infarction. Hypertension was defined as the use of 
antihypertensive drugs before the event, hypercholesterolemia as the use of cholesterol 
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lowering drugs before the event. Diabetes mellitus was defined as the use of oral 
antidiabetic drugs and/or insulin before the event. All strokes were classified according to 
TOAST criteria14 based on all available information.  
Functional short-term outcome was assessed by means of the modified Rankin Scale 
(mRS)15 score at time of discharge from the stroke unit for hospitalized patients, and from 
the outpatient clinic for ambulant patients. The mRS is a score for handicap and level 
of dependency. The scale ranges from 0 (no symptoms) to 6 (dead), with each increase 
denoting more severe disability. At a score of 2, patients have neurological symptoms 
affecting their daily life but are still able to live completely independent; at a score of 3 
patients cannot live independently due to symptoms. The mRS was dichotomized between 
scores of 2 and 3, as favorable (≤2, independent living) or unfavorable (>2, dependent or 
institutionalized living). 
Statistical analysis
Differences between baseline characteristics of patients and controls were assessed with 
Student′s t-test. Differences in fibrinogen levels between patient groups and controls were 
assessed using Student′s t-test; adjustment for confounders was performed using analysis 
of variance (ANOVA). Associations between fibrinogen levels and outcome were assessed 
using multiple logistic regression analysis and expressed as odds ratio (OR) with 95% 
confidence intervals (CI). Analyses were also performed in 2 subgroups of equal size, 
based on time from event to blood drawing. This allowed us to study levels of g′ in the 
acute and subacute stage after ischemic stroke. All analyses were adjusted for age and sex. 
Statistical analyses were performed using SPSS 15.0 for Windows (SPSS Inc., Chicago, 
Illinois). A probability value <0.05 was considered significant. 
RESULTS
Baseline characteristics of patients and controls are shown in Table 1. As expected, 
prevalence of cardiovascular risk factors (smoking, hypertension and hypercholesterolemia) 
was different between patients and controls. 
Levels of total fibrinogen and fibrinogen g′ were significantly higher in patients 
compared with controls, after adjustment for age and sex (Table 2A). Levels of the g′/total 
fibrinogen ratio were similar in patients and controls. 
The median time from onset of symptoms to blood drawing was 7.5 days. Two 
subgroups of patients were formed, by dividing patients in 2 equal groups based on 
7
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time from onset of symptoms to blood drawing, the acute phase and the subacute phase. 
Differences in g′/total fibrinogen ratio between patients and controls were most pronounced 
in the group with blood drawing in the acute phase of stroke (Table 2B). In this group g′/
total fibrinogen ratio was significantly increased, in line with our previous results.8 In the 
group of patients in the subacute phase of ischemic stroke, the g′ ratio was not different 
from controls. 
Outcome was unfavorable (modified Rankin Scale score >2) in 13.5% of patients with 
ischemic stroke. These patients could no longer live independently due to neurological 
symptoms, had severe disabilities, or died. 
 
Table 1. Characteristics of the study population.
Patients Controls p-value
N 200 156
Age (years), mean (SD) 62 (13) 59 (12) 0.04
Female, % 45 51 0.29
Current smoking, % 36 24 0.02
Hypertension, % 55 29 <0.001
Hypercholesterolemia, % 34 18 0.001
Diabetes Mellitus, % 17 13 0.37
Body Mass Index, mean (SD) 26.0 (4.2) 26.7 (4.5) 0.22
TOAST 
classification
N(%)
Large artery atherosclerosis
Cardioembolism
Small vessel occlusion
Other etiology
Undetermined etiology
39 (20)
21 (11)
57 (29)
12 (6)
71 (36)
Time from onset of symptoms to blood drawing (days), 
median (IQR)
7.5 (3-22)
Modified Rankin Scale at discharge, median (IQR) 1 (1-2)
Levels of fibrinogen, fibrinogen g′ and g′/total fibrinogen ratio with respect to 
favorable or unfavorable outcome are shown in Table 3. After adjustment for confounders, 
g′ and total fibrinogen levels and the g′/total fibrinogen ratio were significantly higher in 
patients with unfavorable outcome, compared with patients with a favorable outcome. 
Increased fibrinogen g′ levels and g′/total fibrinogen ratio were significantly associated 
with unfavorable outcome (OR per unit increase g′ 1.48, 95%CI 1.15-1.91 and OR per 
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unit increase g′ ratio 1.27, 95%CI 1.09-1.47; both adjusted for age, sex and time to 
blood drawing; Table 4). The g′/total fibrinogen ratio adjusts fibrinogen g′ levels for total 
fibrinogen levels, the prognostic effect of fibrinogen g′ on outcome was thus independent 
of total fibrinogen level. Effects were similar in subgroups based on time to blood drawing, 
showing that the g′/total fibrinogen ratio was associated with unfavorable outcome in the 
first week as well as later in the course of ischemic stroke (OR 1.25, 95%CI 1.05-1.49 and 
OR 1.20, 95%CI 0.84-1.70, respectively). 
Table 2A. Levels of total fibrinogen, fibrinogen g′ and g′/total fibrinogen ratio in patients and controls.
Controls Patients Model 1, 
p-value*
Model 2, 
p-value†
Model 3, 
p-value‡
Total fibrinogen (g/L) 3.37 (0.72) 3.69 (0.96) <0.001 0.001 <0.001
Fibrinogen g′ (g/L) 0.32 (0.13) 0.37 (0.15) <0.001 <0.001 0.002
g′/total fibrinogen ratio 0.096 (0.028) 0.102 (0.036) 0.19 0.30 0.495
Presented are means (SD). *Model 1: adjustment for age and sex †Model 2: adjustment for age, sex and time 
to blood drawing ‡Model 3: adjustment for age, sex, time to blood drawing, current smoking, hypertension 
and hypercholesterolemia
Table 2B. Levels of total fibrinogen, fibrinogen γ′ and γ′/total fibrinogen ratio in subgroups of patients 
and controls. Subgroups: patients were divided in 2 equal groups of 100 patients based on time from 
event to blood drawing.
0-7 days ≥ 8 days 0-7 days vs controls, 
p-value*
>= 8 days vs 
controls, p-value*
Total fibrinogen (g/L) 3.76 (1.11) 3.62 (0.78) <0.001 0.033
Fibrinogen g′ (g/L) 0.40 (0.17) 0.34 (0.12) <0.001 0.194
g′/total fibrinogen ratio 0.110 (0.040) 0.095 (0.029) 0.015 0.64
Presented are means (SD). *p value after adjustment for age and sex
Table 3. Levels of total fibrinogen, fibrinogen g′ and g′/total fibrinogen ratio in patients with favorable or 
unfavorable outcome
Favorable outcome 
(modified Rankin 
Scale ≤ 2)
Unfavorable 
outcome (modified 
Rankin Scale >2)
Model 1*, 
p-value
Model 2†, 
p-value
N 173 27
Total fibrinogen, g/L (SD) 3.64 (0.89) 3.97 (1.34) 0.112 0.013
fibrinogen g′, g/L (SD) 0.36 (0.14) 0.47 (0.18) <0.001 <0.001
g′/total fibrinogen ratio, SD 0.098 (0.029) 0.129 (0.059) <0.001 0.006
*Model 1: adjusted for age and sex †Model 2: adjusted for age, sex, current smoking, hypertension and 
days to blood drawing
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Table 4. Associations between total fibrinogen levels, fibrinogen γ′ levels and γ′/total fibrinogen ratio and 
outcome of ischemic stroke. 
OR (95% CI) for unfavorable outcome (modified Rankin Scale >2) per unit increase in levels
Unfavorable outcome, N (%) 27 (13,5)
Model 1* Model 2†
Total fibrinogen (g/L) 1.35 (0.90-2.01) 1.31 (0.87-1.96)
Fibrinogen g′ (dg/L) 1.52 (1.18-1.96) 1.48 (1.15-1.91)
g′/total fibrinogen ratio (%) 1.28 (1.10-1.48) 1.27 (1.09-1.47)
* Model 1: adjusted for age and sex † Model 2: adjusted for age, sex and time to blood drawing
DISCUSSION
Our study shows that levels of total fibrinogen, fibrinogen g′ and the g′/total fibrinogen 
ratio are increased in the acute phase of ischemic stroke. Furthermore, this is the first 
study to show that increased relative levels of fibrinogen g′ are significantly associated 
with unfavorable outcome. The g′/total fibrinogen ratio was associated with unfavorable 
outcome both in the acute and subacute phase after ischemic stroke. 
Some methodological issues of our study have to be discussed. Strengths of our 
study are the extent and quality of clinical data and availability of short-term follow-up, 
which enabled us to study fibrinogen g′ in relation to outcome of stroke. Limitations of our 
study are the relatively small number of patients, and the low rate of unfavorable outcome 
among our patients. However, this study provided sufficient precision to allow meaningful 
conclusions about the relationship between fibrinogen g′ and outcome.
We observed that the g′ levels were increased most in patients who were presented 
at the hospital soon after the onset of stroke. In general, patients with severe stroke were 
admitted to the hospital sooner after the onset of complaints than patients with milder 
stroke. Therefore, we cannot distinguish between the effects of the acute phase reaction 
that was initiated by the stroke, and the severity of stroke. Still, adjustment in the analysis 
for the time since onset of complaints has only a minor effect on the associations of g′ 
levels with outcome of stroke. After adjustment for cardiovascular risk factors, levels of 
fibrinogen g′ were still significantly increased in patients, but the g′ ratio was similar in 
patients and controls. Also, when looking at associations with outcome, the absolute g′ 
level had a stronger association with outcome than the g′/total fibrinogen ratio. This may 
indicate that the absolute level of fibrinogen g′ is perhaps more important than the g′/total 
fibrinogen ratio.      
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Our results confirm those of our previous studies that showed increased total 
fibrinogen and fibrinogen g′ levels in the acute phase of ischemic stroke.8 Also, earlier 
studies have found a relation between higher post-stroke total fibrinogen levels and poor 
outcome measured on the modified Rankin Scale.16 We found that higher total fibrinogen 
levels are associated with unfavorable outcome as well, but in addition we found that the 
association between increased fibrinogen g′ levels and unfavorable outcome after ischemic 
stroke is independent of total fibrinogen levels.
Fibrinogen g′ has antithrombotic properties; one of these is a high affinity binding site 
for thrombin, which may result in lower levels of circulating thrombin available for clot 
formation.17 Also, g′ fibrinogen has a disrupted binding site for platelet integrin aIIbb3, which 
diminishes its capacity to facilitate platelet aggregation.7 On the other hand, fibrin formed 
from g′-containing fibrinogen has a finer, more tightly branched network and smaller pores 
than fibrin formed from gA fibrinogen.18,19 In vitro studies have reported that fibrinogen g′-
rich clots show a lower clot lysis rate than clots formed from gA fibrinogen.20,21 
Increased total fibrinogen levels have been shown to increase risk of cardiovascular 
disease.22-24 Several studies in the convalescent phase of thrombotic diseases show a 
decreased fibrinogen g′ level, which is thought to resemble the level before occurrence 
of an event. When considering fibrinogen g′ as a protein with mostly antithrombotic 
properties, it is possible that increased baseline fibrinogen levels, combined with a low 
fibrinogen g′/total fibrinogen ratio, could predispose to atherothrombotic disease. In the 
acute phase of thrombotic diseases, the fibrinogen g′ level then increases, as was seen in 
previous studies1 as well as our study. Based on findings from previous studies and our 
study, it is still too early to use fibrinogen g′ assays for diagnostic or prognostic evaluation 
in acute stroke, for which further studies are needed. 
In conclusion, we have found that levels of fibrinogen g′ are increased in the acute 
phase of ischemic stroke. Furthermore, increased levels of fibrinogen g′ are associated with 
unfavorable outcome. Future research should be aimed at unraveling the role of fibrinogen 
g′ in the pathogenesis and prognosis of cardiovascular diseases such as ischemic stroke, in 
which the genetic background of fibrinogen g′ levels may be of particular interest. 
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ABSTRACT
The fibrinogen g′ variant (g′) has both antithrombotic and prothrombotic properties 
when compared to normal fibrinogen. It may therefore be of relevance in intracerebral 
hemorrhage and intraventricular extension of the bleeding. We studied the role of g′ in 
intracerebral hemorrhage, and in intraventricular extension of the hemorrhage.
We performed a case-control study in 156 controls and 55 patients with intracerebral 
hemorrhage, with and without intraventricular extension. Levels of fibrinogen g′ and the 
g′/total fibrinogen ratio were measured in all participants.
Levels of g′ were increased in patients with intracerebral hemorrhage when compared 
with controls (0.40 vs 0.32 g/L, p<0.001). The g′/total fibrinogen ratio was similar in 
patients and controls (0.092 vs 0.096, p=0.42). There was evidence for an unfavorable 
outcome in patients with fibrinogen levels in the highest tertile compared with the lowest 
tertile (OR 4.0, 95%CI 1.1-15.2), and a nonsignificant trend toward unfavorable outcome 
with higher levels of g′ (p-value for trend=0.06).
Our study shows that absolute levels of fibrinogen g′ are increased in patients with 
intracerebral hemorrhage, but relative levels are similar in patients and controls, suggesting 
that the absolute rise in g′ is an acute phase response.
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INTRODUCTION
Fibrinogen is one of the central proteins in hemostasis, and several isoforms are present in 
the blood. One of these isoforms is fibrinogen g′ (g′), which contains an altered γ chain that 
is present in 8 to 15% of fibrinogen molecules.1 Fibrinogen g′ is produced after alternative 
mRNA processing of the g chain gene product.2,3 It has antithrombotic properties such as a 
binding site for thrombin4 and a disrupted binding site for platelet integrin aIIBb3,
5 as well 
as a high-affinity binding site for factor XIII:B, which is considered prothrombotic. 
Intracerebral hemorrhage (ICH), resulting from rupture of blood vessels in the brain, is 
a severe neurologic disorder leading to a high rate of mortality and disability.6 Hemostasis 
plays an important role in the pathophysiology of hemorrhagic disorders, such as ICH, and 
plays a role in hematoma growth.6 Larger hematomas are associated with extension of the 
bleeding into the brain ventricles (intraventricular extension, IVE).7 IVE is associated with 
an unfavorable prognosis, resulting in a higher mortality.8 
In several cardiovascular disorders, such as myocardial infarction and ischemic 
stroke, a pathogenic role of g′ has been suggested but not yet proven.9,10 The role of g′ 
in hemorrhagic disorders such as ICH has, however, not yet been studied. We therefore 
aimed to determine the association between g′ levels and the g′/total fibrinogen ratio and 
occurrence of ICH, and with intraventricular extension.
METHODS
We performed a case-control study in 55 consecutive patients admitted to our hospital 
with non-traumatic intracerebral hemorrhage between July 2006 and July 2009, and 156 
age- and sex matched stroke-free controls. Participants had no history of coagulation 
disorders. All individuals participated in the Erasmus Stroke Study (ESS), a hospital-based 
registry of patients with cerebrovascular disorders treated at our hospital. The ESS also 
includes population-based controls, mostly friends and spouses of patients, but no family. 
All participants provided written informed consent. The institutional Medical Ethics 
Committee approved the study. Upon admission, all patients underwent a plain brain CT 
scan to confirm the diagnosis and to determine the presence or absence of intraventricular 
extension of the hemorrhage. Functional outcome was evaluated at discharge by means of 
the modified Rankin Scale (mRS),11 which is a score for handicap and disability ranging 
from 0 (no symptoms) to 6 (death). At a score of 2 patients have disabilities interfering 
with activities but are still able to live completely independent; at a score of 3 patients are 
8
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dependent for activities of daily living. Unfavorable functional outcome was defined as 
mRS>2, signifying loss of independency. 
Citrated blood was drawn 3-6 days after admission and centrifuged at 1700g for 15 
minutes. Citrated plasma was frozen at -80°C within 2 hours from collection and stored 
until analysis. 
Laboratory analyses
Total fibrinogen levels were measured according to von Clauss on a fully-automated 
coagulation analyzer (Sysmex CA-1500 system, Siemens Healthcare Diagnostics, Breda, 
the Netherlands). Fibrinogen g′ antigen levels were measured with an enzyme-linked 
immunosorbent assay as described previously12 using anti-g′ fibrinogen antibodies for 
catching and HRP-labeled rabbit anti-fibrinogen antibodies for tagging.  
Statistical analysis
Apart from fibrinogen g′ levels we also determined the g′/total fibrinogen ratio, to adjust for 
total fibrinogen levels, which are known to increase as results of an acute phase reactions. 
Differences in g′ levels and g′/total fibrinogen ratio between patients and controls and 
within patient subgroups were assessed by means of multiple linear regression, adjusted for 
age and sex. The relation between g′ levels and the g′/total fibrinogen ratio and functional 
outcome was assessed using logistic regression and expressed as odds ratio (OR) per tertile 
increase in fibrinogen level, the lowest tertile being the reference category. All statistical 
analyses were performed using SPSS 17.0 for Windows (SPSS Inc., Chicago, Illinois). A 
probability value <0.05 was considered significant.
RESULTS
Median age was 63 years in patients and 60 years in controls (difference not significant), 
55% of patients and 49% of controls were men (not significant). Of all patients, 8 (15%) 
had intraventricular extension of the hemorrhage. 
Total fibrinogen and g′ were significantly higher in patients than in controls (Table 
1). Table 1 also shows levels in patients with and without intraventricular extension of the 
hemorrhage. We found no difference in the g′/total fibrinogen ratio between patients and 
controls. However, the subgroup of patients with IVE had a significantly higher g′/total 
fibrinogen ratio than controls and patients without IVE. 
The median modified Rankin Scale score at discharge was 2 (interquartile range 2-4). 
Elim_Ch_thesis2.indd   100 5/21/12   11:00 AM
101
Fibrinogen γ′ levels in patients with intracerebral hemorrhage
Patients with fibrinogen levels in the highest tertile had a significantly higher probability of 
unfavorable outcome, compared with patients in the lowest tertile. There were also signs of 
a linear relationship (p-value for trend over tertiles 0.12, Table 2). Levels of fibrinogen g′ 
seemed to be higher in patients with unfavorable outcome, but not statistically significant. 
These risks were not attenuated when patients with IVE were left out of the analysis. 
Table 1. Levels of total fibrinogen, fibrinogen g′ and g′/total fibrinogen ratio in patients and controls
Patients Controls
All
N = 55
No IVE 
N = 47
IVE 
present 
N = 8
N = 156 P 
value*
P 
value†
P 
value‡ 
P 
value§ 
Total 
fibrinogen 
(g/L)
4.41 
(1.21)
4.41 
(1.23)
4.40 
(1.13)
3.37 
(0.72)
<0.001 0.95 <0.001 <0.001
Fibrinogen g′ 
(g/L)
0.40 
(0.14)
0.38 
(0.14)
0.51 
(0.13)
0.32 
(0.13)
<0.001 0.02 0.01 <0.001
g′/total 
fibrinogen ratio 
0.092 
(0.031)
0.087 
(0.032)
0.119 
(0.032)
0.096 
(0.028)
0.42 0.01 0.08 0.03
Presented are means (SD). All analyses are adjusted for age and sex. *P value between all patients and 
controls; †P value between patients with and without IVE; ‡P value between patients without IVE and 
controls; §P value between patients with IVE and controls
Table 2. Risk of unfavorable functional outcome (mRS >2) and levels of fibrinogen, fibrinogen g′ and the 
g′/total fibrinogen ratio, in tertiles of the distribution.
Tertiles
1 2 3 p-trend
Fibrinogen
     Distribution
     All patients
     Only patients without IVE
<3.8 g/L
1.00 (ref)
1.00 (ref)
3.8 – 4.4 g/L
1.56 (0.41-5.95)
1.35 (0.32-5.71)
>4.4 g/L
4.00 (1.05-15.21)
2.62 (0.66-10.48)
0.12
0.39
Fibrinogen g′
     Distribution
     All patients 
     Only patients without IVE
<0.33 g/L
1.00 (ref)
1.00 (ref)
0.33 – 0.44 g/L
5.60 (1.36-23.06)
6.24 (1.44-27.06) 
>0.44 g/L
2.80 (0.71-11.10)
2.60 (0.56-12.02)
0.06
0.05
g′/total fibrinogen ratio
     Distribution
     All patients
     Only patients without IVE
<0.078
1.00 (ref)
1.00 (ref)
0.078 – 0.101
0.80 (0.21-3.00)
0.83 (0.21-3.35)
>0.101
1.72 (0.47-6.32)
2.25 (0.54-9.45)
0.50
0.38
Shown are OR (95%CI)
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DISCUSSION
In this case-control study, we found that levels of fibrinogen g′ were strongly elevated 
in patients with intracerebral hemorrhage as compared to control persons. In the total 
patient group, the fibrinogen g′/total fibrinogen ratio was similar to controls, but subgroup 
analyses revealed an increased g′/total fibrinogen ratio in patients with intraventricular 
extension of the hemorrhage, while in patients without IVE, this g′/total fibrinogen ratio 
was somewhat lower, although not statistically significant, than in controls. 
Strengths of our study are the novelty of studying fibrinogen g′ in intracerebral 
hemorrhage, and the availability of a functional outcome measure. A methodological 
concern of our study is the small number of patients. Intracerebral hemorrhage, a rare 
disorder when compared to ischemic stroke, has a high mortality and many patients die 
before arriving in the hospital or within hours from admission.6,14 This makes any study 
of patients with intracerebral hemorrhage, including our own, vulnerable to bias as many 
patients are not included. A second point is the case control design of the study, which 
makes it difficult to study causal relationships between fibrinogen g′ and ICH. 
Although the anti- and prothrombotic properties of g′ have been studied quite 
extensively, most clinical research in this field has been done in thromboembolic disorders 
such as venous thrombosis, myocardial infarction and ischemic stroke.10,12,15-17 No studies 
have yet been performed focusing on the antithrombotic properties of g′ in relation to 
hemorrhage. 
The g′ chain has a binding site for thrombin, with both antithrombotic or prothrombotic 
consequences, which have been subject of discussion.4,18,19 Despite this, thrombin binding 
to the g′ chain overall seems to be antithrombotic, reducing the free thrombin content and 
inhibiting thrombin-mediated platelet activation.20,21 Also, the binding of thrombin leads to 
a selective inhibition of the intrinsic coagulation pathway.19 An additional antithrombotic 
property of g′ is the decreased binding to platelet integrin aIIBb3 by the g′ chain, leading 
to a diminished platelet aggregation activity.22 Given the antithrombotic properties of g′, 
one might hypothesize that g′ might also affect the risk and outcome of (intracerebral) 
hemorrhage. Thus far, no studies have been done on this particular subject. 
In our study we found that g′ levels were indeed increased in patients with intracerebral 
hemorrhage. However, due to the case control design we can′t rule out that this finding is 
the result of an acute phase response in ICH patients.9 
Previous studies have shown a stronger acute phase response in patients with blood in 
the intraventricular or subarachnoid space.23-25 The relevance of intraventricular blood may 
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play a role in our finding that relative fibrinogen g′ levels seem to increase significantly 
only in patients with extension of bleeding into the ventricles. However, in our study 
the presence or absence of IVE did not affect total fibrinogen levels. The reason for this 
discrepancy remains unknown, but it has been hypothesized that the direct contact between 
blood and cerebrospinal fluid might play a role.23 
Our finding that patients with high levels of total fibrinogen had a significantly higher 
chance of unfavorable outcome is in line with findings from previous studies.26,27 The 
prognostic value of fibrinogen g′ in patients with ICH is still unclear. The risk estimates 
we found for unfavorable outcome in higher tertiles of fibrinogen g′, was present in all 
patients, also after removing patients with IVE from the analysis. Larger studies are 
required to explore the prognostic value of fibrinogen g′ in patients with ICH. 
Any hemorrhage leads to consumption of coagulation factors; for intracerebral 
hemorrhage, literature is very limited with very little knowledge on consumption in this 
category of patients. The volume of the hemorrhage is usually small, varying depending 
on the method used, between 30-50 ml.28,29 Considering the small size of the hemorrhage, 
systemic consumption of coagulation factors will be minimal and not affect the results that 
we measured in our study.
In conclusion, the level of fibrinogen g′ is increased in patients with intracerebral 
hemorrhage compared with controls; however, the ratio of g′/total fibrinogen ratio is 
similar, suggesting that the rise in fibrinogen g′ may reflect an acute phase response. 
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ABSTRACT
Fibrin plays an important role in hemostasis, but it also provides a temporary, degradable 
matrix for tissue repair. In the final step of the coagulation cascade fibrinogen is converted 
to fibrin. Plasma fibrinogen is very heterogeneous and one form is the alternative messenger 
RNA processing variant γ′. This fibrinogen form shows increased thrombin and factor XIII 
binding and decreased platelet binding, as compared to the common γA form. In this study 
the effects of γ variants on angiogenesis and wound healing were investigated.
The endothelial cell characteristics on γA and γ′ fibrin matrices were investigated in 
vitro using adhesion, proliferation, migration and tube-formation assays. Moreover, the 
progress of wound healing was studied in vivo with a rat full-thickness wound healing 
model (wound closure rate, new vessel formation, perfusion and wound breaking strength).
Purified γ′ fibrinogen contained more factor XIII (FXIII) and formed a fibrin network 
with thinner fibers than γA fibrinogen, this affect was abolished by using equal FXIII 
concentrations. The in vitro tube formation was slightly more pronounced in γA than 
in γ′ fibrin matrices and was accompanied with an increased fibrinolysis. Endothelial 
cell adhesion, migration and proliferation were similar on γA and γ′ fibrin. The in vivo 
wound healing model suggested that γA was promoting wound healing slightly, but not 
significantly, better than γ′ fibrinogen. 
In conclusion, matrices of γA and γ′ fibrin govern different structural and functional 
characteristics. Small, non-significantly increased in vitro tube formation and in vivo 
wound healing were shown in γA fibrin, compared to γ′ fibrin. However, more data are 
necessary before conclusions can be drawn.
INTRODUCTION
Wound healing is a dynamic, interactive and complex process, which involves interactions 
between many different cells and the extracellular microenvironment. Fibrinogen is a central 
protein in the coagulation cascade and following endothelial injury, a fibrin clot is formed, 
which is the first protection against hemorrhage. In addition to its role in hemostasis, fibrin 
provides a temporary, biodegradable matrix for cell invasion during wound healing.1-3 The 
formation of new capillaries (angiogenesis) depends on the extracellular matrix in the 
wounded area, and on the migration and mitogenic stimulation of endothelial cells.1 Fibrin 
facilitates cell adhesion, migration, proliferation and stimulates angiogenesis.2 Moreover, 
fibrin binds growth factors that influence these processes, such as vascular endothelial 
growth factor (VEGF) and fibroblast growth factor-2 (FGF-2).1-3 
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The fibrinogen molecule comprises two identical disulphide-linked halves, each 
consisting of three polypeptide chains termed Aα, Bβ and γ.4 Numerous fibrinogen 
forms are present in healthy individuals, which are the result of alternative processing 
of fibrinogen messenger RNA, posttranslational modifications and degradation of the 
protein.5 One naturally occurring isoform is the γ′ fibrinogen variant, which comprises 
10% ± 3% of the total circulating fibrinogen in healthy individuals.6 γ′ fibrinogen is the 
result of alternative messenger RNA processing at intron 9 and exon 10, resulting in the 
replacement of the last 4 amino acids (408-411) at the C-terminus of the γ-chain by 20 
amino acids (408-427).7 
The extension of γ′ fibrinogen contains a high affinity binding site for thrombin, which 
results in antithrombin I activity.7 In addition, γ′ fibrinogen contains an extra binding site 
for the factor XIII (FXIII) B subunit8, 9 and lost its platelet integrin aIIbb3 binding site, which 
results in reduced platelet-fibrin(ogen) interactions.10 In the circulation, γA/γA fibrinogen 
(abbreviated as γA) and fibrinogen molecules containing one or two γ′ chain(s) (γA/γ′ or 
γ′/γ′, both abbreviated as γ′) are present. Several studies reported structural and functional 
differences between γA and γ′ fibrin matrices, such as slower fibrinopeptide B release, 
slower fibrin polymerization for γ′ fibrinogen, thinner fibers and more branch points with 
scanning electron microscopy on γ′ fibrin matrices.11, 12
We hypothesized that the functional differences between gA and g′ fibrin, in combination 
with the altered matrix structure, influences angiogenesis and wound healing. The denser 
structure of γ′ fibrin is likely to be associated with impaired fibrinolysis13, 14 and local 
degradation of the extracellular matrix is an important determinant for angiogenesis and 
wound healing.15, 16 The interaction between endothelial cells and γA or γ′ fibrin matrices 
might be modified, and hence affect the inflammatory, proliferative and remodeling phases 
in wound repair. In this study, we investigated the effects of the gA and γ′ fibrinogen 
variants on the in vitro endothelial cell characteristics and in vivo wound healing.
MATERIAL AND METHODS
γA and γ′ fibrinogen characterization
Purification and characterization of fibrinogen γ variants 
gΑ and g′ fibrinogen variants were purified by anion-exchange chromatography8 from 
plasma-purified fibrinogen (in vitro experiments)17 or from commercial fibrinogen (in 
vivo experiments) (Enzyme Research Laboratories, South Bend, IN). Sodium dodecyl 
sulfate polyacrylamide gel electrophoresis (SDS-PAGE) was performed using a 4–15% 
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gradient gel (Criterion Tris-HCL precast, Biorad, Hercules, CA) and total protein was 
stained with colloidal blue (Invitrogen, Carlsbad, CA). Western blotting was performed 
using polyclonal rabbit anti-fibrinogen (Dako, Glostrup, Denmark) and monoclonal 
anti-human γ′ fibrinogen antibodies (2.G2.H9; Millipore, Billerica, MA) followed by 
detection with fluorescent labeled secondary antibodies: goat anti-rabbit 680 (Invitrogen, 
Paisley, UK) and goat anti-mouse 800 (Invitrogen, Paisley, UK) for fibrinogen and γ′ 
fibrinogen, respectively. Factor XIII activity was determined photometrically according 
to manufacturer’s instructions (Berichrom Factor XIII, Siemens healthcare diagnostics, 
Deerfield, IL). Plasminogen activity was measured with chromogenic substrate S-2251 
following manufacturer’s instructions (Instrumentation laboratory, Lexington, MA). The 
clottability was determined by measuring the protein content (optical density at 280nm) 
before and after 2 hours polymerization of purified fibrinogen (1 mg/mL) at ambient 
temperature with 0.5 U/mL thrombin (Organon Teknika, Boxtel, the Netherlands) and 2.5 
mM CaCl2.
18
Confocal microscopy of fibrin matrices
Fibrinogen variants were labeled with fluorescein isothiocyanate isomer I (FITC) (Sigma-
Aldrich, Saint Louis, MI) and fibrin matrices (2 mg/mL) were formed by adding 0.5 U/
mL thrombin and 2.5 mM CaCl2 in a total volume of 100 μL in microchambers. The 
FXIII concentration in the γA fibrinogen matrix was supplemented with human plasma 
coagulation FXIII (Fibrogammin P, CSL Behring, Marburg, Germany) to compensate for 
the higher FXIII activity in γ′ fibrinogen. After 2 hours polymerization, the matrices were 
extensively washed with Tris-HCl buffer. Confocal images were visualized on a Zeiss 
LSM 510 Meta inverted confocal microscope (Carl Zeiss MicroImaging, Jena, Germany) 
with 63x oil immerse objective lens in combination with a 5-W argon laser and 488 nm 
band-pass laser filter for the excitation. Fibrin fiber diameters (n=50) were measured using 
LSM Image Browser software, version 4.2 (Carl Zeiss MicroImaging, Jena, Germany).
In vitro endothelial cell behavior
Cell culture
Human umbilical vein endothelial cells (HUVEC) were isolated from umbilical cords, 
kindly provided by the Department of Obstetrics of the Amstelland Hospital, Amstelveen. 
HUVEC were isolated, cultured and characterized as previously described.19 Human 
microvascular endothelial cells (HMVEC) were isolated from foreskin, kindly provided 
by the Department of Dermatology of the VUMC, Amsterdam. HMVEC were isolated, 
cultured and characterized as previously described.20 
Elim_Ch_thesis2.indd   110 5/21/12   11:00 AM
111
The effect of fibrinogen γ variants on wound healing
Fibrinogen coatings
Fibrinogen coatings were prepared on polystyrene culture plates (Costar, Corning, 
Amsterdam, The Netherlands) as previously described.21 Plates were coated with fibrinogen 
(0.2 μM; 0.068 mg/mL) in phosphate buffered salt solution (PBS) for 1 hour at 37°C, and 
then washed with PBS. Endothelial cells were seeded on fibrinogen coatings to determine 
their adhesion, migration and proliferation.
In vitro adhesion, proliferation and migration
Adhesion was performed by seeding HUVEC on fibrinogen coatings in a density of 2 x 
104 cells/cm2 in medium (M199) supplemented with 100 U/mL penicillin and 100 mg/
mL streptomycin (p/s) and 1% human serum albumin (HSA, Sanquin, Amsterdam, The 
Netherlands). After 0.5, 1, 2 and 4 hour(s) the wells were carefully washed and cells were 
fixated. Pictures were taken using a Qimaging camera on a Zeiss microscope connected to 
a computer with Optimas image analysis software (Media Cybernetics, Bethesda, USA). 
Cell counting was performed using Image J 1.42 software (National institutes of health, 
Bethesda, USA). 
Proliferation of HUVEC was determined using 3H-thymidine incorporation. HUVEC 
were seeded in a density of 6 x 103 cells/cm2 in M199 supplemented with p/s and 1% 
HSA. Cells adhered to the fibrinogen coatings in 4 hours, followed by 72 hours stimulation 
of endothelial cell proliferation with M199 supplemented with p/s, 10 ng/mL vascular 
endothelial growth factor (VEGF) and 10% heat-inactivated newborn calf serum (NBCSi). 
To quantify the proliferation 1 μCi 3H-thymidine was added during the last 16 hours of 
growth. The beta-emission was measured with Ultima Gold scintillation fluid on 1900 TR 
Liquid Scintillation Analyzer (Packard Bioscience, Massachusetts, USA). 
The migration of HUVEC was studied by determining their migration into a cell free 
area. Endothelial cells were seeded in a density of 6 x 104 cells/cm2 in M199 supplemented 
with p/s and 1% HSA. Prior to cell seeding, a device of 1.5 x 20 mm was placed into the 
well to prevent cell adhesion. Cells adhered to the fibrinogen coating, the device was 
removed and migration was stimulated for 16 hours by addition of M199 supplemented 
with p/s, 10 ng/mL VEGF and 10% NBCSi. Five measurements of cell-free area per 
picture were performed using Photoshop 5.0 software (Adobe, San Jose, USA).
In vitro tube formation
The in vitro tube formation was determined using three-dimensional (3D) fibrin matrices 
and HMVEC, as described by Koolwijk et al.22 Prior to polymerization, all fibrinogen 
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fractions were dialyzed to M199 supplemented with p/s, and the γA fibrin matrix was 
supplemented with human plasma coagulation FXIII (final concentration 0.31 U/mL). 
Fibrin matrices were prepared by addition of thrombin (0.01 U/mL) to 2 mg/mL fibrinogen 
solution. After 4 hours polymerization, thrombin was inactivated by 16 hours incubation 
with M199 supplemented with 10% heat-inactivated human serum (HSi) and 10% NBCSi. 
HMVEC were seeded in confluent density and after 24 hours, and subsequently at 48 
hours intervals, the HMVEC were stimulated with M199, 10% HSi, 10% NBCSi, 10 ng/
mL tumor necrosis factor-a (TNFα, Sigma, St Louis, USA) and 25 ng/mL VEGF or 10 
ng/mL fibroblast growth factor-2 (FGF-2, Preprotech, London, UK). The tubular structure 
formation of HMVEC into the fibrin matrices was analyzed after staining the F-actin 
filaments with rhodamine-phalloidine (Molecular Probes, Eugene, USA) and nuclei with 
Hoechst (Molecular Probes). The Zeiss Axiovert 200 MarianasTM inverted microscope with 
2.5 and 10x magnification was used and controlled with Slidebook software (Intelligent 
Imaging Innovations, Denver, USA). The amount of fibrin degradation products in 
conditioned media of the tube formation assay were determined with the enzyme-linked 
immunosorbent assay FDP14-DD13, as described previously.23 
In vivo wound healing
Full-thickness excisional wound healing model
The wound healing model was performed as previously described by Tong et al.24 Briefly, 
24 male 9-week-old WAG/RijHsd rats (Harlan, Zeist, the Netherlands) were anesthetized 
with 5% isoflurane for induction and 2% isoflurane for maintenance (Isoflurane, Rhodia 
Organique Fine Limited, Bristol, UK) and two full-thickness wounds (15 mm diameter 
circles, the centers were 3 cm apart and 4 cm caudal to the scapulae) were excised. 100 
μL fibrinogen (2 mg/mL), mixed with 1U/mL thrombin, was topically applied or an equal 
amount of Tris-HCl buffer was applied for control wounds. Experiments were conducted 
with approval of the Animal Experiments Committee of the Erasmus University Medical 
Center.
Wound closure rates were measured with standardized digital photographs of 
the wounds taken on day 0, 3, 7, 10, 14 and 21 after surgery with an Olympus camera 
(Olympus, Tokyo, Japan). The wound area was determined with Image J 1.42, and the 
wound closure rate was calculated. 
The skin perfusion was determined using Laser Doppler perfusion measurements 
(LDPM, Perimed, Periflux System 5000, Perimed AB, Stockholm, Sweden) of the 
wounded and normal skin on day 14 and 21 after wounding, as described previously.24 
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A stable measurement at 33°C with the thermostatic Laser Doppler probe (PROBE 457, 
Perimed AB, Stockholm, Sweden) was set as baseline. Subsequently, the skin was heated 
to 44°C and the microcirculatory response was measured for 10 minutes using continuous 
coherent laser light at a wavelength of 780 nm. The reactive hyperemia rate was expressed 
as percentage change in baseline. 
The breaking strength of the wounded skin was measured as previously described by 
Tong et al.24 Briefly, after sacrificing the rat on day 21, the skin containing the wounded areas 
and the normal skin between the wounds were excised and uniformly cut into standardized 
dumbbell-shaped strips (central width 4 mm and length 45 mm). Subsequently, the strips 
were fixed perpendicularly between the two clips of the tensiometer (Testometrics AX, 
M250-2.5KN, Testometric Company, Lancashire, UK) and a constant strain rate of 60 
mm/minute using a 1.0 kg force transducer was applied. Before the skin collapsed, the 
maximum load was recorded in Newton (N). The ratio of the wound breaking strength was 
expressed relative to the breaking strength of normal skin. 
Paraffin sections of the wounds were immunohistochemically stained for CD34 
on endothelial cells (goat-anti-rat CD34 IgG, R&D system, Minneapolis, MN).25 The 
positive-signal density of CD34 was quantified using the Cell^D Imaging Solution 
software (Olympus, Tokyo, Japan).
Statistical analysis
Data are presented as mean ± standard error of the mean (SEM). Differences between 
groups were analyzed by univariate ANOVA, and differences between different time points 
were analyzed by ANOVA with pairwise comparisons (Bonferroni correction). Statistical 
analyses were performed with Statistical Package for the Social Sciences for windows 
(SPSS), Version 15.0 (Chicago, IL). Results were considered statistically significant with 
two-sided P-values <0.05. 
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RESULTS
Characterization of γA and γ¢ fibrinogen and fibrin
SDS-PAGE analysis showed the presence of the γ′-chain at approximately 50 kDa in the 
purified fraction of γ′ fibrinogen, and the absence hereof in the γA fibrinogen fraction (Figure 
1A). Western blotting with fibrinogen and γ′ fibrinogen specific antibodies confirmed this 
result (Figure 1B). In the γ′ fibrinogen fraction an extra band of approximately 77 kDa was 
visible, mass spectrometry confirmed that this was the FXIII B unit (data not shown). In 
the γ′ fibrinogen fraction the FXIII activity was significantly higher than those measured 
in the γA fraction (34 U/mg and 1 U/mg, respectively). The plasminogen activity in the 
γA and γ′ fibrinogen fractions was similar (0.012 U/mg and 0.011 U/mg, respectively). 
Purified γA and γ′ fibrinogen were shown to be >95% clottable. Confocal microscopy on 
the fibrin matrices showed thicker fibers in γA fibrin without FXIII (0.37 ± 0.08 µm) than 
in γ′ fibrin (0.29 ± 0.04 µm). However, the thickness of the γA fibers (0.29 ± 0.04 µM) was 
similar to that of γ′ fibrin, when equal amounts of FXIII were supplemented as in γ′fibrin 
(Figure 2). In addition to the fiber thickness, we also observed that the distribution of the 
fibers and the number of branch points differed for γ′ and γA. This is not yet studied in 
more detail, but we included it in the discussion and others have also seen this.
In vitro endothelial cell behavior
The adhesion of HUVEC to γA and γ′ fibrinogen coatings revealed no significant differences 
in the number of adhering endothelial cells. However, the endothelial cells adhered slightly 
faster to γA fibrinogen coatings (P<0.05) after 0.5 and 1 hour. The adhesion of endothelial 
cells to gelatin coatings was 2–fold better than to γA and γ′ fibrinogen coatings, whereas 
BSA coatings showed hardly any cell adhesion (Figure 3A, n=3). The proliferation of 
HUVEC cultured on γA and γ′ fibrinogen coatings did not show significant differences in 
cell growth after adjustment for the cell adhesion (84 ±31% and 85 ±35% respectively) 
(Figure 3B, n=3). Also the migration of HUVEC cultured on γA and γ′ fibrinogen coatings 
was similar (1.89 ± 0.57 A.U and 1.89 ± 0.50 A.U. respectively) (Figure 3C, n=6), whereas 
on gelatin coatings the migration of endothelial cells was slightly better (2.83 ± 0.30 A.U). 
The in vitro tube formation of HMVEC in 3D γA fibrin matrices showed massive and 
uncontrolled tube formation, with many sprouting cells and a high fibrinolytic activity 
explaining the bright structures (Figure 4A). In the γ′ fibrin matrix the endothelial cells 
formed stable tube-like structures with a normal morphology. Quantification of the in vitro 
tube formation revealed 2.2x more ingrowth of endothelial cells into γA fibrin (Figure 4B). 
Elim_Ch_thesis2.indd   114 5/21/12   11:00 AM
115
The effect of fibrinogen γ variants on wound healing
The fibrin degradation products in conditioned media of the in vitro tube formation assay 
was significantly higher in γA fibrin when compared to those measured in γ′ fibrin (Figure 
4C, p<0.05).
Figure 1. Characterization of the γA and γ′ fibrinogen fractions. 
(A) SDS–PAGE with total protein staining and (B) Western blotting of fibrinogen with polyclonal human 
fibrinogen antibody (red) and monoclonal human γ′ fibrinogen antibody (green). M: protein electrophoresis 
marker. 
Figure 2. Confocal microscopy of γA and γ′ fibrin matrices.
Fibrin matrices prepared from γA fibrinogen without additional FXIII (γA), γA supplemented with FXIII 
(γA+FXIII) and γ′ fibrin (γ′) as described in Materials and methods. The scale bars indicate 5 μm.
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Figure 3. In vitro functional characteristics of HUVEC on various fibrinogen coatings. (A) Adhesion of 
HUVEC to gelatin (solid line), γA fibrinogen (dashed line), γ′ fibrinogen (dotted line) and 1% BSA (dashed-
dotted line) coatings (n=3). (B) The proliferation of HUVEC on gelatin, γA and γ′ fibrinogen coatings, 
measured by 3H-thymidine incorporation (n=3). The values were corrected for cell adhesion and expressed 
as percentage of HUVEC proliferation on gelatin coatings. (C) The migration of HUVEC on gelatin, γA and 
γ′ fibrinogen coatings, after 16 hours of migration the area of migration was determined (n=6). 
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Figure 4. Fluorescent microscopy of in vitro tube formation by HMVEC. 
HMVEC were seeded on three dimensional γA and γ′ fibrin matrices and tubular structure formation was 
stimulated. (A) Representative pictures of the in vitro tube formation assay. The staining represents the 
F-actin filaments of endothelial cells, the bright structures represent the tubular structures in the fibrin 
matrix. (B) Quantification of the amount of tube formation in the various fibrin matrices (n=3). (C) Fibrin 
degradation products that were present in conditioned medium of the in vitro tube formation assay, as 
determined by ELISA (n=3).
In vivo skin wound healing
The closure rate of the dorsal full-thickness wounds of the rats was similar for controls 
and unfractionated, γA and γ′ fibrin treated wounds (Table 1 and Figure 5). All wounds 
were closed 21 days after surgery. The wound closure rate on day 7 and day 10 tended 
to be slightly higher in the γA fibrin treated group, when compared to the γ′ fibrin treated 
group (Table 1). In addition, the Laser Doppler perfusion measurements showed that the 
γA fibrin treated wounds had a slightly, but not significantly, higher vasodilator response 
in the skin at day 21 than γ′ fibrin treated wounds (53.0 ± 10.0% versus 41.3 ± 6.5%). Also 
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the breaking strength ratio was slightly, but not significantly, higher in the γA fibrin treated 
group, when compared to the γ′ fibrin treated group (0.15 ± 0.03 versus 0.11 ± 0.02).
The vessel density and vessel size in the wounds were determined from paraffin 
embedded sections after CD34 staining of endothelial cells. No significant differences 
in vessel density and vessel size were observed in control and fibrin treated animals. The 
vessel density showed a higher vessel number in the γA fibrin treated group than the γ′ 
fibrin treated group (127 ± 47 versus 67 ± 13 vessels/mm2). Moreover, the vessel size was 
slightly, but not significantly, smaller in the γA fibrin treated group, when compared to the 
γ′ fibrin treated group (196 ± 25 versus 232 ± 16 μm2/vessel).
Table 1. In vivo wound healing in the rat model. 
Parameters Unfractionated γA γ′
Control fibrinogen fibrinogen fibrinogen
Wound closure rate (%)
day 3 0.3 ± 2.6 -0.1 ± 4.1 0.9 ± 2.6 -2.1 ± 3.7
day 7 43.7 ± 3.4 37.7 ± 4.9 48.5 ± 3.5 45.9 ± 4.6
day 10 82.0 ± 1.8 81.6 ± 2.1 85.0 ± 2.8 81.2 ± 2.8
day 14 97.1 ± 0.5 95.4 ± 0.7 96.2 ± 0.7 97.1 ± 0.7
day 21 100 ± <0.1 100 ± <0.1 99.8 ± 0.2 100 ± <0.1
Laser Doppler perfusion (%)
day 14 27.3 ± 6.7 34.5 ± 6.0 20.4 ± 5.5 28.6 ± 6.4
day 21 26.2 ± 3.6 37.4 ± 4.2 53.0 ± 10.0 * 41.3 ± 6.5
Breaking strength ratio
day 21 0.112 ± 0.021 0.104 ± 0.013 0.151 ± 0.028 0.107 ± 0.017
Immunohistochemistry
Vessels density (n/mm2) 59 ± 7 44 ± 8 127 ± 47 67 ± 13
Vessel size (μm2) 245 ± 14 302 ± 60 196 ± 25 232 ± 16
Vessel area (%) 1.43 ± 0.13 1.31 ± 0.29 2.04 ± 0.44 1.49 ± 0.23
The data are given as mean ± SEM. Laser Doppler perfusion is expressed relative to baseline 
measurements at 33°C (% increase). The breaking strength is expressed as ratio relative to the breaking 
strength of normal skin. * P<0.01 γA fibrin versus control treated wounds.
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Figure 5. Overview of the perfusion, breaking strength and vessel properties of the in vivo wound healing 
assay. Cntr, Unfr, γA and γ′ represent control (Tris-HCl), unfractionated fibrinogen, γA fibrinogen and γ′ 
fibrinogen treated wounds. (A) The perfusion was measured with Laser Doppler and results are expressed 
as percentage change from baseline measurement in the same wound. (B) The breaking strength ratio of 
wounded and normal skin is given. The vessel density (C) and the vessel size (D) were determined with 
immunohistochemistry after staining CD34 on endothelial cells. Means are indicated in the graphs.
9
Elim_Ch_thesis2.indd   119 5/21/12   11:00 AM
120
Chapter 9
DISCUSSION
In this study we showed that γA and γ′ fibrin matrices have different effects on the in 
vitro tube formation, wherein the γA fibrin matrix shows the highest angiogenic potential. 
No clear differences in functional endothelial cell characteristics on γA and γ′ fibrinogen 
coatings were seen in the in vitro endothelial cell adhesion, proliferation and migration 
assays. In the full-thickness wound healing model with these fibrinogen forms, the data 
suggest that γA fibrin has a slightly better wound-healing promoting property. Although 
only minor effects were found on the wound closure rate, the vascularization at day 21 and 
restoration of biomechanical strength. Furthermore, we observed different structures for 
γA and γ′ fibrin matrices, which could be partly explained by FXIII that was co-purified 
in the γ′ fraction, since supplementing FXIII in the γA fraction abolished the difference in 
fibrin diameter. 
The in vitro endothelial cell adhesion, proliferation and migration showed no significant 
differences between γA and γ′ fibrinogen coatings. Coating of fibrinogen to culture plastic 
has previously been shown by Filova et al.26 Furthermore, we showed an altered migration 
and proliferation on HMW and LMW-fibrinogen coatings,21 which was consistent with 
the in vitro endothelial cell tube formation.27 Unlike the tube formation in γA and γ′ fibrin, 
no significant differences in adhesion, migration and proliferation responses of HUVEC 
on γA or γ′ fibrinogen coatings were found. Endothelial cells are known to interact with 
various sites on the C-terminus of the α-chain (such as α95-97 and α572-574),28 but the 
interactions with the C-terminus of γA or γ′ fibrinogen were not shown to play a significant 
role in endothelial cell adhesion.29 
The in vitro tube formation showed more tube-like structures and higher fibrinolysis of 
HMVEC in γA fibrin, than that of γ′ fibrin. γ′ fibrin facilitated controlled tubular structure 
formation, whereas γA fibrin showed massive fibrinolysis and sprout formation. The 
increased fibrinolysis rate was confirmed with higher levels of fibrin degradation products 
in the conditioned media of γA fibrin matrices and is in concordance with previous 
studies.30, 31 Differences in fiber thickness did not explain the effects on angiogenesis and 
fibrinolysis, since the results of confocal microscopy showed that the fiber thickness was 
similar in γA and γ′ fibrin matrices with equal FXIII levels. We did observe that γA fibrin 
matrices were more opaque than γ′ fibrin matrices, and since this can not be explained 
by the different fiber thickness, this may be the result of different clot structure that we 
observed for γ′ fibrin. A similar observation on clot structure was reported by Gersh et 
al., who also reported a higher number of branch points and free fiber ends in γA fibrin 
matrices.32 
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We observed thinner fibrin fibers in γ′ than in γA fibrin matrices, this has also been 
previously reported.11, 12 Our data suggest that the difference in fiber thickness may be the 
result of differences in FXIII concentration. We showed that γA fibrinogen contains very 
little FXIII, while γ′ fibrinogen contains a considerable amount of FXIII. Therefore, we 
supplemented γA fibrinogen with FXIII to obtain similar FXIII concentrations during our 
in vitro experiments. We then observed that γA fibrin matrices have similar fiber thickness 
as γ′ fibrin matrices. In line with Collet et al. no significant differences were observed 
when FXIII was supplemented to γA fibrin.31
The in vivo experiments using the full-thickness wound healing model showed 
no clear differences between γA and γ′ fibrin matrices on day 21 after surgery. Several 
methodological reasons may be underlying this discrepancy; The vascularization parameters 
were determined on day 14 (LDPM) or day 21 (LDPM, immunohistochemistry), this may 
not be the optimal time point. Much of the vascularization may already taken place and 
earlier time points may show better distinctions. On the other hand, the breaking strength 
increases during the process and continues for months, hereof later time points should 
be used. Furthermore, we used healthy rats that showed a very rapid wound healing. 
Fibrinogen did not show benefits over controls in these wounds, an explanation might be 
that the wound healing process is already optimal in healthy rats and improvement cannot 
be made with fibrin matrices. Choosing a model in which wound healing is disturbed, such 
as the diabetic db/db mouse,33 may show an improvement for application of fibrinogen and 
its specific forms. 
In conclusion, this study shows that matrices of γA and γ′ fibrin have different structural 
and functional characteristics, and alter the in vitro tube formation and fibrinolysis of 
endothelial cells. In addition, the in vivo experiments suggest that γA fibrin matrices may 
be beneficial, but more data are needed before any firm conclusion can be drawn.
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ABSTRACT
Ischemic stroke is associated with leucocyte activation. Activated leucocytes release 
elastase, an enzyme that can degrade fibrinogen. Fibrinogen elastase degradation products 
(FgEDP) may serve as a specific marker of elastase proteolytic activity. In a case-control 
study of 111 ischemic stroke patients and 119 controls, significantly higher FgEDP levels 
were observed in cases than in controls, both in the acute phase and in the convalescent 
phase. Results were only slightly affected by adjustment for cardiovascular risk factors, 
C-reactive protein and fibrinogen. Our findings suggest that FgEDP might be involved in 
the pathogenesis of stroke.
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INTRODUCTION
The accumulation and activation of leucocytes have been demonstrated in ischemic 
stroke.1 Activated leucocytes, particularly polymorphonuclear leucocytes (PMNs), release 
several proteolytic enzymes including elastase, which can degrade components of the 
extracellular matrix and plasma proteins.2-3 Previously, an association has been found 
between levels of leucocyte elastase and the risk of cardiovascular events and ischemic 
stroke.4-5 However, elastase levels may not accurately reflect the proteolytic activity of 
elastase in vivo, as proteolysis is dependent on protease levels as well as the concentration 
and activity of protease inhibitors.6-7 Until recently, specific biochemical markers for the 
proteolytic activity of elastase were lacking. One of the proteins that can be degraded by 
elastase is fibrinogen, resulting in fibrinogen elastase degradation products (FgEDP). An 
assay has recently been developed, based on a monoclonal antibody with a high affinity 
and specificity for elastase-degraded fibrinogen, which enables the assessment of elastase 
proteolytic activity by measuring FgEDP levels.7 
PATIENTS AND METHODS
We performed a case-control study that consecutively recruited patients (n = 124) with 
a first-ever ischemic stroke who were admitted to the department of Neurology of the 
Erasmus Medical Centre, Rotterdam.8 Age- and sex-matched population controls (n = 125) 
were partners, friends or neighbours of the patients, without a history of stroke. Ischemic 
stroke was defined as the acute onset of focal cerebral dysfunction due to cerebral 
ischemia with symptoms lasting more than 24 hours. A brain computerized tomography 
(CT) scan was made in all patients within 3 days after symptom onset to confirm the 
diagnosis of ischemic stroke and to rule out hemorrhagic stroke. All patients underwent 
a standard twelve lead electrocardiogram and further cardiological work-up if indicated, 
and duplex ultrasound or angiography of the carotid or vertebral arteries. Stroke severity 
was assessed with the National Institutes of Health Stroke Scale (NIHSS). Aetiological 
stroke type was classified according to the TOAST (Trial of ORG 10172 in Acute Stroke 
Treatment) criteria. Patients with a definite non-atherosclerotic cause for stroke, such as 
a mechanical heart valve, endocarditis, or dissection, as well as persons >75 years or 
using oral anticoagulants were excluded. The Medical Ethics Committee of the Erasmus 
Medical Centre, Rotterdam approved the study and written informed consent was obtained 
from all participants.
10
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In both patients and controls, we collected detailed information about medical history 
and cardiovascular risk factors and fasting venous blood samples were drawn under strictly 
standardized conditions.8 Venepuncture in patients was performed between 7 and 14 days 
after the stroke. In a subgroup of 64 patients, a second blood sample was obtained under 
the same conditions when they visited the outpatient department in the convalescence 
phase, 3 months after the stroke. Blood was collected into citrate (0.105 mol/l) with use of 
the Vacutainer (Becton-Dickinson, Plymouth, UK) system. Blood was centrifuged (2000 g 
for 30 min at 4°C) and plasma was stored in aliquots at −80°C until use. C-reactive protein 
(CRP) and fibrinogen levels were measured according to a previously described protocol.8 
Plasma levels of FgEDP were measured by enzyme-linked immunosorbent assay 
using a monoclonal antibody against FgEDP (1-1/B3) as catching antibody and a 
monoclonal antibody directed to the D-region of fibrinogen as tagging antibody. The test 
had a within-run coefficient of variation of <5% and between-run coefficient of variation 
of <20%.7 FgEDP levels were expressed as nanograms of fibrinogen equivalents (FE) per 
ml, identifying the proportion of fibrinogen that is degraded by elastase directly. Plasma 
for measuring FgEDP levels was available for 111 patients in the acute phase and 48 
patients in the convalescence phase and for 119 control persons.
Student’s t-test was used to compare levels of FgEDP between cases and controls 
and between patients with mild ischemic stroke (NIHSS score <3) and those with more 
severe stroke (NIHSS score ≥3, with 3 being the median NIHSS score in our patient 
group). The association between FgEDP levels and the occurrence of ischemic stroke was 
analysed through multivariate logistic regression, with FgEDP concentration categorized 
into quartiles of the distribution in the control group. The lowest quartile was set as the 
reference category. Analyses were adjusted for smoking, hypertension, diabetes mellitus, 
hypercholesterolaemia, a positive family history of cardiovascular diseases and levels of 
CRP and fibrinogen. All analyses were performed using spss software, version 15.0 (SPSS 
Inc., Chicago, IL, USA).
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RESULTS
Smoking, hypertension, and diabetes were more frequent among cases, and ischemic 
stroke patients had higher levels of CRP and fibrinogen than healthy controls (Table 1). 
FgEDP levels in the acute phase were significantly higher in cases [mean ± standard 
deviation (SD), 251 ± 121 ng FE/ml] compared with control persons (169 ± 41 ng FE/ml; 
P < 0.001). Levels of FgEDP seemed to be slightly higher in patients with more severe 
stroke (259 ± 109 ng FE/ml) as compared with those with mild stroke (235 ± 141 ng FE/
ml), although the difference was not statistically significant (P = 0.33).
Individuals in the highest quartile of FgEDP had a significantly higher risk of ischemic 
stroke compared with those in the lowest quartile (odds ratio [OR], 9.6; 95% confidence 
interval [CI], 3.9–23.2, Table 1). The association was only slightly affected by adjustment 
for cardiovascular risk factors and levels of CRP and fibrinogen (OR, 7.5; 95% CI, 2.2–
25.0). In the samples collected 3 months after the event, FgEDP levels were lower than in 
the acute phase (mean ± SD, 203 ± 58 ng FE/ml; P = 0.004), but still significantly higher 
than in the control group (P < 0.001). Patients for whom second FgEDP measurements 
were available were not significantly different from those without a second measurement 
with respect to baseline characteristics, including NIHSS score. 
Table 1. Baseline characteristics of the study population
Characteristic Cases Controls p-value
n 111 119
Women 52 (47%) 56 (47%) NS
Age (yr), mean (SD) 55 (±12) 56 (±12) NS
Smoking 54 (49%) 34 (29%) 0.002
Hypertension 53 (48%) 22 (19%) <0.001
Diabetes 18 (16%) 5 (4%) 0.002
Hypercholesterolemia 70 (63%) 80 (67%) 0.700
Family history of cardiovascular disease 66 (60%) 60 (50%) 0.120
CRP (mg/l), median (interquartile range) 2.06 (0.41-7.89) 1.42 (0.58-3.34) 0.008
Fibrinogen, (g/l) mean (SD) 3.7 (±1.1) 3.4 (±0.6) 0.012
NIHSS score, median (interquartile range) 3.0 (2.0-5.0)
Values are numbers (percentages), unless stated otherwise. NS, not significant; SD, standard deviation; 
CRP, C-reactive protein; NIHSS, National Institutes of Health Stroke Scale.
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Table 2. Association between FgEDP levels and risk of first ever ischemic stroke. Odds ratio (OR) with 95% 
confidence interval (CI) for quartiles of the distribution.
Quartiles Q1 Q2 Q3 Q4
FgEDP (ng FE/ml) < 138.7 138.7 - 163.2 163.2 - 189.8 >189.8
OR (95% CI)
   Model 1 1.0 (ref.) 1.3 (0.5 - 3.8) 1.57 (0.6 - 4.4) 9.6 (3.9 -23.2)
   Model 2 1.0 (ref.) 1.1 (0.3 - 3.8) 0.7 (0.2 - 2.3) 7.5 (2.2 -25.0)
Model 1: unadjusted model, Model 2: adjusted for smoking, hypertension, diabetes, hypercholesterolaemia, 
family history of cardiovascular diseases, C-reactive protein and fibrinogen.
OR, odds ratio; CI, confidence interval; FgEDP, fibrinogen elastase degradation products.
DISCUSSION
To our knowledge, this is the first study to evaluate the relationship of FgEDP with ischemic 
stroke. Among the strengths of this study are the consecutive inclusion of cases, brain CT-
imaging in all patients, the use of population-based controls and the detailed collection of 
data on potential confounders. Limitations are the relatively small number of participants 
and the fact that we cannot reach a conclusion regarding the causality of FgEDP in stroke 
pathogenesis because of the case-control design of the study. It is possible that the elevated 
levels of FgEDP in stroke patients were due to an acute phase reaction. Yet, adjustment for 
the acute phase proteins CRP and fibrinogen did not affect the risk estimates. In addition, 
FgEDP levels in patients 3 months after the event, although lower than in the acute phase, 
were still significantly higher than those in controls. Furthermore, data on leucocyte counts 
might have provided more insight in the mechanism to explain the association between 
FgEDP levels and ischemic stroke, but unfortunately these were not available in our study.
We used an assay that has been proven to be very specific for FgEDP. The monoclonal 
antibody (1-1/B3) has a high affinity for elastase-degraded fibrinogen, while no reactivity 
was found with plasma fibrinogen or with fibrinogen degradation products generated by 
plasmin or other active proteases, such as metalloproteases or cathepsins (unpublished 
results). FgEDP levels may thus be considered a good marker of PMN-derived elastase 
activity.
The exact significance of the finding that elastase activity is increased in patients with 
ischemic stroke is, as yet, unclear. Previous studies have shown a relationship between 
leucocyte elastase levels and the risk of cardiovascular events and stroke.4-5 Elastase 
levels are generally regarded as a marker of leucocyte activation.2, 4 Thus far, it is not 
Elim_Ch_thesis2.indd   130 5/21/12   11:00 AM
131
Strongly increased levels of fibrinogen elastase degradation products in patients with ischemic stroke thesis
known whether the association between elastase levels and stroke indicates a causal role 
of elastase in stroke pathogenesis or just reflects the involvement of leucocyte activation. 
Accumulation and activation of leucocytes, particularly PMNs, were shown to occur 
in cerebral ischemia.1 Activated PMNs accumulate on platelet thrombi and incorporate 
into the fibrin clot and may thus play a role in activation of the coagulation cascade.2-3, 9 
Elastase released by activated PMNs might also directly contribute to stroke pathogenesis 
because of its pro-atherogenic properties5 or through activation of coagulation pathways.3-4 
Alternatively, leucocyte activation and increased elastase activity might only reflect an 
inflammatory reaction, and not be causally related to stroke risk. An association between 
inflammatory markers and the risk of stroke has repeatedly been observed, although it 
remains controversial whether inflammation actually contributes to the aetiology of 
ischemic stroke or rather occurs in response to atherosclerosis or ischemia.10 A final 
explanation for our findings could be a direct effect of FgEDP on the occurrence of ischemic 
stroke. Evidence suggests that split products of fibrinogen resulting from degradation 
by elastase might be able to influence coagulation activity by prolonging the thrombin-
induced generation of fibrin.11-12 Whether elastase activity or increased FgEDP levels in 
itself play a causal role in stroke pathogenesis or are only markers of PMN activation or 
inflammation needs clarification in further studies.
10
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In this thesis, the main aim was to study the role of genetic variants and protein variants 
of fibrinogen in cardiovascular diseases (CVD) and in wound healing. In addition, the 
relationship between fibrinogen elastase degradation products (FgEDP) and cardiovascular 
disease was studied. In this chapter, the overall interpretations and implications of the 
results will be discussed. Furthermore, we explore the perspectives for future research.
FIBRINOGEN GENE VARIATIONS IN CARDIOVASCULAR DISEASES
The investigations that were performed in the Rotterdam study, a population-based cohort 
study, provide evidence for an association of common variations in the FGG and FGA 
genes with cerebral small vessel disease (Chapter 2) and ischemic stroke (Chapter 4 and 
Chapter 5). However, no association was found between haplotypes and dementia or 
Alzheimer’s disease (Chapter 3) (Table 1).
In both the Rotterdam Scan study (Chapter 2) and the Rotterdam study (Chapter 4), no 
relationship was observed between individual SNPs and risk of cerebrovascular disease, 
but a relationship was observed when the SNPs were combined and haplotypes were 
constructed. This finding suggests that haplotype analysis is a more powerful analysis 
because information of multiple markers is then used simultaneously.1-2
Surprisingly, the carriers of the FGG-H3 haplotype appear to be protected against 
ischemic stroke in the COCOS study (Chapter 5). In contrast, in the Rotterdam study 
(Chapter 4), even though the same arterial thrombotic endpoint has been used, no 
significant interaction was found between this haplotype and ischemic stroke. The reason 
for this discrepancy may be a difference in the study design, since the COCOS study is a 
case-control study and the Rotterdam study is a population-based cohort study. Another 
explanation could be the relative small population size of COCOS study that therefore 
has low statistical power, which increases the chance of false positive and false negative 
results. The SNP that is tagging FGG-H3 and not associated with stroke in the Rotterdam 
study, is also part of the FGG+FGA-H3 haplotype, which was associated with an increased 
risk of ischemic stroke (Chapter 4). This contradictory result may be explained by the 
effect of two other tagging SNPs that are also included in the FGG+FGA-H3.
No association between common variations in the FGG and FGA genes and risk 
of dementia or risk of white matter lesions could be found. Based on this finding, we 
propose that these genes do not modulate the risk of these diseases. Nevertheless, we 
cannot exclude that we have missed small haplotype effects because we used a minor 
allele frequency cutoff value of 1% (the Rotterdam Scan study and the Rotterdam study of 
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dementia) or 5% (studies of stroke). However, if we use a threshold of 1% for the minor 
allele frequency, the groups were very small and therefore the statistical power in the study 
was too low for analysis of these haplotypes. 
The relationship between haplotype-tagging polymorphisms in the total fibrinogen 
gene cluster and fibrinogen plasma levels and the risk of cardiovascular diseases was 
reported.3-5 Yet, no association between fibrinogen levels and haplotypes of the FGG, FGA 
plus FGB genes was observed in our studies. The current hypothesis is that fibrinogen levels 
are most strongly related to variants in the FGB gene since synthesis of the fibrinogen b 
gene is the rate limited step of fibrinogen synthesis.6-8 However, we cannot confirm this 
finding. The single SNPs in the FGB gene explains only 1% of the total variance in plasma 
fibrinogen levels,5 the remaining variations in fibrinogen levels are explained by the 
effects of variants in other genes and environmental factors. Our results are comparable 
with previous reports, which indicate that fibrinogen levels may not play a major causal 
role in CVD.3,9 It remains a possibility that the effect of genetics on CVD may be through 
alternative pathways that are independent of fibrinogen levels. The structure of the fibrin 
clot is one of these possible fibrinogen-related mechanisms by which the pathogenesis of 
thrombosis and vascular disease can be influenced.10-11
Table 1. Comparative analysis of association between fibrinogen haplotypes and risk of diseases
FGG + FGA Chapter 2  Chapter 3  Chapter 4
Haplotype Dementia Alzheimer’s 
disease
 Silent brain 
infarcts
Periventricular white 
 matter lesions
Subcortical white  
matter lesions
 Stroke Ischemic 
stroke
Hemorrhagic 
stroke
H1 (GGT-GGTA) 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref)
H2 (GAT-AGTG) 0.91 0.86 1.41* 1.29 0.9 1.12 1.2 0.98
H3 (GGC-GATA) 0.89 0.83 1.33 1.40* 0.87 1.02 1.36* 0.71
H4 (GGT-GGCA) 0.89 0.93 1.39 1.25 0.95 1.02 1.18 1.25
H5 (GGC-AGTA) 0.89 0.84 1.3 1.08 0.76 0.94 1.14 0.9
H6 (AGTG-GTA) 1.02 1.11 0.43 0.99 0.66 N/A N/A N/A
H7 (GGT-AGTG) 1.13 0.89  1.03 2.08 0.98  N/A N/A N/A
Presented are odds ratio and 95% confidence intervals (OR, 95%CI)
N/A, data not available; * Significant different from the reference group
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Recently, several genome-wide association (GWA) studies of fibrinogen levels and 
fibrinogen g′ levels in relation to CVD were performed.8,12-15 In GWA studies, numerous 
loci are scanned for unsuspected genetic determinants. These studies suggested that 
the fibrinogen levels are related with the inflammatory cascade.8,14 There is one GWA 
study that investigated determinants of fibrinogen g′, which reported that the g′ levels are 
associated with SNPs nearby the fibrinogen gene.15 Unfortunately, fibrinogen g′ levels 
are not available in the Rotterdam Study, hence it is difficult to elucidate the underlying 
mechanism between the genetic variations and risk of CVD via g levels. The GWA approach 
reveals that genetic variations that influence the levels and risk of CVD may provide us 
the novel biological insights in our understanding of diseases, but further replications or 
functional research of genetic variations is needed to verify these findings. 
FIBRINOGEN γ′ LEVELS IN CARDIOVASCULAR DISEASES
The fibrinogen levels were significantly higher in patients with ischemic stroke (IS, 
Chapter 5, 6, 7), acute pulmonary embolism (PE, Chapter 6), refractory unstable angina 
pectoris (UAP, Chapter 6) and intracerebral hemorrhage (ICH, Chapter 8) compared to 
those in healthy controls. The fibrinogen g′ levels and fibrinogen g′/total fibrinogen ratios 
(g′ ratios) were also elevated in patients with various cardiovascular diseases (IS, PE, UAP 
or ICH) compared with those in healthy controls (Table 2). 
Fibrinogen g′ is one of the natural occurring isoforms of the fibrinogen molecule, and 
it may be expected that during an acute phase reaction, all isoforms of fibrinogen increase 
in parallel. If this assumption is correct, an increase in the total amount of fibrinogen 
molecules will give a parallel increase in the number of fibrinogen g′ molecules and 
the g′/total fibrinogen ratio will remain unchanged. We were interested to see whether 
this parallel increase occurred or not. Interestingly, fibrinogen g′ levels and ratios were 
significantly decreased in the IS patients during the convalescent phase (Chapter 5) 
and significantly increased in the stabilized UAP patients compared to healthy controls 
(Chapter 6), while the plasma fibrinogen levels were similar among these patients and 
controls. This finding indicates that the alternative mRNA processing of fibrinogen g′ is 
at least partly independent of fibrinogen levels, which is in accordance with results from 
a previous report.16 Furthermore, levels of fibrinogen g′ were still significantly increased 
in IS patients after adjustment for cardiovascular risk factors, although the g′ ratio was 
comparable in patients and controls (Chapter 7). This result is in agreement with an earlier 
study that the fibrinogen g′ levels, but not the g′ ratios, were significantly higher in patients 
with myocardial infarction than those in controls.17 In addition, the absolute g′ level in IS 
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patients had a stronger association with outcome than the g′/total fibrinogen ratio, which 
suggest that the absolute level of fibrinogen g′ may be more important than the g′/total 
fibrinogen ratio (Chapter 7).
 
Table 2. Summative results of fibrinogen levels, fibrinogen γ′ levels, and fibrinogen γ′/fibrinogen ratios in 
various studies described in this thesis 
Chapter Group Subgroup N Total 
fibrinogen 
(g/L)
Fibrinogen 
γ′ 
(g/L)
 γ′ /total 
fibrinogen 
ratio 
Chapter 5 Controls 119 3.41 (0.61) 0.34 (0.10) 0.10 (0.03) 
Ischemic stroke patients Acute Phase 114 3.69 (1.06)  0.42 (0.17) 0.11 (0.03) 
Convalescent Phase 47 3.34 (0.76) 0.29 (0.09) 0.09 (0.02)
Chapter 6 Controls 173 3.30 (0.59) 0.33 (0.10) 0.10 (0.03)
Patients Ischemic stroke 53 3.87 (1.19)  0.49 (0.18) 0.13 (0.02) 
Pulmonary embolism
     Non-acute phase 13 2.69 (1.42) 0.53 (0.27) 0.20 (0.06)
     Acute phase 16 4.39 (2.30) 0.79 (0.33) 0.24 (0.19) 
Unstable angina pectoris
     Stabilized 130 3.36 (0.76) 0.46 (0.15)  0.14 (0.04) 
     Refractory 72 3.82 (1.00)  0.53 (0.23) 0.14 (0.04)
Chapter 7 Controls 156 3.37 (0.72) 0.32 (0.13) 0.10 (0.03)
Ischemic stroke patients All 200 3.69 (0.96) 0.37 (0.15) 0.10 (0.04)
     0–7 days 100 3.76 (1.11) 0.40 (0.17) 0.11 (0.04) 
     ≥8 days 100 3.62 (0.78) 0.34 (0.12) 0.10 (0.03) 
     Favourable outcome 173 3.64 (0.89) 0.36 (0.14) 0.10 (0.03)
     Unfavourable outcome 27 3.97 (1.34) 0.47 (0.18) 0.13 (0.06)
Chapter 8 Controls 156 3.37 (0.72) 0.32 (0.13) 0.10 (0.03)
Intracerebral hemorrhage 
patients 
All 55 4.41 (1.21) 0.40 (0.14) 0.09 (0.03)
     No IVE 47 4.41 (1.23) 0.38 (0.14) 0.09 (0.03)
     IVE present 8 4.40 (1.13) 0.51 (0.13) 0.12 (0.03)
IVE, intraventricular extension. Data presented are means (SD)
11
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&RPSDUHGWRKHDOWK\FRQWUROVWKH¿EULQRJHQaƍOHYHOVDQGUDWLRVZHUHVWURQJO\LQFUHDVHG
LQ,6SDWLHQWV&KDSWHUGXULQJWKHDFXWHSKDVH7KH\ZHUHFRPSDUDEOHWRWKRVHRI
FRQWUROVLQWKHVXEDFXWHSKDVHGD\VDIWHUWKHHYHQW&KDSWHUDQGHYHQVLJQL¿FDQWO\
GHFUHDVHGLQWKHFRQYDOHVFHQWSKDVHPRQWKVDIWHUWKHHYHQW&KDSWHU7KHLQFUHDVHRI
WKHOHYHOVGXULQJWKHDFXWHSKDVHLVSUREDEO\DFRQVHTXHQFHUDWKHUWKDQDFDXVHRIWKHHYHQW
VLQFHZHLQFOXGHGSDWLHQWVDIWHUWKHHYHQWRFFXUUHG7KHGHFUHDVHLQWKHFRQYDOHVFHQWSKDVH
PD\UHÀHFWWKHSUHVWURNHOHYHOVZKLFKZRXOGVXJJHVWWKDWWKHDQWLWKURPERWLFSURSHUWLHVRI
¿EULQRJHQaƍDUHPRUHLPSRUWDQWWKDQLWVSURWKURPERWLFSURSHUWLHV2QHRIWKHH[SODQDWLRQV
IRUWKHVH¿QGLQJVFRXOGEHWKDWWKHDOWHUQDWLYHSURFHVVLQJPHFKDQLVPLVDIIHFWHGE\WKH
DFXWHSKDVHRIGLVHDVHVLQFHDUHODWLRQVKLSEHWZHHQDFXWHSKDVHUHDFWLRQVDQGDOWHUQDWLYH
P51$SURFHVVLQJKDYHEHHQVXJJHVWHGSUHYLRXVO\IRURWKHUJHQHV It is also possible 
WKDWWKHFOHDUDQFHRI¿EULQRJHQa$DQGaƍLQWKHSODVPDLVGLIIHUHQWGXULQJYDULRXVVWDJHV
of disease.21 
$SDUW IURP WKHDVVRFLDWLRQEHWZHHQ LQFUHDVHG¿EULQRJHQaƍ OHYHOVDQGXQIDYRUDEOH
VKRUWWHUPRXWFRPHLQWKHHDUO\SKDVHDIWHU,6&KDSWHUWKHUHLVDQRQVLJQL¿FDQWWUHQG
WRZDUGXQIDYRUDEOHRXWFRPHLQSDWLHQWVZLWK,&+&KDSWHU+RZHYHUWKH¿EULQRJHQaƍ
OHYHOVRUUDWLRGRQRWSUHGLFWVKRUWRUORQJWHUPRXWFRPHLQSDWLHQWVZLWK8$3&KDSWHU
7KHGLVFUHSDQF\EHWZHHQWKHVHUHVXOWVPD\EHH[SODLQHGE\GLIIHUHQFHVLQHWLRORJ\DQG
pathogenesis of these diseases. It may also partly be due to medication.
FIBRINOGEN Ƣƍ IN WOUND HEALING
Fibrin plays an important role in haemostasis, but it also provides a temporary, degradable 
PDWUL[IRUWLVVXHUHSDLU,Q&KDSWHUZHLQYHVWLJDWHGWKHHIIHFWVRI¿EULQRJHQȖYDULDQWV
RQWKHLQYLWURHQGRWKHOLDOFHOOFKDUDFWHULVWLFVDQGLQYLYRZRXQGKHDOLQJ
$QJLRJHQHVLVRQHRIWKHLPSRUWDQWSURFHVVHVRIZRXQGKHDOLQJGHSHQGVKLJKO\RQ
¿EULQVWUXFWXUHDQGWKH LQWHUDFWLRQVEHWZHHQ¿EULQDQGFHOOXODUUHFHSWRUV:HHYDOXDWHG
angiogenesis by the in vitroWXEHIRUPDWLRQDQGVD\WKDWWKLVZDVPRUHSURQRXQFHGLQȖ$
WKDQLQȖƍ¿EULQPDWULFHVDQGWKXVWKLVZDVDFFRPSDQLHGZLWKDQLQFUHDVHGHQGRWKHOLDOFHOO
PHGLDWHG¿EULQRO\VLV7KLVUHVXOWVXJJHVWVWKDWWKHȖ$¿EULQPDWUL[PD\SOD\DQLPSRUWDQW
UROHLQDOORZLQJWKHHQGRWKHOLDOFHOOWRSHQHWUDWHLQWRWKHWKUHHGLPHQVLRQDOPDWUL[ZKLOH
VWUXFWXUDOVWDELOLW\RIWKHVXSSRUWLQJQHWZRUNLVQRWGDPDJHG)XUWKHUPRUHWKHHQGRWKHOLDO
FHOOPHGLDWHG¿EULQRO\WLFDFWLYLW\ZDV LQKLELWHGGXULQJ WKHDQJLRJHQHVLV LQ WKHȖƍ¿EULQ
PDWUL[ZKLFKZDVLQOLQHZLWKSUHYLRXVVWXGLHVWKDWWKHȖƍ¿EULQFORWZHUHPHFKDQLFDOO\
VWLIIHU WKDQ WKH Ȗ$¿EULQ FORW DQG UHVLVWDQW WR ¿EULQRO\VLV<HW WKH FORW VWUXFWXUH RI
¿EULQRJHQȖƍLVVWLOOXQGHUGHEDWH 
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The dynamic balance between proangiogenic and antiangiogenic factors is the 
key determinant for angiogenesis. The special characteristics of fibrinogen γ′ include a 
high affinity binding site for thrombin and an extra binding site for the FXIII B subunit. 
Furthermore, thrombin and factor XIII (FXIII) are angiogenic factors that contribute to 
new vessel formation.27-28 Therefore, it was surprising that the angiogenic effect in fibrin γ′ 
matrices is not as strong as in the γA fibrin matrix. We speculate that the thrombin binding 
site, which served as antithrombin I,29-30 inhibits  thrombin activity, as well as the loss of 
platelet integrin aIIbb3 binding site are not in favor of angiogenic activity,
31 therefore the 
angiogenic effect of fibrinogen γ′ was decreased. 
There were no significant differences between γA and γ′ fibrinogen coating when 
we studied the intrinsic endothelial cells (EC) functions that contribute to angiogenesis 
(adhesion, proliferation and migration). Since we examined the EC behavior on a two-
dimensional (2D) coating while the in vitro tube formation was performed in the three-
dimensional (3D) matrix, this may explain the discrepancy between EC behavior in 
functional assays and the angiogenesis assay. Moreover, in agreement with previous studies 
we demonstrated that the proliferation was strongly inhibited in human microvascular 
endothelial cells (HMVEC) but not in human umbilical vein endothelial cells (HUVEC),32 
which suggested that angiogenesis is mainly driven by HMVEC.33 Therefore, no major 
effect was observed while we performed the adhesion, proliferation and migration assays 
in the 2D coating using HUVEC.
The in vivo full-thickness wound healing model suggests that γA promotes wound 
healing slightly, but not significantly, better than γ´ fibrinogen. The wound healing process 
is very rapid in healthy normal rats, and this may be the reason that no clear improvement 
could be made with fibrin matrices. The diabetic rodents with impaired repairing ability 
may be a good model for the wound healing study.34 It may also have greater clinical 
relevance since most of wound healing disturbances are linked to diseases, such as diabetes 
and infection. 
Furthermore, we examined the vascularization on day 14 and both vascularization and 
immunohistochemical structure on day 21. The nonsignificant difference may also simply 
result from the non-optimal time points, since the vascularization may already taken place, 
and the earlier time point could give better distinctions. For this reason, after the study 
described in Chapter 9, we conducted a pilot study with 12 rats using the same model, 
focusing on the first week. On day 7, the rats were sacrificed for the immunohistochemical 
examination. The result showed that the wound healing was improved with the fibrin and 
its variants applications, which was in good agreement with previous observations on the 
11
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improvement of wound healing by fibrin.35-38 However, vascularization was comparable 
in both γA and γ′ fibrin, suggesting that γA and γ′ fibrin have a similar contribution in the 
wound healing processes during the first 7 days. On the other hand, we cannot exclude 
the possibility that day 7 is still a non-optimal time points concerning the rapid wound 
healing in the healthy rats. In summary, the increased in vitro tube formation and in vivo 
wound healing in γA fibrin showed the same trend, which implies a beneficial effect for 
scaffold vascularization during wound healing. Nevertheless, more research is warranted 
to confirm this finding.  
FIBRINOGEN ELASTASE DEGRADATION PRODUCTS AND CARDIO-
VASCULAR DISEASES 
In Chapter 10, the fibrinogen elastase degradation products (FgEDP) levels in patients 
with IS were evaluated using a newly developed assay, which enables the assessment of 
elastase proteolytic activity. In the COCOS study, FgEDP levels were significantly higher 
in cases than in controls, both in the acute phase and in the convalescent phase. The results 
indicate that the FgEDP levels are a good marker for stroke and independent of acute phase 
response, since we observed a significant association after adjustment for CRP levels and 
when we analyzed the association in the convalescent phase 3 months after the event. 
Apart from being a predictor for stroke, elastase activity, as reflected by FgEDP 
levels, also appears to be involved in stroke pathogenesis, just like other inflammatory 
markers.39-40 An association has been established between levels of leukocytes and the 
risk of cardiovascular events and IS.41 Additionally, elastase might also directly contribute 
to stroke pathogenesis because of its pro-atherogenic properties41 or through activation 
of coagulation pathways.42-43 While the mechanism remains unknown, more research is 
needed to fully elucidate the causal role of elastase in stroke.
FUTURE PERSPECTIVES 
Nowadays, one of the most important challenges facing the biomedical research is the gain 
the basic mechanistic knowledge, and translates this information into effective clinical 
therapeutics. However, with respect to genetic contributions and diseases, the results are 
often not straightforward and numerous research questions still remain unanswered.
Large scale prospective studies are required to explore the causal role of fibrinogen 
γ′ or elastase in thrombotic diseases. These studies will need baseline values and several 
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time points before and after the thrombotic event. Only using this approach, and then it 
can be determined at what time point the fibrinogen γ′ levels or FgEDP levels are elevated 
and how they contribute to CVD. 
GWA studies are not only a good approach to unveil the genetic variations that 
influence the fibrinogen or fibrinogen γ′ levels and risk of CVD, 8,12-15 it also provides a 
step towards building predictive models of disease processes and the selection of new 
biomarkers and potential drug targets. Eventually, the ultimate goal of personalized 
medication (pharmacogenetics) can be achieved. Hence the understanding of genetic 
profiles is of great interest. Once a strong association has been established between genetic 
variations and CVD, high risk persons can be identified and preventive treatment could 
be started.
In addition to studies on variations in the fibrinogen genes, we attempted to explore 
the potential clinical applications of fibrin matrices. In this thesis, the effects of fibrinogen 
g variants on the in vitro endothelial cell characteristics and in vivo wound healing were 
described. However, the wound healing process is dynamic and complex, and more 
knowledge is needed on the structure of γA and γ′ fibrin matrices, especially regarding the 
interaction with various blood cells, platelets and growth factors. Another challenge is to 
fully understand the interplay between EMC, cellular responses and intracellular signaling 
during wound healing. This knowledge might encourage the future development of the 
best fibrin composition to achieve haemostasis and accelerate wound healing.
In conclusion, the results described in this thesis may improve the understanding of 
the important role of fibrinogen variants in CVD and wound healing. The accumulation of 
insights in fibrinogen studies can overcome medical challenges, which can develop into 
individualized therapeutic interventions to manage the CVD and facilitate the development 
of regenerative fibrin matrices for tissue engineering. Expectantly, these new treatment 
can provide great benefit to the patients in the future. 
11
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Summary
SUMMARY
Fibrinogen is a plasma glycoprotein that plays a key role in the haemostatic system. Its 
plasma levels are a well-known independent risk predictor for cardiovascular diseases 
(CVD). Plasma fibrinogen levels are modulated by both genetic and environmental factors. 
In order to fulfill its multiple functions, a large number of fibrinogen variants are present in 
the plasma of healthy individuals. The heterogeneity in fibrinogen influences the plasma 
fibrinogen concentration and the clot structure, and therefore it may also affect the risk of 
cardiovascular events and the process of wound healing. In this thesis, we investigated the 
role of fibrinogen variants and fibrinogen elastase degradation products (FgEDP) in CVD, 
and the role of the fibrinogen gA and g′ variants in wound healing. 
Recently, the relationship between haplotype-tagging polymorphisms in the total fibrinogen 
gene cluster and fibrinogen plasma levels and the risk of cardiovascular diseases was 
reported. We hypothesized that common genetic variation in the FGG and FGA genes play 
a role in regulating fibrin clot structure and may therefore be involved in the pathogenesis 
of vascular diseases and cerebrovascular events. We tested this hypothesis in Chapters 
2-4. In the studies described in these chapters the plasma fibrinogen levels were measured, 
and in addition seven haplotype-tagging single nucleotide polymorphisms (SNPs) that 
cover the total common variations in the FGG and FGA genes were determined and seven 
haplotypes (frequency >0.01) were constructed. 
In Chapter 2, we investigated the association between plasma fibrinogen levels 
and the presence of cerebral small vessel disease (SVD), as determined with magnetic 
resonance imaging (MRI) of the brain. In addition, the relationship between common 
variations in FGG, FGA and FGB genes and SVD was examined. We performed the study 
as part of the Rotterdam Scan Study, a population based imaging study in 1077 elderly 
patients undergoing cerebral MRI. Haplotype 2 was associated with the presence of silent 
brain infarcts compared with the most frequent haplotype (OR 1.41, 95% CI 1.03 to 1.94). 
Haplotype 3 was associated with periventricular white matter lesions in the highest tertile 
of the distribution (OR 1.40, 95% CI 1.01 to 1.92). Our study provides evidence for an 
association of common variation in the FGG and FGA genes with cerebral SVD. It is 
therefore possible that the structure of the fibrin clot rather than plasma fibrinogen levels 
plays a role in the pathogenesis of cerebral SVD. 
In Chapter 3, we examined the association between variation in FGG and FGA 
genes and dementia within the Rotterdam Study, a prospective population-based study. 
This study included 7,983 persons aged 55 years and over, and is ongoing since 1990. 
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In this study, 743 dementia patients were identified. No association was found between 
haplotypes and dementia or Alzheimer’s disease, suggesting that common variations in the 
FGG and FGA genes are not important risk factors for dementia.  
Furthermore, we investigated the relationship between common variations in FGG 
and FGA genes with ischemic stroke (IS) and hemorrhagic stroke in Chapter 4. The study 
included 6,275 participants from the Rotterdam Study, who were free from stroke, and had 
successful assessment of at least one SNP. We observed 668 strokes, of which 393 were 
ischemic and 62 hemorrhagic, during a median follow-up time of 10.1 years. FGG+FGA 
haplotype 3 (H3) was associated with an increased risk of IS (OR 1.36, 95% CI 1.09–1.69) 
and the risk estimate for hemorrhagic stroke was 0.71 (95% CI 0.46–1.09) compared to the 
most frequent H1. The results suggested that opposite associations for H3 may exist for 
ischemic and hemorrhagic stroke.
Recent studies have reported associations between the plasma fibrinogen g′ levels, 
the fibrinogen g′/total fibrinogen ratio and deep venous thrombosis, myocardial infarction 
and coronary artery disease. These results indicate that FGG gene variations, which are 
a main determinant of the plasma fibrinogen g′ levels, may contribute to the pathology 
of thrombotic disease and influence the risk of CVD. In Chapter 5, we conducted the 
COCOS study, a case-control study including 124 IS patients and 125 population controls. 
The fibrinogen g′/total fibrinogen ratio is associated with IS, especially in the acute phase 
of the disease. In addition, the FGG-H3 haplotype appears to be protective against IS (OR 
0.60; 95% CI, 0.38 to 0.94). 
In Chapter 6, we tested this hypothesis that the acute phase reaction alters the mRNA 
processing of fibrinogen g′, thereby increasing the g′/total fibrinogen ratio in patients with 
IS, pulmonary embolism (PE) and unstable angina pectoris (UAP). The fibrinogen g′/total 
fibrinogen ratios are elevated in patients with various cardiovascular diseases (IS, PE, 
or UAP) compared with the g′ ratios in healthy controls. An altered mRNA processing 
of fibrinogen g′ during the acute phase may contribute to this observation. However, the 
fibrinogen g′/total fibrinogen ratio does not predict short- or long-term outcome in patients 
with UAP.
Subsequently, we compared the differences in fibrinogen g′ levels and g′/total fibrinogen 
ratio between 200 patients with IS (Chapter 7), 55 patients with intracerebral hemorrhage 
(ICH, Chapter 8) and 156 population-based controls from the Erasmus Stroke Study. Our 
study shows that fibrinogen g′ levels were significantly higher in patients with IS than in 
controls (p<0.001), and similar results were observed in patients with ICH. Furthermore, 
increased fibrinogen g′/total fibrinogen ratios are associated with unfavorable short-term 
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outcome in the early phase after IS, and a trend toward unfavorable outcome in patients 
with ICH.
We hypothesized that the structural and functional differences between gA and g′ 
fibrin are associated with an altered matrix structure, and that may influence angiogenesis 
and wound healing. In Chapter 9, we investigated the effects of fibrinogen g variants on 
the in vitro endothelial cell characteristics and in vivo wound healing. The in vitro tube 
formation was more pronounced in γA than in γ′ fibrin matrices and this was accompanied 
with an increased fibrinolysis. The in vivo wound healing model suggested that γA fibrin 
was promoting wound healing slightly better than γ′ fibrin. However, more research is 
warranted before conclusions can be drawn.
Previously, an association has been found between levels of leucocyte elastase and 
the risk of cardiovascular events and IS. In Chapter 10, the FgEDP levels in patients 
with IS was evaluated using a newly developed assay, which enables the assessment of 
elastase proteolytic activity. In a case-control study, significantly higher FgEDP levels 
were observed in cases than in controls, both in the acute phase and in the convalescent 
phase. Our findings suggest that FgEDP might be involved in the pathogenesis of stroke.
In Chapter 11, the results of our studies are discussed regarding the current fibrinogen 
research.  Further investigation is needed for understand the mechanism, which can develop 
therapeutic interventions to manage the CVD and promote wound healing in the future.
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Fibrinogeen is een plasma glycoproteine dat een sleutelrol speelt in het hemostase 
systeem. De plasma spiegels zijn een bekende, onafhankelijke voorspeller van risico op 
hart- en vaatziekten (HVZ). Plasma fibrinogeen spiegels worden gereguleerd door zowel 
genetische als omgevingsfactoren. Om de grote hoeveelheid aan functies te kunnen 
vervullen, is er een groot aantal fibrinogeen varianten aanwezig in het plasma van gezonde 
personen. De heterogeniteit van fibrinogeen beïnvloedt de plasma fibrinogeen concentratie 
en de stolselstructuur, en kan daardoor een effect hebben op het risico van HVZ en het 
wondgenezingsproces. In dit proefschrift hebben we rol van fibrinogeen varianten en 
fibrinogeen elastase degradatie producten (FgEDP) in HVZ onderzocht, en de rol van 
fibrinogeen γA en γ′ varianten in wondgenezing. 
Recent is de relatie tussen haplotype bepalende polymorfismen in het totale fibrinogeen 
cluster met fibrinogeen plasma spiegels en met het risico op HVZ gerapporteerd. Onze 
hypothese is dat veelvoorkomende genetische variatie in de FGG en FGA genen een rol 
speelt bij de regulatie van de fibrine stolselstructuur and daardoor betrokken kan zijn bij 
de pathogenese van HVZ. Wij hebben deze hypothese getest in Hoofdstukken 2-4. In 
de studies die in deze hoofdstukken worden beschreven zijn de spiegels van fibrinogeen 
in plasma gemeten, en daarnaast zijn zeven haplotype-bepalende single nucleotide 
polymorphismen (SNPs) bepaald die de totale veelvoorkomende variatie in de FGG en 
FGA genen beschrijven, en zijn zeven haplotypes (frequentie >0.01) samengesteld. 
In Hoofdstuk 2 hebben we de relatie tussen plasma fibrinogeen spiegels en de 
aanwezigheid van ziekte van de kleine vaten van de hersenen (SVD), zoals bepaald met 
magnetische resonantie beeldvorming (MRI) van het brein. Daarnaast is de relatie tussen 
veelvoorkomende varianten in de FGG, FGA en FGB genen met SVD bestudeerd. We 
hebben een studie uitgevoerd als onderdeel van de Rotterdam Scan Studie, een populatie 
imaging studie in 1077 oudere patiënten die een MRI van de hersenen ondergingen. 
Haplotype 2 was geassocieerd met een verhoogd voorkomen van stille herseninfarcten, 
vergeleken met het meest voorkomende haplotype 1 (OR 1.41, 95% CI 1.03 to 1.94). 
Haplotype 3 was geassocieerd met periventriculaire witte stof laesies in het hoogste tertiel 
van de verdeling (OR 1.40, 95% CI 1.01 to 1.92). Onze studie levert bewijs voor een 
associatie tussen veelvoorkomende variatie in de FGG en FGA genen met cerebrale SVD. 
Het is daarom mogelijk dat de structuur van het fibrine netwerk, eerder dan de plasma 
fibrinogeen spiegel, een rol speelt bij de pathogenese van hersen SVD. 
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In Hoofdstuk 3 hebben we de relatie tussen variatie in de FGG en FGA genen en 
dementie onderzocht binnen de Rotterdam Studie, een prospectieve populatie studie. 
In deze studie zijn sinds de start in 1990, 7983 personen geïncludeerd met een leeftijd 
van 55 jaar en ouder. In deze studie zijn 743 patiënten geïdentificeerd met dementie. 
Geen associatie werd gevonden tussen de haplotypes en dementie of Alzheimer, hetgeen 
suggereert dat veelvoorkomende varianten in de FGG en FGA genen geen belangrijke 
risicofactoren zijn voor dementie.  
Daarnaast hebben we de relatie bestudeerd tussen veelvoorkomende varianten in de 
FGG en FGA genen met ischemische beroerte (IS) en hersenbloeding in Hoofdstuk 4. De 
studie vond plaats in 6275 deelnemers van de Rotterdam studie die geen beroerte hadden 
gehad en in wie we minstens 1 SNP konden bepalen. We zagen 668 beroertes, waarvan 
393 ischemisch en 62 hemorrhagisch tijdens de mediaan follow-up van 10.1 jaren. Het 
FGG+FGA haplotype 3 (H3) was geassocieerd met een verhoogd risico op IS (OR 1.36, 
95% CI 1.09–1.69) en het risico op een hersenbloeding was 0.71 (95% CI 0.46–1.09), 
vergeleken met het meest voorkomende H1. Deze resultaten suggereren tegenovergestelde 
associaties tussen H3 met ischemische en hemorrhagische beroerte. 
Recente studies hebben associaties gerapporteerd tussen plasma fibrinogeen g′ 
spiegels, de fibrinogeen g′/total fibrinogeen ratio en diep veneuze trombose, hartinfarct en 
coronaire hartziekte. Deze resultaten suggereren dat FGG genvariaties, die de belangrijkste 
determinant zijn van plasma fibrinogeen g′ spiegels, bij zouden kunnen dragen aan de 
pathologie van trombose en het risico op HVZ kunnen beïnvloeden. In Hoofdstuk 5 
beschrijven we de resultaten van onze substudie in de COCOS studie, een case controle 
studie met 124 IS patiënten en 125 populatie controles. De fibrinogeen g′/totaal fibrinogeen 
ratio is geassocieerd met IS, vooral in de acute fase van de ziekte. Daarnaast blijkt het 
FGG-H3 haplotype beschermend te zijn tegen IS (OR 0.60; 95% CI, 0.38 tot 0.94).
In Hoofstuk 6 hebben we de hypothese getest dat de acute fase reactie de mRNA 
processing van fibrinogeen g′ verandert, en daarbij de fibrinogeen g′ / total fibrinogeen 
ratio verhoogd in patiënten met IS, longembolie (PE) en onstabiele angina pectoris (UAP). 
De fibrinogeen g′ totaal fibrinogeen ratio is verhoogd in patiënten met de verschillende 
HVZ (IS, PE en UAP) vergeleken met de g′ ratios in gezonde controles. Een veranderde 
mRNA processing van fibrinogeen g′ tijdens de acute fase zou kunnen bijdragen aan deze 
observatie. Daarentegen voorspelt de fibrinogeen g′ /totaal fibrinogeen ratio niet de korte 
of lange termijn uitkomst in patiënten met UAP. 
Vervolgens hebben we de verschillen in fibrinogeen g′ spiegels en g′ / totaal 
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fibrinogeen ratio vergeleken tussen 200 patiënten met IS (Hoofdstuk 7), 55 patiënten met 
hersenbloeding (ICH, Hoofdstuk 8) en 156 populatie controles uit de Erasmus Stroke 
Studie. Onze studie laat zien dat fibrinogeen g′ spiegels significant hoger zijn in patiënten 
met IS dan in controles (p<0.001), en vergelijkbare resultaten werden gezien in patiënten 
met ICH. Verder waren verhoogde fibrinogeen g′/totaal fibrinogeen ratio geassocieerd met 
ongunstige korte termijn uikomst in de vroege fase na IS, en er was een trend naar een 
ongunstige uitkomst in patiënten met ICH. 
Wij hypothetiseerden dat de structurele en functionele verschillen tussen gA en g′ 
fibrine geassocieerd zouden zijn met een veranderde matrix structuur, en dat dit angiogenese 
en wondherstel zou beïnvloeden. In Hoofdstuk 9 hebben we de effecten van fibrinogeen g 
varianten op de in vitro endotheelceleigenschappen en het in vivo wondherstel bestudeerd. 
The in vitro vaatvorming was sterker in gA dan in g′ fibrine matrices en dit ging samen met 
een verhoogde fibrinolyse. Het in vivo wondgenezingsmodel suggereerde dat gA fibrine 
wondgenezing enigszins beter stimuleerde dan g′ fibrine. Maar meer onderzoek is nodig 
voor conclusies kunnen worden getrokken.
Eerder is een associatie beschreven tussen de spiegels van leukocyten elastase en 
het risico op HVZ. In Hoofdstuk 10 zijn de FgEDP spiegels in patiënten met IS gemeten 
met een nieuw ontwikkelde meetmethode voor het bepalen van de elastase proteolytische 
activiteit. In een case controle studie werden significant hogere FgEDP spiegels gezien in 
patiënten dan in controles, zowel in de acute fase als in de stabiele fase. Onze bevindingen 
suggereren dat FgEDP betrokken kan zijn bij de pathogenese van beroerte.
In Hoofdstuk 11 worden de resultaten van onze studies bediscussieerd in relatie tot 
het huidige fibrinogeen onderzoek. Verdere onderzoeken zijn nodig om alle mechanismen 
te begrijpen, hetgeen kan leiden tot toekomstige therapeutische interventies bij HVZ en 
het stimuleren van wondgenezing.
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ABBREVIATIONS
g′ Fibrinogen gamma prime variant
aE Fibrinogen extended Aa variant 
ANOVA Analysis of variance 
CI Confidence interval
CRP C-reactive protein 
CT Computed tomography 
CVD Cardiovascular diseases 
DVT Deep venous thrombosis 
EC Endothelial cells
ECG Electrocardiogram 
ECM Extracellular matrix 
ELISA Enzyme-linked immunosorbent assay
EM Expectation-maximization
ESS  Erasmus Stroke Study
FE Fibrinogen equivalents 
FGA Fibrinogen alpha gene
FGB Fibrinogen beta gene
FgEDP Fibrinogen elastase degradation products 
FGF-2 Fibroblast growth factor-2 
FGG Fibrinogen gamma gene
FITC Fluorescein isothiocyanate isomer I 
FpA Fibrinopeptides A 
FpB Fibrinopeptides B
FXIII  Factor XIII 
g′ ratio Fibrinogen g′/total fibrinogen ratio 
GP1ba Platelet glycoprotein Ib-α 
GWA Genome-wide association 
H Haplotype
HDL High-density lipoprotein 
HMVEC Human microvascular endothelial cells 
HMW High molecular weight fibrinogen
HSA Human serum albumin 
HSi  Heat-inactivated human serum 
HUVEC Human umbilical vein endothelial cells 
I-CAM Intercellular adhesion molecule 
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ICH Intracerebral hemorrhage
IL-6 Interleukin 6
IS Ischemic stroke
IVE Intraventricular extension
kb Kilobases 
kDa Kilo Dalton
LDPM Laser Doppler perfusion measurements 
LMW Low molecular weight fibrinogen
MI Myocardial infarction 
MRI Magnetic resonance imaging
mRNA Messenger ribonucleic acid
mRS Modified Rankin Scale
MW Molecular weight 
NBCSi Heat-inactivated newborn calf serum 
NIHSS National Institutes of Health Stroke Scale 
OR Odds ratio
PA Plasminogen activators 
PAI-1 Plasminogen activator inhibitor 1 
PE Pulmonary embolism
PMNs Polymorphonuclear leucocytes 
SD  Standard deviation
SDS-PAGE Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SEM Standard error of the mean 
SERPINS Serine protease inhibitors
SNPs Single Nucleotide Polymorphisms 
SVD Small vessel disease 
TAFI Thrombin-activatable fibrinolysis inhibitor
TIA Transient ischemic attack 
TNFα Tumor necrosis factor-a 
TOAST Trial of ORG 10172 in Acute Stroke Treatment
t-PA Tissue-type plasminogen activator 
UAP Unstable angina pectoris
u-PA Urokinase-type plasminogen activator 
u-PAR Urokinase-type plasminogen activator receptor 
VE Vascular Endothelial
VEGF Vascular endothelial growth factor 
α2-AP α2-antiplasmin
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